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Cardiovascular diseases (CVDs) are currently the main cause of mortality and morbidity 
worldwide and expected to remain the leading cause of death at least till 2030 according to the 
World Health Organization. CVDs are a group of disorders involving the heart and blood vessels 
and most people die of coronary heart disease and stroke. The root cause of most cases of CVD 
is atherosclerosis. Atherosclerosis affects medium and large sized arteries in the body and was 
primarily thought to be solely caused by accumulation of lipids in the vessel wall. Russell Ross 
was one of the first researchers to state that inflammatory processes play an important role 
in the pathogenesis of atherosclerosis.1 Nowadays, disturbances in lipid levels and increased 
inflammation are the two established contributors to atherosclerosis development. Since the 
liver is a key role player in both lipid metabolism and regulation of inflammatory processes, it is 
a potential interesting organ to study in atherosclerosis development. 
In practice, in a single patient CVD is often present in combination with other diseases, such 
as diabetes, cancer, arthritis and chronic obstructive lung disease (COPD). Some features of these 
comorbidities, such as poor lung function in COPD, are found to be strong independent predictors 
of cardiovascular risk.2 Like CVD, COPD is a major cause of mortality and morbidity globally. It is 
the only leading cause of death that still has a rising mortality rate, and projected to be ranking as 
the third leading cause of death by 2020.3 Even though the respiratory and cardiovascular systems 
interact closely, not many experimental studies have been performed in which the role of both 
organ systems in atherosclerosis development have been investigated. Furthermore, next to the 
elucidation of the pathogenic process, it is important to develop new therapies to control the risk 
factors and inhibit the initiation and progression of CVD and its comorbidities. 
This chapter provides background information on dyslipidemia and increased inflammation 
in atherogenesis and on a new promising anti-atherogenic drug, resveratrol. Furthermore, 
effects of modulations in lipid metabolism and inflammation in the liver and lungs on 
atherosclerosis development are highlighted. 
1. Dyslipidemia
Nikolai N. Anichkov demonstrated for the first time in 1913 that cholesterol alone caused the 
atheromatous changes in the vascular wall.4 Cholesterol is essential for life, it is required to 
build and maintain cell membranes, involved in intracellular transport, cell signaling, nerve 
conduction and it is an important precursor molecule for the synthesis of bile and hormones. 
As it is insoluble in blood due to its lipophilic characteristics, it is transported through the 
circulation in lipoproteins.5 These particles have a lipid-rich core containing triglycerides (TGs) 
and cholesteryl esters (CEs) and an amphipathic surface consisting of phospholipids (PLs), 
unesterified cholesterol and proteins. These proteins, called apolipoproteins, bind lipids and 
solubilize them, and act as coenzymes and ligands for lipoprotein receptors on tissues, like 
the liver. Lipoproteins are classified based on their density (in the order of increasing density): 
chylomicrons, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), 
low-density lipoprotein (LDL) and high-density lipoprotein (HDL). 
In the fed state, dietary lipids form chylomicrons in the intestine. Here, the products of 
fat digestion, TG, PL and CE are combined with apolipoprotein (apo) B48 in the enterocyte. 
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The lipoproteins formed in this manner are secreted into the lymph (chyle) and are termed 
chylomicrons. TG in chylomicrons is hydrolyzed by lipoprotein lipase (LPL) and the released fatty 
acids (FAs) are subsequently taken up by adipose and muscle tissue. An endogenous source for 
FA from TG is VLDL, which is synthesized by the liver. After processing by LPL, VLDL is converted 
to IDL and LDL. Remnants of apoB-containing lipoproteins can be taken up by the liver. 
HDL is the smallest and only anti-atherogenic lipoprotein.6 Its most abundant apolipoproteins 
are apoAI and apoAII. The liver synthesizes HDL as complexes of apolipoproteins and PLs, 
which are capable of picking up cholesterol from the periphery, e.g.  atherosclerotic lesions, 
and transporting it back to the liver, where it can be excreted out of the body through the bile. 
This process is termed reverse cholesterol transport. HDL also delivers cholesterol to adrenals, 
ovaries, and testes for the synthesis of steroid hormones. 
The process of atherogenesis was considered for many years merely to constitute of 
progressive accumulation of lipids within the vessel wall. Indeed at the earliest stages, 
accumulation and modification of LDL was observed and has been recognized as the initiating 
factor of atherosclerosis development.7 Healthy endothelium forms a smooth monolayer of 
elongated endothelial cells, without adhesive capacities. However, especially in areas where the 
blood flow is disturbed, e.g. branched or curved points, the permeability of the endothelium is 
increased.8 Endothelial dysfunction and increased permeability can also be caused by elevated 
levels of LDL, hypertension, hyperglycemia, increased inflammation and oxidative stress, e.g. by 
cigarette smoking.1 Remnant lipoproteins and mainly the small, dense LDL, can enter the intima 
of the blood vessel.9 LDL is retained in the intima by binding of apoB to proteoglycans of the 
extracellular matrix.10 Although disturbances in lipid metabolism have long been held responsible 
for atherosclerosis development, the earliest stage of atherogenesis is characterized by 
accumulation of (lipid-laden) inflammatory cells, and more specifically macrophages. In recent 
years, atherosclerosis research has turned its focus more to the inflammatory processes involved. 
2. Inflammation
Small, dense LDL particles easily penetrate into the endothelium, become entrapped in the 
intima, where they become modified by e.g. oxidation (Figure 1). This activates the endothelium 
and resident macrophages to produce adhesion molecules and chemokines, such as monocyte 
chemoattractant protein 1 (MCP-1) and vascular cell adhesion molecule (VCAM), to attract 
monocytes (the most numerous of the leukocytes recruited), dendritic cells (DCs), and T cells into 
the intima.11 In early atherosclerosis, vascular smooth muscle cells (VSMCs) may contribute to the 
development of the atheroma through the production of pro-inflammatory mediators and through 
the synthesis of matrix molecules required for the retention of lipoproteins. After stimulation with 
macrophage colony-stimulating factor (M-CSF), monocytes differentiate into macrophages in the 
intima, which take up the modified LDL (mLDL) through their scavenger receptors. As cholesterol 
accumulates, these macrophages transform into foam cells, the prototypical cell in atherosclerosis, 
when the LDL particles cannot be mobilized out of the cell to a sufficient extent. 
Antigens of mLDL are presented by macrophages and DCs in the intima and trigger 
the activation of other macrophages and antigen-specific T-cells.12 Most of the activated 
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macrophages and T-cells produce cytokines, e.g. interferon (IFN)γ, interleukin (IL)-6, tumor 
necrosis factor (TNF)α, which attract and activate more inflammatory cells, e.g. mast cells, 
natural killer (NK)T-cells, leading to magnification and sustainment of the inflammatory 
response and the formation of a complex conglomeration of lipids, cholesterol crystals, 
inflammatory and necrotic cells. In addition, cytokines and growth factors secreted by 
macrophages and T-cells are important for VSMC migration, proliferation and production of 
collagen to form a fibrous cap covering the lesion. The fibrous cap maintains stability of the 
plaque by protecting the thrombogenic mixture of leukocytes, lipid, and debris from the blood 
stream. Extracellular lipid derived from dead and dying cells can accumulate in the plaque, 
Fig. 1. Stages in atherogenesis. 1) When LDL becomes entrapped in the vessel wall, it becomes modified 
(mLDL). This mLDL induces an inflammatory response leading to 2) expression of adhesion molecules on 
the activated endothelium, by which leukocytes, such as monocytes are attracted to migrate into the vessel 
wall. 3) The monocytes mature into macrophages, take up the mLDL through scavenger receptors and 4) 
become foam cells. 5) In the progressing atherosclerotic lesion, smooth muscle cells (SMCs) proliferate, 
migrate and produce collagen to form a fibrous cap covering 6) the lipid-rich core consisting of necrotic 
and apoptotic foam cells, cholesterol crystals and other debris. 7) If this thrombotic content becomes 
exposed to the blood stream, due to weakening and rupture of the cap by e.g. proteases, a thrombus is 
formed which can occlude the vessel, causing an infarction.  
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often denoted the lipid or necrotic core. On the other hand, proteases (e.g. metalloproteinases 
(MMPs)), cytokines and radicals are also produced that can destabilize the lesions and break 
down the fibrous cap. While clinical complications, e.g. angina pectoris, can arise from growing 
plaques creating flow-limiting stenoses, the most severe adverse events follow the rupture of 
a plaque, which exposes the prothrombotic material in the plaque to coagulation factors in the 
blood and causes a sudden occlusion of the artery, which can result in ischemia and infarction 
of the supplied tissue.13
2.1. Nuclear factor-κB (NF-κB)
Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) is a family of five 
protein products belonging to two classes. Class I consists of NF-κB1 (p50) and NF-κB2 (p52), 
which are synthesized from the precursors p105 and p100, respectively. Class II includes RelA 
(p65), RelB and cRel.14 The most common and best-characterized form of NF-κB is the p65/p50 
heterodimer.
In unstimulated cells, the NF-κB p65/p50 dimer is kept inactive in the cytosol bound with 
its inhibitor, IκBα (Figure 2). IκBα keeps NF-κB inactive by masking the nuclear localization 
site and sequestered in the cytoplasm.15 The classical activation of the NF-κB pathway can be 
initiated by a wide range of extracellular stimuli, including cytokines, such as TNFα and IL-1β, 
viral products, bacterial components (pathogen-associated molecular patterns (PAMPs)), 
but also saturated FAs16 and endogenous stress signals following tissue damage, termed 
danger-associated molecular patterns (DAMPs)17 through different receptors, such as pattern 
recognition receptors (PRRs). This results in the activation of different signal transduction 
cascades which eventually activate the IκB kinase (IKK) complex, which consists of IKKα, 
-β and -γ (the latter is also called NF-κB essential modulator (NEMO)). This complex will 
mediate the phosphorylation of IκBα, resulting in its ubiquitination and degradation, allowing 
nuclear entry of the liberated NF-κB, where it can induce expression of specific target genes, 
encoding cytokines, growth factors, immunomodulatory molecules, apoptosis related genes 
and others.
Under physiological circumstances, NF-κB activation is rapid and short-acting 
(approximately 30-60 min), and expression of NF-κB-dependent genes is downregulated after 
a limited period of time. One of the target genes of NF-κB is IκBα, thereby forming a negative 
feedback loop. In atherosclerosis and many other chronic pathological conditions, however, 
NF-κB is persistently activated by a combination of numerous factors.
In the initial stages of atherosclerosis development, NF-κB regulates the expression of 
cytokines, chemokines and adhesion molecules.18 Later in the progression of the lesion, NF-κB 
regulates gene expression of M-CSF, which is important for the formation of foam cells.19 NF-κB 
is an essential regulator of MMP gene expression, especially MMP-2 and MMP-9, which are 
critical in plaque rupture.20 Increased NF-κB activity was found especially in unstable regions of 
atherosclerotic plaques.21 Thus, NF-κB regulates the expression of a wide spectrum of factors 
influencing different stages of atherosclerosis development. Furthermore, many of these 
factors increase NF-κB activity which propagates a positive feedback loop. Increased NF-κB 
activity was not only observed locally within the lesion, but also in circulating leukocytes as 
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demonstrated in a study showing highest activity in circulating leukocytes from unstable 
angina patients when compared to stable angina patients, and low activity in control patients.22 
Nowadays, many research projects on the discovery of anti-atherogenic drugs are targeted 
on the inhibition of NF-κB activity.23 NF-κB signaling and its interactions with other networks 
are very complex and hence the inhibition of the whole NF-κB system will be detrimental. It 
is therefore essential to identify and dissect the crucial signaling connections and in this way 
develop more specific and safer therapeutic agents.24 
3. Lipid metabolism and inflammation
The term ‘lipemia of sepsis’ was coined already in the late 1950s, when patients with cholera 
were noted to have lipidemic blood and high serum levels of TGs.25 The functional importance 
of this cytokine-induced hyperlipidemia lies not only in the mobilization of lipid stores to 
fuel the host immune system to combat the pathogen, but also in the capacity of TG-rich 
lipoproteins to bind and neutralize lipopolysaccharide (LPS), the most toxic component of the 
cell membrane of Gram-negative bacteria.26 In addition, apolipoproteins, e.g. apoAI and apoE 
have been shown to have strong anti-inflammatory features, next to their more classical role 
in lipid metabolism.27
Fig. 2. Activation of the NF-κB pathway. Extracellular and endogenous triggers, such as pathogen-
associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and saturated 
fatty acids (FAs), bind to pattern recognition receptors (PPRs) and activate the IκB kinase (IKK) complex. 
IKK phosphorylates the inhibitor of NF-κB (IκBα), resulting in the release and phosphorylation of NF-κB, 
after which it can translocate to the nucleus to activate the transcription of its target genes.
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So, there is ample evidence that lipid metabolism and inflammatory pathways interact 
with each other. As mentioned above, they are the two key contributors to atherosclerosis 
development. Thus, studying their crosstalk in atherosclerosis-prone animal models will provide 
more insight in the involved processes in atherogenesis. For example, hypercholesterolemic 
mice have a peripheral blood monocytosis that develops over time in both chow-fed and fat-fed 
apoe-/- mice.28 This monocytosis is mainly attributed to an increase in the pro-inflammatory 
population of Ly6Chi expressing monocytes compared with the ‘patrolling’ Ly6Clo expressing 
subset. The Ly6Chi monocytes are pro-atherogenic because they adhere more strongly to 
activated endothelium, accumulate in plaques and become lesional macrophages.28 
4. Animal models for atherosclerosis
Analysis of human atherosclerosis has been predominantly observational, although with the 
advancement of non-invasive techniques, e.g. intravascular ultrasound, atherogenesis in 
humans in a more experimental setting is increasingly being studied. However, for mechanistic 
insight into the processes involved, studies in animal models remain to be a necessary resource. 
One of the main reasons why mice form suitable models is the possibility to generate transgenic, 
knock-out or knock-in strains to study the role of specific genes and their ensuing products. 
These advantages of murine models not only account for the field of atherosclerosis research.
Since the plasma cholesterol levels of wild-type mice are low (approximately 2 mM) and 
mainly confined to HDL, they do not develop atherosclerosis. Therefore, atherosclerosis-prone 
mouse models are developed through alteration of key components controlling circulating 
lipoprotein levels, causing hyperlipidemia and/or -cholesterolemia. ApoE and LDL receptor 
(LDLr) knockout and transgenic APOE*3-Leiden (E3L) models are most widely used. 
ApoE is essential for the uptake of (remnants of) apoB-containing lipoproteins by the 
liver via LDLr, LDLr-related protein (LRP) and heparan-sulphate proteoglycans (HSPGs). 
Furthermore, apoE derived from macrophages has been shown to have an important role 
in cholesterol efflux from foam cells.29 Apoe-/- mice have a pronounced elevation of plasma 
VLDL-cholesterol level on a normal chow diet (approximately 9 mM) and, as such, develop 
spontaneously atherosclerotic lesions. In addition, evidence indicates that apoE has anti-
atherogenic properties independent of plasma lipoprotein regulation.30 On chow as well 
as on a high cholesterol (1.25%) diet, apoe-/- mice have higher systemic cytokine levels than 
wild-type mice.31 In addition, apoe-/- mice have an increased number of circulating monocytes, 
and upon high fat and high  cholesterol diet feeding, these monocytes are skewed to a pro-
inflammatory phenotype.32 A possible mechanism for the immunomodulatory characteristics 
of apoE is that it can bind LPS directly, redirecting it to bile, and thereby preventing it from 
binding to its receptor.33, 34 Another mechanism described, involves apoE binding to cell surface 
receptors and HSPG and the consequential inhibition of JNK and c-Jun phosphorylation that is 
required for IL-6, IL-1β, and TNF-α secretion in Toll-like receptor (TLR) signaling.35 Irrespective 
of the involved mechanism, it is clear that not only the hyperlipidemia, but also the increased 
inflammatory state of apoe-/- mice accounts for their susceptibility to develop atherosclerosis. 
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Ldlr-/- mice lack the expression of a functional LDLr due to an insertion of a neomycin 
resistance cassette into exon 4 of the gene, which leads to the production of an inactive truncated 
protein.36 On chow diet, the plasma cholesterol levels are not high enough (approximately 
6 mM) for atherosclerosis development. To this end, these mice are fed a cholesterol-rich diet 
for atherosclerosis studies, resulting in plasma cholesterol levels up to 50 mM, predominantly in 
the LDL fraction. The elevated levels of LDL as a consequence of the lack of a functional LDLr can 
augment inflammation. LDL becomes immunogenic when it undergoes modifications such as 
oxidation and glycation in vivo.37 mLDL not only promotes the transformation of macrophages 
into foam cells but their recognition by auto-antibodies also triggers the release of pro-
inflammatory cytokines by human monocyte-derived macrophages.38 Thus, ldlr-/- mice are likely 
to have an enhanced inflammatory state, at least indirectly, due to higher levels of LDL.
 E3L mice carry a construct containing the human APOE*3-Leiden gene, a dominant negative 
mutation of apoE that causes hyperlipidemia, together with apoCI that elevates plasma TG by 
inhibiting LPL activity. In addition, apoCI also interferes with apoE-mediated uptake of apoB-
containing lipoproteins. This results in moderately raised plasma cholesterol and TG levels 
compared to the apoe-/- and ldlr-/- models, which in addition can be modulated by varying the 
dose of cholesterol in the diet. Furthermore, E3L mice are more sensitive to lipid modulating 
drugs, such as statins, fibrates and nicotinic acids, than apoe-/- and ldlr-/- mice.39, 40 
To further humanize the lipoprotein profile of E3L mice, E3L mice have been crossbred 
to mice expressing human cholesteryl ester transfer protein (CETP). This protein is naturally 
missing in wild-type mice and transfers cholesteryl esters from HDL to (V)LDL in exchange for 
triglycerides, thereby lowering HDL and increasing VLDL. These E3L.CETP mice respond to 
HDL-modifying drugs similar to humans and are therefore used extensively in studies in which 
potential anti-atherogenic therapies are investigated,41, 42 such as described in chapter 5. 
Crossbreeding of these atherosclerosis-prone mice with mice that carry deletions in genes 
encoding crucial components of the immune system or bone marrow transplantation has 
provided important information on the role of the immune system in atherogenesis.43 Organ-, 
tissue- or cell-restricted genetic altering of mice is another technique to gain more insight in 
the role of certain cell populations or organs in the pathogenesis of atherosclerosis, which will 
be further elaborated in the next section.
5. Extravascular lipid metabolism and inflammation 
To study how the interaction of different organ systems plays a role in atherosclerosis 
development, experimental animals form a suitable model. CVD has been associated with 
other chronic inflammatory autoimmune diseases, e.g. systemic lupus erythematosus and 
rheumatoid arthritis.44 Chronic inflammation can also derive from exogenous and/or infectious 
agents, when they are not eradicated effectively by the acute inflammatory response, as has 
been shown for e.g. Porphyromonas gingivalis, one of most important bacteria implicated in 
periodontitis45 and Chlamydophila pneumoniae, a gram-negative bacterium that is a frequent 
cause of low-grade respiratory infection. 
General Introduction
17
Most pathogens enter their host through the mucosa of the lungs and gut by the route of 
inhalation or ingestion, respectively. Following the gut, the liver is the second line of defense for 
incoming pathogens. The lungs and liver are therefore equipped with critical immune defense 
mechanisms. Apart from their role in immunity, the liver is known to be a key regulator of lipid 
metabolism. In the framework of the two main contributors to atherosclerosis, dyslipidemia 
and especially, enhanced inflammation, the role of the liver and the lungs in atherosclerosis 
development are described in the following paragraphs. 
5.1. Liver
The liver is the largest internal organ in the human body comprising about 1/50 of the adult body 
weight. It is the only organ in the body that receives blood from both the systemic circulation 
(via the hepatic artery, ~20%) and the gastrointestinal tract (via the portal vein, ~80%). In the 
liver, blood from the portal vein and arterioles derived from the hepatic artery flows to the 
central vein, while passing the hepatic sinusoids. The hepatic sinusoids are fenestrated and 
lack a basement membrane, which facilitates the interaction between the contents of both 
blood supplies with liver sinusoidal endothelial cells,  hepatic immune cells in the space of 
Disse, and hepatocytes, arranged in cords (Figure 3).46 This blood passing the hepatic sinusoids 
contains products of digestion, including carbohydrates, peptides, FAs, along with antigens 
and microbial products that originate from the bacteria in the small and large intestine. Apart 
from its role in energy metabolism and immunity, which will be discussed more extensively 
below, the liver, or more specifically, the hepatocytes, carry out various vital functions, such 
as the production of coagulation factors, break down or modification of toxic substances and 
drugs, storage of vitamins, production of albumin and synthesis of angiotensinogen. 
The liver is composed of many different cell types which are divided into parenchymal cells 
(hepatocytes) and non-parenchymal cells, i.e. sinusoidal endothelial cells (SECs), lymphocytes, 
Kupffer cells, biliary epithelial cells, hepatic stellate cells (HSCs) and DCs (Figure 3). The 
hepatocyte population accounts for approximately 80% of all cells in the liver, while non-
parenchymal cells constitute 20%, of which about 50% are endothelial cells, 25% lymphocytes 
and 20% Kupffer cells. Compared with peripheral blood, the liver is enriched with NK and 
NKT cells.47
5.1.1. Lipids
The liver plays a major role in energy metabolism of the three nutrients, carbohydrates, 
proteins and fat. It synthesizes, stores and releases carbohydrates through gluconeogenesis, 
glycogenolysis and glycogenesis. In addition, it is responsible for the synthesis and the 
degradation of proteins and removal of ammonia from the body by synthesis of urea. Excess 
carbohydrates and proteins are converted into FAs and TGs to be exported to the rest of the 
body. Because of its prominent role in atherogenesis, the role of the liver in lipid metabolism is 
described more in detail. 
Chylomicrons from the intestine travel through the lacteals to join lymph from other parts 
of the body, and enter the blood circulation via the thoracic duct. LPL releases TG from the core 
of the chylomicron by hydrolyzing them to FA and monoglycerides, which are taken up by the 
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Fig. 3. Anatomical organization of the liver. Hepatic lobule. When blood drained from the gastrointestinal 
system flows from the portal vein to the central vein, it passes cords of hepatocytes through sinusoids. 
Hepatic sinusoid. Sinusoidal endothelial cells (SECs) form the specialized, fenestrated endothelium lining 
the sinusoids. Hepatic stellate cells (HSCs) are found in the space of Disse, while Kupffer cells, lymphocytes 
and dendritic cells (DCs) can be found both in the sinusoids and space of Disse. 
tissues locally. Remaining chylomicron remnants are removed from the circulation largely by 
the liver. VLDL is synthesized by the liver and hydrolyzed by LPL resulting in the formation of 
IDL, which is partly taken up by the liver by apoE. The remainder is further processed by LPL 
and hepatic lipase to become LDL, which is recognized by the receptors on liver and peripheral 
tissues. VLDL, IDL and LDL are apoB100-containing particles. Within the hepatocyte, lipidation 
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of apoB100 requires an adequate supply of lipids and microsomal triglyceride transfer protein 
(MTTP).48 The lipids added to apoB100 can originate from the diet or be synthesized de novo 
by hepatocytes. De novo lipogenesis is upregulated via insulin-mediated stimulation of sterol 
response element-binding protein 1c (SREBP-1c), a major lipogenic transcription factor. Fatty 
acid synthase (FAS) is one of the most important genes involved in de novo synthesis of TG, 
while carnitine palmitoyltransferase 1A (CPT1A) is an enzyme essential for fatty acid oxidation. 
High circulating levels of LDL can cause retention of LDL within the vessel wall, which is 
the first step of atherosclerosis development, as described above. Hepatic synthesis of bile 
acids accounts for the majority of cholesterol removal out of the body. Bile is excreted in the 
duodenum and facilitates the digestion and transport of lipids. The largest amount (~95%) of 
bile acids excreted in the duodenum, are absorbed back into blood within the ileum, where it 
returns to the sinusoids of the liver through the portal vein (enterohepatic recirculation). Bile 
acids are then transported across the hepatocytes to be resecreted into bile canaliculi.
5.1.2. Inflammation
Facing the continuous exposure to gut-derived antigens present in portal venous blood, the 
liver’s immune cells exist in a state of tolerance which is also termed ‘liver tolerance’.46 On the 
one hand, a reasonable speculation is that most of these antigens originate from harmless 
material in food, on the other hand, however, this makes the liver also susceptible to invasion 
by pathogens that breach the intestinal mucosa and invade the circulation. Therefore, the 
liver is an organ with a specialized immune system. Kupffer cells and lymphocytes, including 
a relative high number of NK cells and NKT-cells, make up the majority of immune cells in the 
liver. Kupffer cells are specialized macrophages located in the liver and form the body’s largest 
compartment of macrophages. They reside within the lumen of the liver sinusoids; therefore, 
they are the first cells to be exposed to materials absorbed from the gastrointestinal tract. In 
addition to their phagocytic capacities, Kupffer cells process and present antigens.49 Cytokines 
produced by Kupffer cells induce the expression of acute phase proteins, such as C-reactive 
protein (CRP), serum amyloid A (SAA), α1-antitrypsin, ceruloplasmin or haptoglobin, partly 
through NF-κB signaling, in hepatocytes.
NK cells make up as many as 50% of liver lymphocytes and respond both to cytokine 
activation and to engagement of an excess of activating receptors over inhibitory receptors, 
i.e. recognizing major histocompatibility complex (MHC) class I alleles. NKT cells recognize 
glycolipid antigens that are conserved features of bacterial walls, thus respond to those 
derived from the intestinal bacteria.50 From this perspective, NKT cells can be considered to 
represent a bridge between lipids and inflammation. Given that lipid accumulation is a hallmark 
of atherosclerosis and the fact that NKT cells are activated by glycolipid antigens, it is not 
surprising that NKT cells were hypothesized to play a role in atherogenesis. ApoE on circulating 
lipoproteins can enhance NKT cell responses to glycolipid antigen presented by human DCs51 
and activation of NKT cells has been demonstrated to accelerate atherogenesis.52
The other non-parenchymal cells in the liver, i.e. SECs, DCs and biliary epithelial cells 




5.1.3. Lipids and inflammation
Hypercholesterolemic apoe-/- mice on chow diet display not only inflammation in atherosclerotic 
lesions, but also in periadventitial and visceral adipose tissue, liver and pancreatic islets.31 Dietary 
cholesterol can induce hepatic inflammation in ldlr-/ 54 and E3L mice.55, 56 Like atherosclerosis, 
insulin resistance is commonly associated with both chronic inflammation and a metabolic 
dyslipidemic profile with increased levels of atherogenic apoB-containing lipoproteins. In 
an insulin resistant experimental animal model, it was shown that inhibition of NF-κB activity 
resulted in reduced apoB100 synthesis by primary hamster hepatocytes.57 This implies that 
hepatic inflammation is an important factor underlying hepatic atherogenic lipoprotein 
production observed in insulin resistance and atherosclerosis. Moreover, Luchtefeld et al. have 
shown that hepatocyte-specific deficiency of gp130, a key component of the IL-6 signaling 
pathway, reduces atherosclerosis development in apoe-/- mice.58 The liver is a prototypical 
organ in which lipid metabolism and inflammation converge, thus it is not surprising that it 
plays a central role in atherosclerosis.
5.2. Lungs
The lungs are not only the organ system that is localized nearest to the heart, but also work 
in close collaboration with the cardiovascular system. Lungs are filled with about 90% air 
and 10% tissue, which reflect their most important function, i.e. gas exchange of oxygen 
and carbon dioxide. Inhaled air travels from the nose to the trachea, bronchi, bronchioles, 
terminal bronchioles, respiratory bronchioles and finally the alveoli, which are the functional 
units of lungs, where most of gas exchange takes place (Figure 4). Oxygen and carbon dioxide 
are transported to and from the rest of the body respectively, in erythrocytes and dissolved 
in plasma.
The pulmonary epithelium in the bronchi and bronchioles consists of different cell types: 
ciliated cells, goblet cells, basal cells, brush cells and Clara cells. The cilia of the ciliated cells beat 
in concert cranially, effectively moving secreted mucus containing trapped foreign particles to 
the oropharynx for either expectoration or swallowing to the stomach where the acidic pH 
helps to neutralize foreign material and micro-organisms. Goblet cells secrete mucus, which 
acts as a barrier and traps particulate material and pathogens moving through the airway. Basal 
cells serve as a reserve population by maintaining individual cell replacement in the epithelium. 
Brush cells have a synaptic contact with an afferent nerve ending at the basal surface and are 
therefore regarded as receptor cells with microvilli. Clara cells increase in number as the ciliated 
cells decrease along the length of the bronchiole. They secrete surfactant-related proteins, 
which are needed to prevent luminal adhesion in case the wall of the airway folds on itself, 
particularly during expiration. 
The most important types of cells surrounding the alveoli are type I pneumocytes, type II 
pneumocytes and alveolar macrophages (Figure 4). Type I pneumocytes are the major cell type 
lining the alveolar surfaces, through which gas is exchanged. The type II cells serve as stem cells 
for themselves and the type I cells. They secrete a fluid which acts as a surfactant by reducing 
surface tension, and thereby increase pulmonary compliance, prevent atelectasis (collapse of 
the lung) at the end of expiration and facilitate recruitment of collapsed airways. The alveolar 
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Fig. 4. Epithelium of the bronchial tree and alveoli. Inhaled air first passes the nasal cavities, naso-, 
oropharynx, larynx, trachea, primary bronchi, before it enters the lungs, where it sequentially travels 
through the internal bronchi, bronchioles, alveolar ducts, - sacs, and alveoli. Bronchial epithelium. Basal 
cells, ciliated columnar cells, and goblet cells are the principal cell types in the bronchial epithelium. The 
basal cells, located at the base of the epithelial layer, are the stem cells from which the other cell types 
arise. The ciliated columnar cells are the most numerous and provide sweeping of the mucus toward the 
pharynx, thus serving as an important protective mechanism for removing small inhaled particles from the 
lungs. Subepithelial glands are present in the larger bronchi and are a main source of mucus in the central 
airways. Bronchiolar epithelium. The composition of the epithelium changes as the ducts narrows from 
bronchi, the larger diameter bronchioles towards smaller ones: cartilage plates and subepithelial glands 
are not present in bronchioles, the ciliated columnar epithelium transforms to simple cubiodal epithelium, 
the number of goblet cells decreases, while Clara cells increase in number. Clara cells are nonciliated cells 
that secrete surfactant-related proteins. Alveoli. Alveoli are surrounded and separated from each other 
by a thin connective tissue layer that contains numerous blood capillaries. The tissue between adjacent 
alveolar air spaces is called the alveolar septum. The alveolar epithelium is composed of two types of 
pneumocytes: type I which line most of the surface of the alveoli, and type II that secrete surfactant and 
are important for host defense. Alveolar macrophages are present both in the connective tissue of the 
septum and in the air space of alveoli. 
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macrophages phagocytose the bacteria, dust particles or other debris and move towards the 
bronchioles, where phagocytosed materials are eliminated by coughing. 
5.2.1. Lipids
The role of lipids in the lungs has not been a subject of extensive study in current literature. 
Lipids are naturally secreted in the pulmonary surfactant in the lungs by type II pneumocytes 
and play an important role in the maintenance of airway patency by lowering the surface tension 
during respiration. Surfactant consists for 90% of lipids (mainly saturated phospholipids) and 
10% of protein. It has been demonstrated that deletion of the ATP-binding cassette (ABC) 
transporter, ATP-binding cassette sub-family G member 1 (ABCG1) in macrophages causes 
lipid accumulation in the alveolar macrophages.59 Traditionally, ABCG1 is known for its role 
in facilitating cellular cholesterol and phospholipid efflux from macrophages to mature HDL. 
Another ABC transporter, ATP-binding cassette sub-family A member 1 (ABCA1) mediates 
the efflux of cholesterol and PLs from macrophages. In addition, ABCA1 has been shown to 
be expressed in the lung and highest expressed in type II pneumocytes,60 implying a role 
in surfactant regulation.61 It controls transport of cholesterol and phospholipids to apoA1 
in type II pneumocytes. Defective ABCA1 manifests as Tangier’s disease, characterized by 
severely reduced levels of HDL, and abc1-/- mice have pulmonary lesions consisting of foamy 
type II pneumocytes, lipid-laden alveolar macrophages and cholesterol clefts and display 
pathophysiologic hallmarks similar to human Tangier’s disease.62 Abca1-/-/abcg-/- mice exhibit 
extreme lipid accumulation in tissue macrophages of the lung amongst other organs (liver, 
spleen, Peyer’s patches, and lymph nodes).63 Whether the accumulation of lipid-laden cells 
in these murine models is also accompanied with increased pulmonary inflammation is likely, 
but not reported. Together, these data demonstrate that lipids do play an important role 
in the lungs, which becomes evident when ABC transporters involved in lipid trafficking 
are affected.
5.2.2. Inflammation
The obstructive lung diseases COPD and asthma are the most frequent causes of respiratory ill 
health, covering all ages.64 Both conditions are associated with many comorbidities, including 
CVD,65, 66 albeit asthma to a lesser extent than COPD. One of the most obvious reasons for this 
is that most COPD patients are aging individuals, and therefore are at higher risk to have more 
comorbidities. It has been proposed that COPD and CVD are entities of the same systemic 
inflammatory syndrome, of which other diseases, such as Alzheimer’s disease, osteoporosis 
also take part. This syndrome has also been called ‘inflamm-aging’ by some,67 with a reduction 
in adaptive immunity and an increase in innate immunity driven by NF-κB activation.68 There is 
abundant evidence of increased systemic inflammation in COPD and CVD, as demonstrated by 
the presence of activated circulating leukocytes and increased levels of circulating inflammatory 
mediators.69 CRP for example, known as a biomarker of systemic inflammation, is not only a 
marker of increased mortality in COPD,70 but also a marker of increased cardiovascular risk.71 
Although, it is often hypothesized that inflammation in the systemic compartment is the result 
of ‘spill over’ of the inflammatory process locally, in this case from the lungs, evidence from 
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cross-sectional studies did not point out a correlation between pulmonary and circulatory 
inflammatory markers in stable COPD.72 As mentioned before, a poor lung function has been 
shown to be a strong independent risk factor for CVD-related morbidity and mortality in many 
epidemiological studies.2, 65 It is not clear however whether COPD also plays a causative role in 
this increased risk, or COPD and CVD are part of a ‘syndrome’ where systemic inflammation is 
a common denominator.
5.2.3. Lipids and inflammation
In clinical COPD studies, the prevalence of obesity is higher with a lower GOLD stage, i.e. less 
severe COPD, in line with the intriguing finding that a higher body mass index (BMI) (and higher 
fat-free mass) is associated with a lower mortality rate in COPD patients.73, 74 On the other hand, 
obesity can cause low-grade systemic inflammation and as high CRP levels in young healthy 
adults are associated with a faster decline in lung function, obesity may be a risk factor for 
COPD. This obesity paradox in COPD can be ascribed to several possible causes. Firstly, the 
different phenotypes of COPD partly contributed to this paradox. Obesity in COPD is more 
prevalent in the chronic obstructive phenotype, whereas underweight is more prevalent in the 
emphysematous phenotype.75 A reduced respiratory function in COPD impairs physical activity 
and increases the risk of developing obesity. In addition, there is no plausible reason why 
adiposity should protect against mortality in COPD.74 In fact, one study indicates that lean mass 
index is a better predictor of mortality than BMI in moderate to severe COPD, while fat mass 
index is not a significant prognostic indicator.76 Another study demonstrated that excessive 
visceral fat (independent of total fat mass) contributes to increased plasma IL-6, which, in turn, 
is strongly associated with all-cause and cardiovascular mortality in patients with obstructive 
lung disease.77 These data suggest that the overall physical condition as reflected by a larger lean 
mass index and/or the fat composition rather than obesity per se are important determinants 
of the severity and inflammatory state of COPD. 
Interestingly, feeding apoe-/- mice a Western-type diet (high fat 21% and high cholesterol 
0.15% content) also induces increased inflammation in the lung.78 These mice had higher levels 
of pro-inflammatory cytokines than the control wild-type mice on the same diet. Furthermore, 
Goldklang et al. demonstrated that apoe-/- mice fed a Western-type diet (21% fat and 0.21% 
cholesterol) for 10 weeks compared to chow-fed apoe-/- mice exhibited elevated number of 
macrophages and lymphocytes in the lung, accompanied by an increase in MMP-9 and -12 
activity and more importantly, air space enlargement, i.e. emphysema, a major feature of 
COPD.79 These changes did not occur in ldlr-/- mice fed the same diet. In addition, macrophages 
from the apoe-/- mice treated with a TLR4 ligand showed enhanced MMP-9 expression, which 
was further augmented with the addition of oxidized LDL. These studies provide a possible 
mechanism linking emphysema and atherosclerosis, where persistent systemic inflammation, 
from multiple different sources, act through e.g. the TLR4 signaling pathway with the resultant 
inflammatory and protease cascade contributing to the development and disease progression 
of both COPD and atherosclerosis. Moreover, they support the hypothesis that COPD and 





Among all available anti-atherogenic drugs, e.g. fibrates, nicotinic acid, peroxisome 
proliferator-activated receptor (PPAR)α and -γ agonists, and statins are the most well-
studied and proven to be effective in preventing CVD events.80 Although powerful drugs for 
atherosclerosis, like statins, are abundantly used in developing countries, CVDs remain to be 
the leading cause of morbidity and mortality in the Western world. Next to statins, a new multi-
target therapeutic agent, resveratrol is discussed below. Resveratrol is a moderate activator 
of sirtuin (silent mating type information regulation 2 homolog 1, (SIRT1), a nicotinamide 
adenosine dinucleotide-dependent histone deacetylase with anti-aging and anti-inflammatory 
properties. The potential benefit of the use of statins and SIRT1 activation has been studied in 
CVD, but notably, also in COPD.81, 82 
6.1. Statins
Numerous clinical trials have established that statins, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors, can reduce various atherosclerotic complications.80 As more 
than two thirds of the body’s total cholesterol is synthesized by the body itself (mainly in the 
liver) and not consumed through diet, blocking this pathway to decrease serum cholesterol 
is a logical step to take in an effort to lower cholesterol levels. By blocking HMG-CoA 
reductase, the rate limiting enzyme in cholesterol synthesis, statins lower the endogenous 
VLDL production and thereby reduce plasma LDL levels. Some classes of statins also induce an 
increase in HDL levels by an enhancing apoA1 production up to approximately 15%, primarily in 
the liver.83 Statin treatment not only results in a more favorable lipoprotein profile by reducing 
LDL and increasing HDL levels, but there is evidence that part of the clinical benefit of statins 
can be ascribed to other effects, e.g. anti-inflammatory, antithrombotic, and improvement of 
endothelial function.84 Part of the pleiotropic actions of statins is through NF-κB suppression. 
It has been reported that statins stabilize IκB by inhibiting kinases in monocytes and VSMCs.85 
These off-target beneficial side-effects of statins have expanded the attention of these drugs 
to non-cardiovascular fields. Simvastatin, for instance, has been demonstrated to be able 
to reverse or inhibit pulmonary emphysema, a common manifestation of COPD in animal 
models.86, 87 Trials are being undertaken to evaluate the potential benefit of statins on morbidity 
and mortality in COPD.81 Given that the majority of COPD patients die due to a cardiovascular 
event, it is also important, but difficult to delineate the beneficial effects of statins on COPD 
independently from their favorable effects on the cardiovascular system. 
6.2. Resveratrol
NF-κB appears to be a tempting therapeutic target, because it is a point of intersection of 
multiple pathways in atherogenesis. A number of compounds, especially anti-oxidants, 
proteasome- and IKK inhibitors, have been shown to suppress NF-κB. NF-κB modulation is often 
part of the pleiotropic actions from pharmaceutical drugs, e.g. glucocorticoids and statins.88, 89 
In addition, NF-κB inhibiting compounds have been present in our diet from ancient times, 
such as curcumin,90 and resveratrol, a polyphenol found in red wine.91 Resveratrol is primarily 
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present in the skins of grapes and thus in red wine. In addition, resveratrol is present in Chinese 
herbs, peanuts and a large variety of fruits including various berries and jackfruit.
The mechanism of action of resveratrol is not completely understood. As mentioned 
before, resveratrol is also a moderate activator of SIRT1, which has been shown to physically 
interact with the p65 subunit of NF-κB and to inhibit its activity by deacetylating p65 at 
lysine 310.92 Resveratrol has been shown to potentiate the SIRT1-mediated anti-inflammatory 
response.93 Atheroprotective effects of resveratrol are numerous, such as suppression of IL-6 
and M-CSF secretion,94, 95 prevention of oxidation of LDL and uptake into the vascular wall,96 
lowering of blood pressure and glucose levels.97 Similar to statins, resveratrol is reported to 
have many pleiotropic effects. Thus, resveratrol is considered a promising candidate for the 
new generation of anti-atherosclerotic drugs, and as mentioned previously, its therapeutic 
possibilities are currently also being explored in lung diseases. Whether resveratrol can beat 
the current leading anti-atherogenic drug statin, is a challenging question which remains to be 
answered. 
7. Outline of thesis
Increased inflammation is a main contributor to atherogenesis. Inflammatory processes within 
the vessel wall are studied extensively. Less is known about the effects of more distal organs. The 
studies in this thesis focus on the role of two organs, i.e. the liver and lungs, in atherosclerosis 
development. 
The liver is an important organ in the regulation of both lipid metabolism and inflammation, 
the two key role players in atherosclerosis. In chapter 2, we studied the interaction between 
liver inflammation and lipid metabolism. We investigated whether hepatocyte-specific 
NF-κB activation by transgenic expression of IKKβ affected VLDL production in E3L mice. 
Increased levels of VLDL are an important risk factor for CVD. So, it is reasonable that any 
effect of hepatocyte-specific NF-κB activation on lipid metabolism found in chapter 2 would 
influence atherosclerosis development. By using the same transgenic mouse model the role of 
transgenic NF-κB activation in hepatocytes on both lipid metabolism and inflammation, with 
atherosclerosis development as primary outcome was examined in chapter 3. 
Apart from the classical risk factors such as dyslipidemia and inflammation, poor lung 
function, most commonly caused by COPD, has been identified as another predictor for CVD.98 
Pulmonary emphysema is a major component of COPD and is characterized by loss of alveolar 
integrity leading to an alveolar space enlargement. We studied whether alveolar destruction 
per se would have an effect on atherosclerosis development in chapter 4.
New therapies are continuously being developed to reduce evolving and existing CVD. One 
of the most promising therapeutic components which currently receives a lot of attention, not 
only in the field of CVD, is resveratrol. In chapter 5 we evaluated the potential anti-atherogenic 
capacity of resveratrol alone or combined with atorvastatin. 
Finally, the major findings of the studies described in this thesis, the clinical implications 
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Abstract 
Low-grade inflammation in different tissues, including activation of the nuclear factor-κB 
(NF-κB) pathway in liver, is involved in metabolic disorders such as type 2 diabetes and 
cardiovascular diseases (CVD). In this study we investigated the relation between chronic 
hepatocyte-specific overexpression of IKKβ and hypertriglyceridemia, an important risk 
factor for CVD, by evaluating whether activation of IKKβ only in the hepatocyte affects 
VLDL-triglyceride (TG) metabolism directly. Transgenic overexpression of constitutively 
active human IkB kinase (IKKβ) specifically in hepatocytes of hyperlipidemic APOE*3-Leiden 
mice clearly induced hypertriglyceridemia. Mechanistic in vivo studies revealed that the 
hypertriglyceridemia was caused by increased hepatic VLDL-TG production, rather than 
a change in plasma VLDL-TG clearance. Studies in primary hepatocytes showed that IKKβ 
overexpression also enhances TG secretion in vitro, indicating a direct relation between IKKβ 
activation and TG production within the hepatocyte. Hepatic lipid analysis and hepatic gene 
expression analysis of pathways involved in lipid metabolism suggested that hepatocyte-
specific IKKβ overexpression increases VLDL production not by increased steatosis or 
decreased FA oxidation, but most likely by ChREBP-mediated upregulation of Fas expression. 
These findings implicate that specific activation of inflammatory pathways exclusively within 
hepatocytes induces hypertriglyceridemia. Furthermore, we identify the hepatocytic IKKβ 




Obesity is associated with diseases such as dyslipidemia, type 2 diabetes and cardiovascular 
disease (CVD). The accumulation of lipids in numerous tissues is accompanied by increased 
inflammatory processes, such as macrophage infiltration and production of inflammatory 
mediators in white adipose tissue. In liver, fat accumulation increases the activity of the 
pro-inflammatory nuclear factor-κB (NF-κB), and liver-specific activation of NF-κB induces 
metabolic disturbances.1,2
Hypertriglyceridemia is caused by accumulation of VLDL particles in the plasma as a 
consequence of changes in lipid metabolism that are associated with obesity. Pro-inflammatory 
cytokines can cause hypertriglyceridemia3 and, conversely, suppression of inflammation may 
reduce hypertriglyceridemia4 suggesting a direct causal role for inflammatory pathways in the 
development of hypertriglyceridemia. In fact, administration of lipopolysaccharide (LPS), an 
inflammatory component of the outer membrane of Gram-negative bacteria, increases plasma 
triglyceride (TG) levels.5 However, many inflammatory mediators affect multiple tissues, such 
as muscle, adipose tissue and liver and, moreover, they can act on multiple cell types including 
macrophages. The specific contribution of hepatocytes in the relation between inflammation 
and TG metabolism has never been studied. 
In the current study we, therefore, aimed to investigate whether activation of the 
inflammatory NF-κB pathway exclusively in hepatocytes affects VLDL-TG metabolism and, 
as a consequence, causes hypertriglyceridemia. To this end, we used hepatocyte-specific 
transgenic IKKβ (LIKK) mice, which have been described before.1 LIKK mice have an albumin 
promoter to drive expression of constitutively active human IκB kinase β (IKKβ), which activates 
the NF-κB pathway selectively in hepatocytes. To study the effects of the hepatocyte-specific 
inflammation on VLDL-TG metabolism, we crossbred the LIKK mouse with the transgenic 
APOE*3-Leiden (E3L) mouse that expresses human APOE*3-Leiden (a mutant form of APOE3) 
and human APOC1,6 both of which attenuate the clearance of apoE-containing TG-rich 
lipoproteins. Therefore, the E3L mouse shows increased plasma TG and cholesterol levels 
and is a well-established model of human-like lipoprotein metabolism.7 By using the E3L.LIKK 
mouse, we were able to study the effects of the inflammatory NF-κB pathway in the hepatocyte 
on TG-rich lipoprotein metabolism directly. Our results show that activation of NF-κB in 




LIKK mice, which express constitutively active human IKKβ selectively in hepatocytes under 
control of the albumin promoter1 were crossbred with E3L mice,6 expressing both human 
APOE*3-Leiden and human APOC1, in our animal facility to obtain heterozygous E3L.LIKK mice 
on a C57Bl/6J background. Male E3L.LIKK and E3L littermates were housed under standard 
conditions with a 12-hour light-dark cycle and were fed a standard mouse chow diet with free 
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access to water. Experiments were performed in 14-week old animals after an overnight fast. 
All experiments were approved by the institutional ethical committee on animal care and 
experimentation.
Western blot analysis
Tissues were homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold buffer (pH 7.4) 





(v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors (Complete, Roche, Mijdrecht, The 
Netherlands) at a 1:6 (w/v) ratio. Homogenates were centrifuged (16,000 rpm; 15 min, 4°C) and 
the protein content of the supernatant was determined using the BCA protein assay kit (Pierce, 
Rockford, IL). Proteins (20-50 µg) were separated by 7-10% SDS-PAGE followed by transfer 
to a polyvinylidene fluoride (PVDF) membrane. Membranes were blocked for 1 h at room 
temperature in Tris-buffered saline with Tween-20 (TBST) with 5% non-fat dry milk followed 
by an overnight incubation with the following antibodies: p-Ser536 NF-κB p65 (#3031), NF-κB 
p65 (#3034), p-Ser32/36 IκBα (#9246), IκBα (#9242) (all from Cell Signaling), MTP (#612022) 
(BD Biosciences, Erembodegem, Belgium) and DGAT1 (#54037) (Abcam, Cambridge, UK). Blots 
were then incubated with a horseradish peroxidase (HRP)-conjugated secondary antibodies 
for 1 h at room temperature. Bands were visualized by enhanced chemiluminescence (ECL) and 
quantified using Image J (NIH).
Plasma lipids and lipoprotein profiles
Blood was collected from the tail vein into chilled paraoxon (Sigma, St Louis, MO)-coated 
capillaries to prevent ongoing lipolysis.8 Capillaries were placed on ice, centrifuged and plasma 
was assayed for TG, total cholesterol (TC), and phospholipids (PL) using commercially available 
enzymatic kits from Roche Molecular Biochemicals (Indianapolis, IN). Free fatty acids (FFA) were 
measured using NEFA-C kit from Wako Diagnostics (Instruchemie, Delfzijl, The Netherlands). 
For the determination of lipid distribution over plasma lipoproteins, 50 µL of pooled plasma 
was used for fast performance liquid chromatography (FPLC). Plasma was injected onto a 
Superose 6 column (Äkta System; Amersham Pharmacia Biotech, Piscataway, NJ), and eluted at 
a constant flow rate of 50 µL/min with PBS pH 7.4. TG and TC were measured as described above 
in collected fractions of 50 µL. 
Liver lipids
Lipids were extracted from livers according to a modified protocol from Bligh and Dyer.9 Briefly, 
a small piece of liver was homogenized in ice-cold methanol. After centrifugation, lipids were 




 (3:1 v/v) to 45 µL homogenate. The CHCl
3
 phase 
was dried and dissolved in 2% Triton X-100. Hepatic TG and TC concentrations were measured 
using commercial kits as described earlier. Liver lipids were expressed per mg protein, which 
was determined using the BCA protein assay kit.
FA composition of liver TG
Liver samples (100 mg) were homogenized with 0.5 mL saline. Subsequently, 5 mL of 
chloroform: methanol (2: 1 by volume) was added containing butylated hydroxytoluene (BHT). 
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In addition, an internal TG standard was added before extraction. Liver lipids were extracted 
according to the method of Folch et al.10 Total TG were separated by spotting lipid extracts 
onto silica gel 60 (Merck) thin-layer chromatography plates and running in hexane: diethyl 
ether: acetic acid (85: 15: 1, v/v/v). Lipid bands were visualized under UV light after spraying with 
0.1% ANS (8-anilino-1-naphthalene sulfonic acid), and identified using commercial standards. 




 in methanol 
for 2 h. TG-derived FA were eluted into hexane. Separation and quantification of the FA methyl 
esters (FAMEs) from liver TG was achieved using gas chromatography, on an Agilent 6890 GC 
(Agilent Technologies, UK) fitted with a 30 m x 0.53 mm (film thickness 1 µm) capillary column 
(RTX-Wax). Individual FA peaks were identified by a reference containing known FAMEs. FA 
compositions (mol%) were then determined.
Generation of VLDL-like emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described 
previously.11,12 Lipids (100 mg) at a weight ratio of triolein: egg yolk phosphatidylcholine: 
lysophosphatidylcholine: cholesteryl oleate: cholesterol of 70: 22.7: 2.3: 3.0: 2.0, supplemented 
with 200 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TO) were sonicated at 10 µm output using a 
Soniprep 150 (MSE Scientific Instruments, Crawley, UK). Density gradient ultracentrifugation was 
used to obtain 80 nm-sized emulsion particles, which were used for subsequent experiments. 
TG content of the emulsions was measured as described above. Emulsions were stored at 4°C 
under argon and used within 7 days.
In vivo clearance of VLDL-like emulsion particles
To study the in vivo clearance of the VLDL-like emulsion particles, overnight fasted mice 
were anesthetized by intraperitoneal injection of acepromazine (6.25 mg/kg Neurotranq, 
Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg Dormicum, Roche 
Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg Janssen Pharmaceuticals, 
Tilburg, The Netherlands). Mice were injected (t=0) via the tail vein with 200 µL of [3H]TO-
labeled emulsion particles at a dose of 100 µg of TG per mouse. Blood samples were taken 
from the tail vein at 1, 2, 5, 10 and 15 minutes after injection and plasma 3H-activity was 
counted. Plasma volumes were calculated as 0.04706 x body weight (g) as determined from 
125I-BSA clearance studies as described previously.13 After taking the last blood sample, the 
liver, heart, spleen, muscle and white adipose tissue (i.e. gonadal, subcutaneous and visceral) 
were collected. Organs were dissolved overnight at 60°C in Tissue Solubilizer (Amersham 
Biosciences, Roosendaal, The Netherlands) and 3H-activity was counted. Uptake of [3H]TO-
derived radioactivity by the organs was calculated from the 3H activity in each organ divided by 
plasma-specific activity of [3H]TG and expressed per mg wet tissue weight.
In vivo hepatic VLDL-TG and VLDL-apoB production
To measure VLDL production in vivo, mice were fasted overnight and anesthetized as described 
above. Mice were injected intravenously with Tran35S label (150 µCi/mouse; MP Biomedicals, 
Eindhoven, The Netherlands) to label newly produced apolipoprotein B (apoB). After 30 minutes, 
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at t=0 min, Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g body weight, 
10% solution in PBS) to block serum VLDL clearance. Blood samples were drawn before (t=0) 
and 15, 30, 60 and 90 min after injection and used for determination of plasma TG concentration 
as described above. After 120 min, mice were exsanguinated via the retro-orbital plexus and 
euthanized by cervical dislocation. VLDL was isolated from serum after density gradient 
ultracentrifugation at d<1.006 g/mL by aspiration14 and counted for incorporated 35S-activity. 
Isolation of primary mouse hepatocytes
Primary hepatocytes were isolated from mouse livers according to the method of Berry and 
Friend15 modified by Groen et al.16 Briefly, the portal vein was cannulated and liver was first 
perfused with a calcium-free Krebs/bicarbonate buffer, saturated with 95% O
2
 and 5% CO
2
 
at a flow rate of 5 mL/min. Subsequently, perfusion of the liver was continued with calcium-
containing Krebs/bicarbonate buffer with 0.0125% collagenase (Roche, Penzberg, Germany) 
during 10-15 min until cellular dissociation was observed. Cells were gently released and 
centrifuged four times at 50g for 1 min at 4°C to remove non-parenchymal cells from pelleted 
hepatocytes. Isolated hepatocytes were washed and suspended in complete Williams’ E medium 
containing insulin (Actrapid), fetal calf serum, dexamethasone and penicillin/streptomycin 
(P/S). Hepatocytes were isolated with similar yields from livers of E3L.LIKK and E3L mice, 70-80% 
viable, as assessed by trypan blue dye exclusion, and 99% free of non-parenchymal cells by 
visual inspection. No differences with respect to viability were observed between cells isolated 
from E3L.LIKK and E3L mice. Cells were seeded into 12-well dishes, pre-coated with collagen at 
a density of 1.0x106 viable cells/well in 2 mL complete Williams’ E medium. After a 2 h adherence 
period, non-attached cells were removed from the cultures by careful washing. 
In vitro measurement of TG secretion by hepatocytes
TG secretion in vitro was measured as described previously.17 After an overnight incubation, 
cells were washed 2 times and incubated 4 h in fetal calf serum-free and hormone-free (SF-HF) 
Williams’ E medium. To measure rates of secretion of TG, cells were subsequently incubated 
in SF-HF medium containing 4.4 µCi of [3H]glycerol (Amersham; UK) with or without 0.75 mM 
oleate (C18:1) complexed with BSA to stimulate lipogenesis. After 1, 2, 4 or 20 h incubation, 
medium was collected and cells were washed three times and harvested in 2 mL PBS. Lipids 
were extracted from medium according to a modified protocol from Bligh and Dyer.9,17 The lipids 
were dried under nitrogen, dissolved into chloroform with 2 mM tripalmitin added as a carrier 
and subjected to TLC (Silica gel 60, Merck, Belgium) using hexane: diethylether: acetic acid 
(80/20/1; v/v/v) as mobile phase. Lipid spots were visualized using iodine vapor, and tripalmitin-
positive spots were scraped off, dissolved in 0.5 M acetic acid, and assayed for radioactivity by 
scintillation counting. Protein content of the cells was determined using the BCA protein assay 
kit as described earlier. Data are expressed as dpm/mg protein.
Hepatic gene expression analysis
Total RNA was extracted from liver tissues using the Nucleospin RNA II kit (Macherey-Nagel, 
Düren, Germany) according to manufacturer’s instructions. RNA quality of each sample was 
examined by lab-on-a-chip technology using Experion Std Sens analysis kit (Biorad, Hercules, 
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CA, USA). One µg of total RNA was reverse-transcribed with iScript cDNA synthesis kit (Bio-Rad) 
and the obtained cDNA was purified with Nucleospin Extract II kit (Macherey-Nagel). Real-Time 
PCR was carried out on the IQ5 PCR machine (Biorad) using the Sensimix SYBR Green RT-PCR 
mix (Quantace, London, UK). mRNA levels were normalized to mRNA levels of cyclophilin 
(Cyclo) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Primer sequences are listed 
in Supplemental Table S1. 
Statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the Mann-
Whitney U test for two independent samples with SPSS 16.0 (SPSS Inc, Chicago, IL). P<0.05 was 
regarded statistically significant.
Results
LIKK increases liver NF-κB signaling in E3L mice
To verify that LIKK expression in E3L mice increases hepatic NF-κB signaling, livers from E3L and 
E3L.LIKK mice were assayed for the presence of phosphorylated over total NF-κB and IκBα using 
Western blot (Fig. 1). Indeed, expression of LIKK increased the ratio of pNF-κB Ser536 over NF-κB 
(1.6 ± 0.4 fold; P<0.05) (Fig. 1A, B) as well as that of pIκBα Ser32/36 over IκBα (1.9±0.6 fold; P<0.05) 






    
    
 
Fig. 1. LIKK increases hepatic NF-κB signaling in E3L mice. E3L and E3L.LIKK mice were fed a chow diet 
and sacrificed at the age of 14 weeks after an overnight fast. NF-κB signaling was measured in liver tissue 
by phosphorylation of NF-κB (A,C) and IκB (B,D). Representative Western blots of phosphorylated NF-κB 
(NF-κB Ser536) and total NF-κB (A) and phosphorylated IκBα (pIκBα Ser32/36) and total IκBα (B) are shown for 
3 mice per group. Ratios of phosphorylated proteins over total proteins were quantified (B,D). Values are 
means ± SD (n=5-7). *P<0.05.
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(Fig. 1C, D). The increased ratio of pIκBα Ser32/36 over IκBα was mainly caused by a decrease of 
total IκBα (0.8±0.1 fold; P<0.05), indicating increased IκBα ubiquitination and degradation by 
the proteasome, which reflects activation of the NF-κB pathway. These data are in line with the 
increased NF-κB signaling previously observed in LIKK mice as compared to wild-type (WT) mice.1
Fig. 2. LIKK induces hyperlipidemia in E3L mice. Plasma triglycerides (TG) (A), total cholesterol (TC) (B), 
phospholipids (PL) (C) and free fatty acid (FFA) (D) levels were measured in plasma of overnight fasted 
E3L and E3L.LIKK mice. Values are means ± SD (n=5-7). *P<0.05. Plasma was collected, pooled per group, 




LIKK induces hypertriglyceridemia in E3L mice
To determine whether the hepatocyte-specific inflammation affects plasma lipid levels, TG, TC, 
PL and FFA levels were measured in plasma of E3L and E3L.LIKK mice (Fig. 2). LIKK expression 
in E3L mice increased TG by +39% (2.90±0.52 vs 2.09±0.28 mmol/L; P<0.05; Fig. 2A), TC by +18% 
(2.24±0.25 vs 1.90±0.28 mmol/L; P<0.05; Fig. 2B), and PL by +22% (2.12±0.18 vs 1.74±0.27 mmol/L; 
P<0.05; Fig. 2C). LIKK did not affect plasma FFA levels (Fig. 2D). Lipoprotein profiling showed 
that the LIKK-induced increase in plasma TG could be explained by a rise in VLDL-TG (+42%) 
(Fig. 2E). Likewise, the increase in TC was mainly reflected by an increase in VLDL-C (+54%), 
LDL-C (+34%) and HDL-C (+25%) (Fig. 2F).
LIKK does not affect clearance of VLDL-like emulsion particle-TG in E3L mice
Hypertriglyceridemia is caused by a decrease in VLDL-TG clearance and/or an increase in hepatic 
VLDL-TG production. To investigate whether LIKK inhibits the clearance of VLDL-TG, the plasma 
clearance and organ distribution of [3H]TO-labeled TG-rich VLDL-like emulsion particles was 
evaluated in E3L.LIKK versus E3L mice (Fig. 3). LIKK did not affect the plasma half-life of [3H]
TO (Fig. 3A), nor the uptake of [3H]TO-derived fatty acids (FA) by the various organs (Fig. 3B), 
indicating that LIKK does not increase plasma TG levels by decreasing TG clearance.
LIKK increases VLDL-TG production in E3L mice
As no difference was observed in TG clearance between E3L.LIKK and E3L mice, it is likely that 
the LIKK-induced increase in plasma TG levels can be explained by an increase of VLDL-TG 
production. The rate of hepatic VLDL-TG production was measured by determining plasma 
TG levels after intravenous Triton WR1339 injection (Fig. 4). Indeed, LIKK strongly increased 
the accumulation of plasma TG at all time points (Fig. 4A). The VLDL-TG production rate, 
Fig. 3. LIKK does not affect clearance of VLDL-like emulsion particle-TG in E3L mice. E3L and E3L.LIKK mice 
that were fasted overnight were injected with [3H]TO-labeled VLDL-like emulsion particles. Blood was 
collected at the indicated time points and radioactivity was measured in plasma (A) of E3L mice (open 
circles) and E3L.LIKK mice (closed circles). Uptake of [3H]TO-derived activity by various organs was 
determined, and total FA uptake was calculated from the specific activity of TG in plasma, and expressed 
as nmol FA per mg wet tissue weight (B). Values are means ± SD (n=8). WAT, white adipose tissue; visc, 
visceral; sc, subcutaneous; gon, gonadal.
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as determined from the slope of the curve from all individual mice, was increased by +48% 
(3.90 ± 1.01 vs 2.64 ± 0.82 mM/h, P<0.05) (Fig. 4B), whereas the rate of VLDL-apoB production 
did not change significantly (P=0.52) (Fig. 4C). Since each VLDL particle contains a single 
apoB molecule, LIKK apparently increases plasma TG levels by enhancing VLDL-TG production 
without affecting VLDL particle production.






























































































Fig. 4. LIKK increases VLDL-TG production in E3L mice. E3L and E3L.LIKK mice were fasted overnight and 
injected with Trans35S (t=-30 min) and Triton WR1339 (t=0) and blood samples were drawn at the indicated 
time points. TG concentrations were determined in plasma of E3L mice (open circles) and E3L.LIKK mice 
(closed circles), and plotted as the increase in plasma TG relative to t=0 (A). The rate of TG production was 
calculated from the slopes of the curves from the individual mice (B). After 120 min, VLDL was isolated 
by ultracentrifugation, 35S-activity was counted, and the production rate of newly synthesized VLDL-35S-
apoB was determined (C). Values are means ± SD (n=5-8). *P<0.05.
LIKK does not affect liver lipid levels
To investigate whether the increase in hepatic VLDL-TG production was the result of increased lipid 
substrate availability in the liver, the effect of LIKK on the hepatic lipid content was investigated 
(Fig. 5). However, E3L and E3L.LIKK mice did not differ with respect to liver TG levels (Fig. 5A) and 
TC levels (Fig. 5B). LIKK did not influence the FA composition of hepatic TG, apart from a mild 
increase in the relative abundance of linoleic acid (18:2 n-6) by +19% (P<0.05) (Suppl. Fig. S1).
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Fig. 6. LIKK increases TG secretion in hepatocytes from E3L mice. Hepatocytes were isolated from E3L 
(open circles) and E3L.LIKK mice (closed circles), cultured overnight, and incubated without or with 
oleate complexed with bovine serum albumin. [3H]Glycerol was added to quantify newly synthesized 
triacylglycerols. Medium was collected at the indicated time points, [3H]TG was measured and expressed 
as dpm per mg cell protein. Values are means ± SD of 3-6 mice per group, in vitro experiments were 
performed in triplicate (n=3-6). *P<0.05.
Fig. 5. LIKK does not affect liver lipid content in E3L mice. Livers were obtained from overnight fasted 
E3L and E3L.LIKK mice and lipids were extracted. Triglycerides (TG, A) and total cholesterol (TC, B) 
concentrations were measured and expressed per mg protein. Values are means ± SD (n=5-7). *P<0.05.
LIKK directly increases TG secretion in hepatocytes from E3L mice
To evaluate whether IKKß overexpression in hepatocytes directly increases VLDL-TG 
production, we next studied TG secretion from isolated hepatocytes of E3L and E3L.LIKK mice 
in vitro. We used [3H]glycerol as precursor for TG synthesis, by measuring the accumulation of 
[3H]TG in the medium (Fig. 6). In the absence of oleate, the [3H]TG secretion was low, but LIKK 
significantly increased the [3H]TG secretion after 20 h of incubation as compared to the [3H]TG 
secretion from control E3L hepatocytes (2.3-fold; P<0.05) (Fig. 6A). In the presence of oleate, 
as a substrate for TG synthesis, [3H]TG secretion was markedly increased, and LIKK caused an 
additional increase in [3H]TG secretion, reaching significance after 20 h of incubation (1.9-fold 
at 20 h; P<0.05) (Fig. 6B).
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LIKK increases hepatic expression of fatty acid synthase, but does not affect protein 
levels or expression of genes involved in VLDL production
To obtain further insight into the mechanism underlying the effects of IKKß overexpression on 
VLDL-TG production, we evaluated the hepatic expression of genes involved in VLDL secretion, 
lipogenesis, FA oxidation, cholesterol metabolism, bile acid metabolism, lipid droplets and 
Table 1. Effect of LIKK on hepatic expression of genes involved in lipid metabolism in E3L mice. 
Gene Protein E3L E3L.LIKK Change
VLDL secretion
ApoB ApoB 1.00 ± 0.35 1.01 ± 0.34 n.s.
Mttp MTP 1.00 ± 0.46 1.34 ± 0.36 n.s.
Lipogenesis
Srebp-1c SREBP1c 1.00 ± 0.39 1.10 ± 0.74 n.s.
Dgat1 DGAT1 1.00 ± 0.32 1.21 ± 0.41 n.s.
Fas FAS 1.00 ± 0.52 2.43 ± 1.07** +143%
FA oxidation
Acox1 ACO 1.00 ± 0.70 1.13 ± 0.20 n.s.
Cpt1a CPT1a 1.00 ± 0.58 0.95 ± 023 n.s.
Glucose metabolism
Pklr L-PK 1.00 ± 0.48 1.72 ± 0.80* +72%
Cholesterol metabolism
Abcg5 ABCG5 1.00 ± 0.22 1.05 ± 0.31 n.s.
Abcg8 ABCG6 1.00 ± 0.16 0.93 ± 0.16 n.s.
Hmgcr HMG-CoA 1.00 ± 0.19 0.98 ± 0.08 n.s.
Bile acid metabolism
Cyp7a1 CYP7A1 1.00 ± 0.59 1.19 ± 0.55 n.s.
Cyp8b1 CYP8B1 1.00 ± 0.60 1.21 ± 0.27 n.s.
Cyp27a1 CYP27A1 1.00 ± 0.41 1.85 ± 0.51** +85%
Lipid droplets
Plin2 PLIN2/ADRP 1.00 ± 0.98 1.04 ± 0.33 n.s.
Plin5 PLIN5/PAT-1 1.00 ± 0.72 1.64 ± 0.55* +64%
Cidec CIDE-3/FSP27 1.00 ± 0.98 1.05 ± 0.42 n.s.
Cidea CIDEA 1.00 ± 0.65 0.85 ± 0.59 n.s.
Transcription factors
Ppara PPARα 1.00 ± 0.28 0.89 ± 0.16 n.s.
Ppargc1b PGC-1β 1.00 ± 0.63 0.77 ± 0.26 n.s.
Nr1h3 LXRα 1.00 ± 0.35 1.09 ± 0.09 n.s.
Nr1h4 FXR 1.00 ± 0.50 1.58 ± 0.43* +58%
Livers were isolated from overnight fasted E3L and E3L.LIKK mice. mRNA was isolated and mRNA expression of the 
indicated genes was quantified by RT-PCR. Data are calculated as fold difference as compared to the control group. 
Values are means ± SD (n=8). *P<0.05 and **P<0.01 compared to the control group. n.s., not significant. Abcg5, ATP-
binding cassette sub-family G member 5 ; Abcg8, ATP-binding cassette sub-family G member 8; Acox1, acyl-coenzyme 
A oxidase  1; ApoB, apolipoprotein B; Cidea, cell death activator CIDE-A; Cidec, fat-specific protein FSP27; Cpt1a, 
carnitine palmitoyltransferase 1a; Cyp27a1, cholesterol 27 hydroxylase; Cyp7a1, cholesterol 7 alpha hydroxylase; Cyp8b1, 
sterol 12 alpha-hydrolase; Dgat1, diglyceride acyltransferase 1; Fas, fatty acid synthase; Hmgcr, HMG-CoA reductase; 
Mttp, microsomal triglyceride transfer protein; Nr1h3, liver X receptor alpha; Nr1h4, farnesoid X activated receptor; 
Pklr, liver-type pyruvate kinase; Plin2, perilipin 2; Plin5, perilipin 5; Ppara, peroxisome proliferator activated receptor 
alpha; Ppargc1b, PPAR-gamma coactivator 1-beta; Srebp-1c, sterol-regulatory element binding protein.
Chapter 2
44
nuclear receptors in livers of E3L and E3L.LIKK mice (Table 1). Even though LIKK induced an 
increase of VLDL-TG production in vivo and in vitro, LIKK did not affect hepatic gene expression 
or protein level (Suppl. Fig. S2A,B) of microsomal TG transfer protein (Mttp), which is involved 
in the assembly and secretion of VLDL. In addition, LIKK did not affect apoB (ApoB) expression, 
in line with the observation that LIKK did not increase VLDL-apoB secretion in vivo. Also, LIKK 
did not affect expression of sterol regulatory element binding protein 1c (Srebp-1c), which 
regulates genes required for de novo lipogenesis, nor did it affect expression or protein levels 
(Suppl. Fig. S2A,C) of acyl:diacylglycerol transferase 1 (Dgat1), which catalyzes the final and only 
committed step in TG synthesis. 
In addition, LIKK did not largely affect clusters of genes involved in FA oxidation (acyl-
coenzyme A oxidase 1 (Acox1) and carnitine palmitoyltransferase 1a (Cpt1a), cholesterol 
metabolism (ATP-binding cassette sub-family G member 5 (Abcg5), ATP-binding cassette 
sub-family G member 8 (Abcg8) and HMG-CoA reductase (Hmgcr) or bile acid metabolism 
(cholesterol 7 alpha hydroxylase (Cyp7a1) and sterol 12 alpha-hydrolase (Cyp8b1)), apart from 
a 1.9-fold increase in cholesterol 27 hydroxylase (Cyp27a1) expression. Additionally, LIKK did 
not affect clusters of genes involved in lipid droplet formation (perilipin 2 (Plin2), fat-specific 
protein FSP27 (Cidec) and cell death activator CIDE-A (Cidea)),or expression of nuclear 
receptors (peroxisome proliferator activated receptor alpha (Ppara), PPAR-gamma coactivator 
1-beta (Ppargc1) and liver X receptor alpha (Nr1h3)), apart from a 1.6-fold increase in expression 
of perilipin 5 (Plin5) and farnesoid X activated receptor (Nr1h4) respectively. 
However, LIKK did increase expression of FA synthase (Fas), which plays a key role in FA 
synthesis, by 2.4-fold, and of liver-type pyruvate kinase (Pklr) by 1.7-fold, both of which are 
target genes of ChREBP. Taken together, these data suggest that LIKK increases VLDL-TG 
production by ChREBP-mediated upregulation of Fas expression, suggesting an increase in de 
novo lipogenesis.
Discussion
Obesity leads to an increase in inflammatory processes in numerous organs including the liver.18 
In the current study, we questioned whether increased activation of inflammatory pathways 
in the liver, specifically in hepatocytes, induces hypertriglyceridemia. Indeed, we show that 
chronic activation of the inflammatory NF-κB pathway specifically in hepatocytes increases 
plasma TG, which was caused by an increased VLDL-TG production rather than a decreased 
clearance of VLDL-TG. Furthermore, we provide evidence that the increased TG production 
induced by hepatocyte-specific IKKβ overexpression is a direct effect of the transgene 
expression in the hepatocyte.
The strong relation between inflammation and hypertriglyceridemia has largely been 
derived from the observed increase in plasma TG during acute infection, which is believed to 
contribute to the host defense.19 However, although similar inflammatory pathways are involved, 
metabolic inflammation is clearly different from acute inflammation with respect to its cause, 
intensity and duration. The inflammation that is observed in obesity, is a chronic and low-grade 
inflammation that is caused by a metabolic overload, rather than a pathogen.20 The NF-κB 
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activity in the liver of E3L.LIKK mice in this study is about 1.5-fold higher compared to control E3L 
mice, which is similar to hepatic NF-κB activation levels seen after HFD feeding and in obesity.1 
The present study shows that this low-grade activation of hepatocyte-specific IKKβ induces 
an increase in plasma TG levels in E3L mice, a model for human-like lipoprotein metabolism, 
which was due to an increase in plasma VLDL-TG levels. Additional investigation of VLDL-TG 
metabolism revealed that the increased VLDL-TG levels were not caused by decreased clearance 
of TG from VLDL-like particles, but rather by increased hepatic production of VLDL-TG. These 
findings are in line with a study showing that injection of a low dose of LPS increases secretion 
of VLDL-TG, without affecting its clearance.5 However, LPS associates with macrophages rather 
than with hepatocytes,21 which hampers interpretation which cell type is primarily responsible 
for the increase in VLDL-TG secretion. In addition to LPS, individual cytokines, that activate 
various cell types, increase VLDL-TG production.3,22 Since both LPS and cytokines can activate 
NF-κB signaling, our findings could suggest that the increase in VLDL secretion caused by LPS 
and cytokines in these earlier studies has been mediated, at least in part, via direct or indirect 
activation of NF-κB in the hepatocytes. In the present study, even though LIKK clearly increased 
VLDL-TG secretion, there were no significant effects of LIKK on apoB production or hepatic 
ApoB gene expression. This suggests that NF-κB activation increases the intracellular lipidation 
of apoB, but not the number of VLDL-particles secreted. This is in contrast with a study of Tsai 
et al.,23 showing that adenoviral-mediated overexpression of IKK did increase apoB secretion in 
HepG2 cells. This discrepancy could possibly be explained by the level of IKK overexpression, 
which was higher with adenoviral-mediated IKK overexpression in their in vitro HepG2 model 
than with transgenic overexpression in our in vivo study. It is thus reasonable to postulate that 
low-grade NF-κB activity mainly increases lipidation of the VLDL particles, whereas a higher 
degree of NF-κB activation could in addition increase the number of secreted VLDL-particles.
It is interesting to speculate about the mechanism why hepatocyte-specific NF-κB activation 
increases VLDL-TG secretion, as many different factors could theoretically be involved. For 
example, IKKβ overexpression can cause insulin resistance,1 which could result in an inability of 
insulin to suppress VLDL-TG production.24 Furthermore, Kupffer cells have been suggested to 
play an important role in hepatic lipid metabolism.25 Additionally, Kupffer cell products could 
possibly suppress lipid oxidation in hepatocytes via NF-κB mediated suppression of PPARα 
activity.26 Furthermore, although plasma FFA levels were unaltered by LIKK, liver-directed 
FA flux may have been influenced, resulting in altered substrate availability for VLDL-TG 
production. Therefore, to evaluate the effect of IKKβ overexpression in hepatocytes on 
VLDL-TG production in absence of these potentially confounding factors, we studied the effect 
of IKKβ in hepatocytes on TG production in vitro. In fact, IKKβ expression in hepatocytes per se 
appeared to directly increase VLDL-TG production. Although additional factors may contribute 
to the effect of LIKK on VLDL-TG production in vivo, a direct effect of IKKβ overexpression in 
hepatocytes thus at least contributes to this phenomenon.
PPARα, LXR and FXR have shown to be activated during inflammation and interact with 
inflammatory processes27,28 and could possibly underlie the mechanism by which hepatocyte-
specific NF-κB activation increases VLDL-TG secretion directly within the hepatocyte. However, 
no change was observed in expression of hepatic PPARα and LXR or expression of their target 
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genes. NF-κB activation did increase FXR expression, but FXR activation has been linked to 
a lower VLDL-TG secretion,29 making a causal relationship between FXR activation and the 
increase in VLDL-TG secretion unlikely. Apparently, chronic hepatocyte-specific activation 
of NF-κB by IKKβ overexpression does not induce identical changes in lipogenic pathways 
that are seen in acute inflammation, however, it clearly increases VLDL-TG production and 
induces hypertriglyceridemia. Increased hepatic lipid availability, by increased lipogenesis 
and/or decreased lipid oxidation, could also underlie the mechanism by which hepatocyte-
specific NF-κB increases VLDL-TG secretion. Acute inflammation has been shown to increase 
hepatic lipogenesis as measured by incorporation of 3H
2
O into FA in vivo.5,30,31 In our study 
we measured expression of genes involved in hepatic FA oxidation and de novo lipogenesis. 
Despite the fact that LIKK did not decrease the expression of genes involved in FA oxidation, 
LIKK clearly increased expression of Fas, which is a key enzyme in the regulation of FA synthesis. 
Although upregulation of Fas could be mediated by the transcription factors LXR, Srebp-1c 
and ChREBP,32,33 the observed upregulation of Pklr as a main ChREBP target gene suggests that 
LIKK most likely activates ChREBP, thereby increasing Fas expression. The fact that activation 
of NF-κB has been linked to local disturbances in glucose metabolism that could activate 
ChREBP would underscore this observation.1,34,35 It is thus conceivable that increased ChREBP 
mediated Fas expression increases hepatic lipogenesis and thereby increases lipid availability 
for VLDL-TG production.36 In fact, activation of lipogenesis results in large, but not more, VLDL 
particles, which is consistent with our findings.37 The fact that we did not observe an increase 
in the hepatic TG content or FA oxidation that could have been expected by increased Fas 
expression,38 can be explained by efficient incorporation of newly synthesized TG into nascent 
VLDL resulting in the increased hepatic VLDL-TG secretion. 
In conclusion, we show that activation of hepatocyte-specific NF-κB through overexpression 
of IKKß increases TG levels in E3L mice by stimulation of VLDL-TG secretion, directly within the 
hepatocyte, without effects on VLDL-TG clearance. The stimulation of VLDL-TG secretion is not 
driven by increased steatosis or decreased FA oxidation, but most likely by ChREBP mediated 
upregulation of Fas expression.
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Supplemental data
Supplemental Table S1. Primers used for quantatitive real-time PCR analysis. 

























Abcg5, ATP-binding cassette sub-family G member 5 ; Abcg8, ATP-binding cassette sub-family G member 8; Acox1, acyl-
coenzyme A oxidase 1; ApoB, apolipoprotein B; Cidea, cell death activator CIDE-A; Cidec, fat-specific protein FSP27; 
Cpt1a, carnitine palmitoyltransferase 1a; Cyp27a1, cholesterol 27 hydroxylase; Cyp7a1, cholesterol 7 alpha hydroxylase; 
Cyp8b1, sterol 12 alpha-hydrolase; Dgat1, diglyceride acyltransferase 1; Fas, fatty acid synthase; Hmgcr, HMG-CoA 
reductase; Mttp, microsomal triglyceride transfer protein; Nr1h3, liver X receptor alpha; Nr1h4, farnesoid X activated 
receptor; Pklr, liver-type pyruvate kinase; Plin2, perilipin 2; Plin5, perilipin 5; Ppara, peroxisome proliferator activated 
receptor alpha; Ppargc1b, PPAR-gamma coactivator 1-beta; Srebp-1c, sterol-regulatory element binding protein.
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Supplemental Figure S1. Effect of LIKK on fatty acid composition of hepatic triglycerides in 
E3L mice. 
Livers were obtained from overnight fasted E3L and E3L.LIKK mice and lipids were extracted. 
TG were isolated by thin-layer chromatography followed by fatty acid separation and 
quantification using gas chromatography. Fatty acid composition was then determined (in 
mol%). Values are means ± SD (n=5-7). 
Supplemental Fig. S1. Effect of LIKK on fatty acid composition of hepatic triglycerides in E3L mice. Livers 
were obtained from overnight fasted E3L and E3L.LIKK mice and lipids were extracted. TG were isolated by 
thin-layer chromatography followed by fatty acid separation and quantification using gas chromatography. 
Fatty acid composition was then determined (in mol%). Values are means ± SD (n=5-7).
Supplemental Fig. S2. LIKK does not affect hepatic MTP and DGAT1 protein levels. E3L and E3L.LIKK mice 
were fed a chow diet and sacrificed at the age of 14 weeks after an overnight fast. MTP and DGAT1 levels 
were measured in liver tissue by Western blots and actin was used as an internal control. Representative 
Western blots are shown for 3 mice per group (A). Ratios of MTP (B) and DGAT1 (C) proteins over actin 
levels were quantified. Values are means ± SD (n=5-7).
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Abstract
The liver is the key organ involved in systemic inflammation, but the relation between hepatic 
inflammation and atherogenesis is poorly understood. Since nuclear factor-κB (NF-κB) is a 
central regulator of inflammatory processes, we hypothesized that chronically enhanced 
hepatic NF-κB activation, through hepatocyte-specific expression of IκB kinase-β (IKKβ) 
(LIKK), will aggravate atherosclerosis development in APOE*3-Leiden (E3L) mice. E3L.LIKK and 
E3L control littermates were fed a Western-type diet for 24 weeks. E3L.LIKK mice showed a 
2.3-fold increased atherosclerotic lesion area and more advanced atherosclerosis in the aortic 
root with less segments without atherosclerotic lesions (11 vs. 42%), and more segments with 
mild (63% vs. 44%) and severe (26% vs. 14%) lesions. Expression of LIKK did not affect basal 
levels of inflammatory parameters, but plasma cytokine levels tended to be higher in E3L.LIKK 
mice after lipopolysaccharide (LPS) administration. E3L.LIKK mice showed transiently increased 
plasma cholesterol levels, confined to (V)LDL. This transient character resulted in a mild (+17%) 
increased cumulative plasma cholesterol exposure. We conclude that selective activation of 
NF-κB in hepatocytes considerably promotes atherosclerosis development which is (at least 
partly) explained by an increased sensitivity to pro-inflammatory triggers and transiently 




Increased inflammation, in addition to disturbances in lipid metabolism, is the other main 
contributor to the development of atherosclerosis.1 Nuclear factor-κB (NF-κB) has been 
identified as the most important transcription factor in the regulation of inflammatory 
processes during atherosclerosis development.2 In unstimulated cells, NF-κB p65/p50 dimer is 
kept inactive by its inhibitory protein: inhibitor of κB (IκB). A wide range of extracellular stimuli, 
including cytokines, microbial components, and also free fatty acids, induce activation of the 
IκB kinase complex, which consists of two kinases (IKKα and -β) and a regulatory subunit, 
NEMO/IKKγ. This complex mediates the phosphorylation of IκB, resulting in its ubiquitination 
and degradation, leaving the NF-κB dimer free to translocate to the nucleus and activate its 
target genes.2
While general inhibition of the NF-κB pathway by pharmacological agents reduces 
atherosclerosis development in mice,3, 4 the relative contribution of NF-κB may differ at 
cellular- or tissue-specific level. Suppression of the NF-κB pathway in endothelial cells by 
ablation of NEMO/IKKγ has been shown to decrease atherosclerosis development.5 In murine 
bone marrow transplantation models, inhibition of the NF-κB pathway at distinct levels in 
hematopoietic cells can have different outcomes, i.e. deficiency of the NF-κB p50 subunit 
resulted in smaller atherosclerotic lesions,6 whereas deletion of IKKβ increased atherosclerosis 
development.7 Surprisingly, the role of the NF-κB pathway in hepatocytes on atherosclerosis 
development has not been investigated thus far.
The liver plays a central role in both lipid metabolism8 and inflammation.9 Disturbances in 
lipid metabolism and increased inflammation are the two main risk factors for atherogenesis.1 
Hepatocytes form the largest population of cells in the liver and execute most of its important 
functions. During inflammation, acute phase proteins are mainly synthesized by the 
hepatocytes.10 Interestingly, hepatocyte-specific deficiency of gp130, a receptor component 
of IL-6 signaling which signals independent of the NF-κB pathway, decreases atherosclerosis 
in apoe-/- mice,11 suggesting that reduced hepatic inflammation is associated with less 
atherosclerosis development.
Despite ample evidence implicating the involvement of NF-κB in atherogenesis, the 
hepatocyte-specific role of NF-κB in atherosclerosis has not been investigated directly. 
Therefore, in this study we aimed to investigate whether chronic activation of hepatocyte-
specific NF-κB aggravates atherosclerosis development. We used transgenic mice with 
hepatocyte-specific expression of human IKKβ (Liver-specific IKKβ or LIKK mice), resulting 
in an increase of active NF-κB,12 crossbred with atherosclerosis-prone APOE*3-Leiden (E3L) 
mice. E3L mice exhibit a human-like lipoprotein distribution on a cholesterol-rich diet due to 
transgenic expression of a human mutant of the APOE3 gene, and are therefore susceptible to 
atherosclerosis development.13 Collectively, our results show that hepatocyte-specific NF-κB 
activation markedly aggravates atherosclerosis development in E3L mice.
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Methods
Animals and study design
Transgenic LIKK mice expressing constitutively active human IKKβ in the hepatocytes by an 
albumin promoter12 were crossbred with E3L mice14 to generate heterozygous E3L.LIKK and 
control E3L littermates, as described before.15 Mice were housed under standard conditions 
with a 12-hour light/dark cycle and had free access to food and water. Female mice of 10-12 
weeks of age were fed a Western-type diet containing 15% (w/w) cacao butter supplemented 
with 0.25% (w/w) cholesterol (Hope Farms, Woerden, The Netherlands). Food intake and body 
weight were measured weekly. Unless indicated otherwise, blood was drawn every 4 weeks 
after 4 hours of fasting in EDTA-containing tubes by tail bleeding, and plasma was isolated by 
centrifugation. All animal experiments were approved by the Institutional Ethical Committee 
on Animal Care and Experimentation of the Leiden University Medical Center (Leiden, The 
Netherlands).
mRNA expression analysis 
Total RNA from livers of E3L and E3L.LIKK mice was isolated using an RNA isolation kit according 
to manufacturer’s specifications, including a 15 min. DNAse I treatment (Macherey-Nagel, 
Düren, Germany). Quality control of the isolated RNA was checked with the lab-on-a-chip 
technology using Experion Stdsens analysis kit (Bio-Rad, Hercules, CA). One µg of total RNA 
was converted to cDNA with iScript cDNA Synthesis kit (Bio-Rad) and purified with Nucleospin 
Extract II kit (Macherey-Nagel, Düren, Germany). Real time PCR (RT-PCR) was carried out on 
an iQ5 Single-Color real-time PCR detection system (Bio-Rad) using the Sensimix SYBR Green 
RT-PCR mix (Quantace, London, UK). Expression levels were normalized using hypoxanthine-
guanine phosphoribosyl transferase (Hprt), cyclophilin (Cyclo) and glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh). Primer sequences are listed in Supplemental Table 1. 
Western blot analysis
Liver tissue was homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold buffer (pH 





(v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors (Complete, Roche, Mijdrecht, The 
Netherlands) at a 1:6 (w/v) ratio. Homogenates were centrifuged (16,000 rpm; 15 min., 4°C) and 
the protein content of the supernatant was determined using the BCA protein assay kit (Pierce, 
Rockford, IL). Proteins (20-50 µg) were separated by 7-10% SDS-PAGE followed by transfer to a 
polyvinylidene fluoride membrane. Membranes were blocked for 1 hour at room temperature 
in Tris-buffered saline with Tween-20 with 5% non-fat dry milk followed by an overnight 
incubation with either IKKβ (ab32135, Abcam, Cambridge, UK), tubulin, pSer536 NF-κB p65 or 
NF-κB p65 antibodies (#2148, #3031, #3034, resp., Cell Signaling, Danvers, MA). Blots were then 
incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room 
temperature. Bands were visualized by enhanced chemiluminescence and quantified using 




Plasma levels of serum amyloid A (SAA) were determined using the murine Phase Serum Amyloid 
A Assay kit (Tridelta, County Kildare, Ireland) according to manufacturer’s instructions. Plasma 
levels of inflammatory cytokines and chemokines (IFNγ, IL-12 p70, IL-1β, IL-6, TNFα and IL-10) 
were measured using a multiplex murine inflammatory cytokine profile immunoassay from 
Meso Scale Discovery (MSD) on a MSD 2400 plate reader according to the manufacturer’s 
protocol (MSD, Gaithersburg, MD). 
Lipopolysaccharide stimulation
Mice were injected i.v. with Salmonella minnesota Re595 lipopolysaccharide (LPS) (Sigma-
Aldrich, St. Louis, MO) (50 mg/kg body weight). Blood was collected 90 min. after injection in 
heparin-coated capillaries. Plasma was assayed for cytokines as described above.
FACS staining of leukocyte subpopulations in peripheral blood
Nonfasted, whole blood was drawn in EDTA-containing tubes by tail bleeding and incubated 
with antibodies against Ly6C-FITC (kindly provided by dr P.J. Leenen, Erasmus University, 
Rotterdam, The Netherlands), Ly6G-PE, CD115-biotin and CD11b-APC (all from Pharmingen, 
Alphen a/d Rijn, The Netherlands). In between all steps, cells were washed with PBS containing 
1% BSA and 0.05% Na-azide.
Binding of anti-CD115-biotin was detected with streptavidin conjugated with PerCP-Cy5.5 
(Pharmingen, Alphen a/d Rijn, The Netherlands). Red blood cells were lysed with shock-buffer, 
cells were fixed with 1% paraformaldehyde and measured with an LSRII (Becton Dickinson, 
Erembodegem, Belgium).
To obtain leukocyte profiles, the following gating strategy was applied: debris was gated 
out in a forward (FSC)/side scatter (SSC) plot and leukocytes minus debris were divided 
according to their CD11b expression (myeloid lineage: CD11b-pos; lymphoid lineage: CD11b-
neg). CD11b-pos cells were then selected and using Ly6G expression and SSC, cells were divided 
in neutrophilic granulocytes (Ly6G-hi/SSC-hi), eosinophilic granulocytes (Ly6G-neg/SSC-hi) 
and a non-granulocyte population (Ly6G-neg/SSC-low). The non-granulocyte population was 
then selected and using their CD11b and CD115 expression, monocytes (CD11b-pos/CD115-pos) 
and NK cells (CD11b-med/CD115-neg) were identified. Next, the monocyte population was 
selected and using Ly6C expression and FSC, classical monocytes (Ly6C-hi/FSC-low), non-
classical monocytes (Ly6C-low/FSC-low) and intermediate monocytes (Ly6C-med/FSC-low) 
were identified. Going back to the lymphoid lineage (CD11b-neg cell population), using Ly6C-
expression, lymphocytes (Ly6C-low/FSC-low) and lymphoblasts (Ly6-ly6C-med/FSC-hi) were 
identified.
Plasma lipids, lipoprotein profile, hepatic VLDL-TG production and liver lipids analysis
Plasma total cholesterol (TC), triglycerides (TG) and phospholipids (PL) levels were determined 
using enzymatic kits from Roche Molecular Biochemicals (Woerden, The Netherlands) 
according to the manufacturer’s protocols. We used the following formula to calculate the 
cumulative plasma TC levels over 24 weeks of Western-type diet feeding which equals the area 
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). The correlation between cumulative plasma TC level and 
atherosclerotic lesion area was assessed for both E3L and E3L.LIKK mice. For the determination 
of lipid distribution over plasma lipoproteins, pooled plasma per group was size-fractionated 
using an ÄKTA fast performance liquid chromatography (FPLC) system (Pharmacia, Roosendaal, 
The Netherlands). Each sample was injected onto a Superose 6 HR3.2/30 column and eluted at 
a constant flow rate of 50 µL/min in PBS, pH 7.4. Fractions of 50 µL were collected and assayed 
for TC as described above. 
Mice were fasted for 4 hours prior to the start of the  hepatic VLDL-TG production 
experiment, and, subsequently, sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/kg 
midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag). At timepoint zero, blood was 
taken via tail bleeding and mice were i.v. injected with 100 µL PBS containing 100 µCi Trans35S 
label to measure de novo total apolipoprotein B (apoB) synthesis. After 30 min., the animals 
received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body weight as a 10% 
(w/w) solution in sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-
TG.16 Additional blood samples were taken at regular timepoints after tyloxapol injection and 
used for determination of plasma TG concentration. At timepoint 120 min., the animals were 
sacrificed and blood was collected by orbital puncture for isolation of VLDL by density gradient 
ultracentrifugation.17 35S-labeled total apoB content was measured in the VLDL fraction after 
precipitation with isopropanol.18
Lipids from liver tissue were extracted according to a protocol adapted from Bligh and 
Dyer.19 Hepatic TG, PL concentrations were determined using the enzymatic kits as described 
previously. TC, free cholesterol (FC) and cholesteryl ester (CE) content were assessed with 
a cholesterol/cholesteryl ester quantitation enzymatic kit according to manufacturer’s 
specifications (Biovision Research Products, Mountain View, CA). Liver lipids were expressed 
per mg protein, which was measured using the BCA protein assay kit (Pierce, Rockford, IL). 
Atherosclerosis quantification
Mice were euthanized by carbon dioxide inhalation after 24 weeks of diet. Hearts were isolated 
and fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin, and were cross-
sectioned (5 µm) throughout the entire aortic root area. Of each mouse, 4 sections with 50-µm 
intervals were used for quantification of atherosclerotic lesion area. Characterization of lesion 
severity was performed separately in each of the 3 segments between the aortic valves in the 
4 sections.20
Sections were stained with hematoxylin-phloxine-saffron (HPS). Atherosclerotic lesions 
were categorized for severity by one blinded observer, according to the guidelines of the 
American Heart Association, adapted for mice. Various types of lesions were distinguished: 
type 0 (no lesions) (Supplemental Fig. 8A), type I to III (early fatty streak-like lesions containing 
foam cells) (Supplemental Fig. 8B-D), and type IV to V (advanced lesions containing foam 
cells in the media, presence of fibrosis, cholesterol clefts, mineralization, and/or necrosis) 
(Supplemental Fig. 8E-F). 
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Immunohistochemistry for determination of adhering monocytes and macrophage-, and 
smooth muscle cell content in the lesions was performed as described previously.21, 22 The sections 
were incubated overnight with antibody M18 (1:100, Santa Cruz Biotechnology, Santa Cruz, Calif) 
and, subsequently, with biotinylated rabbit anti-goat conjugate (1:400, Brunschwig chemie, 
Amsterdam, The Netherlands) for quantification of MCP-1. AIA 31240 rabbit antiserum (1:1000, 
Accurate Chemical and Scientific, Westbury, NY) in combination with biotinylated donkey 
anti-rabbit conjugate (1:3000, Amersham Pharmacia Biotech) were used for quantification of 
both the number of monocytes adhering to the endothelium as well as the macrophage area. 
Antibody M0851 (1:800, Dako, Carpinteria, CA) and biotinylated horse anti-mouse conjugate 
(1:400, Vector Laboratories, Burlingame, CA) were used to quantify smooth muscle actin. 
Immunostaining was amplified using Vector Laboratories Elite ABC kit (Vector Laboratories, 
Burlingame, CA) and the immunoperoxidase complex was visualized with Nova Red (Vector 
Laboratories, Burlingame, CA). Counterstaining was performed with Mayer’s hematoxylin. Sirius 
red was used to stain for collagen in the lesions (Chroma, Stuttgart, Germany).
Total lesion size, MCP-1-, macrophage-, smooth muscle cell-, and collagen content were 
quantified using Cell^D image analysis software (Olympus Soft Imaging Solutions, Münster, 
Germany).
Statistical analysis
Data are presented as means ±SEM. SPSS 17.0 for Windows (SPSS, Chicago, Ill) was used for 
statistical analysis. Statistical differences were assessed with the Mann-Whitney U test. For 
lesion typing, differences were determined by the χ2 test. To assess the correlation between 
cumulative cholesterol exposure and atherosclerotic lesion area, the Pearson correlation test 
was performed after log transformation of the atherosclerotic lesion area. Differences at P<0.05 
were regarded as statistically significant. 
Results
LIKK causes low-grade inflammation 
The overall appearance of E3L and E3L.LIKK mice during the study was similar. To assess whether 
expression of LIKK affects body weight gain, we measured food intake and body weight weekly. 
Both were not different between E3L.LIKK and E3L control mice (Supplemental Fig. 1A-B). 
The liver- and spleen weight and histological morphology of the liver were also comparable 
between E3L.LIKK and E3L mice (data not shown). To gain more insight in the effects of LIKK on 
inflammation, we determined whether LIKK expression increased the inflammatory state of the 
liver and systemic inflammatory markers in E3L.LIKK mice on a Western-type diet. We confirmed 
previous findings15 showing that the enhanced expression of hepatocyte-specific human IKKβ 
(Supplemental Fig. 2A) resulted in a 1.4-fold increased hepatic NF-κB activation, as shown by an 
increase in the phosphorylated p65 subunit (pNF-κBSer536) (Supplemental Fig. 2B). IKKβ kinase 
phosphorylates subunit p65 of NF-κB at the position Ser536, which activates the transcriptional 
activity of NF-κB.23 The transgenic expression of human IKKβ mRNA was present only in E3L.LIKK 
mice and did not alter murine IKKβ mRNA expression (Supplemental Fig. 2C-D). The enhanced 
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Fig. 1. LIKK does not increase plasma SAA levels. SAA levels were determined in plasma from E3L.LIKK 
(black bars) and E3L (white bars) mice fed a Western-type diet for 0, 8 and 24 weeks. Values are means 
±SEM; n=15/group; **P<0.01.
hepatic NF-κB activation in E3L.LIKK mice did not result in increased IL-6 expression in whole 
liver, but did result in a tendency towards increased IL-1β expression (P=0.085) and a significant 
increase in MCP-1 expression (Supplemental Table 2).
To evaluate whether the increased hepatocyte-specific NF-κB activation in E3L.LIKK mice 
enhanced the systemic inflammatory state, we determined the plasma inflammation marker 
SAA and plasma cytokines under basal conditions. LIKK expression did not affect SAA before 
(3.1 ±0.17 vs. 3.4 ±0.15 µg/mL) and after 8 weeks (4.4 ±0.28 vs. 4.2 ±0.31 µg/mL) and 24 weeks (4.9 
±0.51 vs. 5.4 ±0.78 µg/mL) of Western-type diet feeding (Fig. 1), and neither the determined 
plasma cytokine levels (Supplemental Fig. 3A-F). SAA levels increased with Western-type diet 
feeding in both E3L and E3L.LIKK mice, but this difference only reached statistical significance 
in E3L.LIKK mice (Fig. 1).
Since we did not observe a clear increased systemic pro-inflammatory state under basal 
conditions, we challenged the mice with LPS to boost the inflammatory response. Interestingly, 
after injection of LPS, pro-inflammatory cytokines (e.g. IL-1β, IFNγ) showed a tendency 
towards increased plasma levels in E3L.LIKK mice as compared to E3L mice (Fig. 2A-F). The anti-
inflammatory IL-10:IL-1β ratio was significantly lower in E3L.LIKK mice (Fig. 2G). Overall, these 
data indicate that E3L.LIKK mice are more sensitive to pro-inflammatory triggers compared to 
their E3L littermates.
To study whether this chronic low-grade inflammation in E3L.LIKK mice also resulted in 
increased inflammatory cell counts in liver and plasma, we determined the hepatic mRNA 
expression of various cell-type markers of inflammatory cells present in the liver, which are 
likely to influence atherogenesis,24 and the number of circulating monocytes. Hepatic mRNA 
expression of CD68 (Kupffer cells), CD3 ((NK)T cells), and Vα14 (NKT cells) were not different 
between the genotypes (Supplemental Table 2), neither were the total number of circulating 
monocytes, the pro-inflammatory Ly6C-hi  monocyte subset, the intermediate Ly6C-med 
monocyte subset and the less inflammatory Ly6C-lo monocyte subset (Supplemental Fig. 4A-D). 
Together, the above findings indicate that the enhanced hepatocyte-specific NF-κB activation 
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Fig. 2. LIKK tends to enhance plasma cytokines after LPS stimulation. LPS was injected intravenously in 
E3L.LIKK (black bars) and E3L (white bars) mice. Cytokine levels were measured 90 minutes after LPS 
injection (A-F). The IL-10:IL-1β ratio was calculated (G). Values are means ±SEM; n=7/group; *P<0.05.
in E3L.LIKK mice results in a tendency towards a mildly enhanced hepatic pro-inflammatory 
state and an elevated sensitivity to pro-inflammatory stimuli as compared to E3L littermates. 
LIKK transiently enhances VLDL cholesterol levels
To assess the effect of hepatocyte-specific NF-κB activation on plasma lipid levels, TC, TG and 
PL concentrations were determined every 4 weeks in E3L.LIKK and E3L mice. LIKK expression 
caused a transient increase of plasma TC levels only at 8 weeks (+50%; P<0.0001) and 12 weeks 
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Fig. 3. LIKK transiently increases (V)LDL. Plasma cholesterol levels of E3L.LIKK (black symbols) and E3L 
(white symbols) mice fed a Western-type diet were assessed (A), and cumulative total cholesterol exposure 
was calculated (B). Lipoprotein profiles were determined at 8 (left) and 16 (right) weeks (C). Values are 
means ±SEM; n=15/group; *P<0.05, **P<0.01, ****P<0.0001.
(+28%; P<0.05) of Western-type diet feeding (Fig. 3A). Accordingly, the cumulative total 
cholesterol exposure was higher in E3L.LIKK than in E3L mice (+17%; P<0.05; Fig. 3B). A similar 
transient increase was found for plasma TG and PL levels (Supplemental Fig. 5A-B).
To determine which lipoproteins contribute to the transient elevated plasma TC levels, 
lipoproteins were size-fractionated by FPLC, and cholesterol was measured in the individual 
fractions. The transient increase in plasma TC levels at 8 weeks of Western-type diet feeding in 
E3L.LIKK mice was confined to (V)LDL, whereas at 16 weeks the lipoprotein distribution in the 
E3L.LIKK mice was similar to that of the E3L mice, in line with the plasma lipid levels (Fig. 3C). 
Consistent with our previous finding that expression of LIKK increased the VLDL production in 
male mice on chow diet,15 we found that expression of LIKK increased, albeit not significantly, 
the VLDL-TG production rate  (+24%) (Supplemental Fig. 6A), and tended to increase the VLDL-
apolipoprotein B (apoB) production rate (+33%) (Supplemental Fig. 6B). No differences were 
observed in the liver lipid content between E3L.LIKK and E3L mice (Supplemental Fig. 7A-E). 
Taken together, these findings indicate that hepatocyte-specific NF-κB activation results in a 
modest and transient increase in plasma lipid levels in E3L mice. 
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Fig. 4. LIKK aggravates atherosclerotic lesion area and severity. After 24 weeks of Western-type diet 
feeding, E3L.LIKK (black bars) and E3L (white bars) mice were sacrificed and cross-sections of aortic roots 
were stained with HPS. Representative pictures are shown. Arrows indicate lesions (A). Total lesion area 
was assessed in 4 sections of the aortic root (B) and lesion severity was determined separately in each 
of the 3 segments between the aortic valves of the 4 sections (C). Statistical analysis for lesion area was 
performed using the Mann-Whitney U test, and for lesion severity the χ2 test. Values are means ±SEM; 
n=15/group; *P<0.05, ***P<0.001.
LIKK enhances atherosclerosis development
To investigate the effect of LIKK expression on atherosclerosis development, E3L.LIKK and E3L 
mice were sacrificed after 24 weeks of Western-type diet feeding, and lesion size and severity 
were measured in the aortic root. Representative pictures of both groups are shown in Fig. 4A. 
E3L.LIKK mice developed more than 2-fold larger atherosclerotic lesions (+131%; P<0.05; Fig. 4B) 
as compared to their E3L littermates. This increased lesion area coincided with more advanced 
lesion progression, since we found markedly fewer segments without atherosclerotic lesions 
(11% vs. 42%; P<0.001) and more segments with mild (63% vs. 44%; P<0.001) and severe lesions 
(26% vs. 14%; P<0.001) as compared to E3L mice (Fig. 4C). Examples of mild and severe lesions 
are shown in Supplemental Figure 8. These data indicate that chronic hepatocyte-specific 
NF-κB activation severely augments atherosclerosis development in E3L mice. 
LIKK aggravates atherosclerotic lesion composition
We next evaluated whether LIKK expression would affect monocyte adherence and recruitment 
to the vascular wall, as well as the composition of the atherosclerotic lesions with respect to the 
macrophage, smooth muscle cell, and collagen content of the lesions. Adherence of monocytes 
to the vessel wall and the content of the chemokine monocyte chemoattractant protein-1 
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Fig. 5. LIKK induces more advanced atherosclerotic lesions. In the sections obtained as described in 
Fig. 4, the number of adhering monocytes (A), monocyte chemoattractant protein-1 (MCP-1) content (B), 
macrophage content (C), smooth muscle content (D) and collagen content (E) was determined. Values are 
means ±SEM; n=15/group; *P<0.05, **P<0.01.
(MCP-1) of the atherosclerotic lesions were not significantly enhanced in E3L.LIKK mice as 
compared to E3L mice (Fig. 5A-B). LIKK expression did not affect the relative macrophage and 
collagen content of the lesions (Fig. 5C+E), but did result in an increased smooth muscle cell 
content of the lesions (+79%, P<0.05; Fig. 5D).
Aggravated atherosclerosis development in E3L.LIKK mice does not solely depend on 
the transient increase in plasma cholesterol levels
In E3L mice on Western-type diet, the cumulative plasma cholesterol exposure is highly predictive 
for the atherosclerotic lesion area (unpublished data, J.F.P. Berbée, P.C.N. Rensen). To verify if 
the transient increase in plasma TC levels (Fig. 3) alone could account for the aggravation in 
atherosclerosis development observed in E3L.LIKK mice, or whether additional mechanism(s) 
could contribute, including the low-grade systemic inflammation, we assessed the correlation 
between the cumulative plasma total cholesterol exposure and the atherosclerotic lesion area of 
the E3L.LIKK and E3L mice. As expected, there was a significant positive logarithmic correlation 
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between the atherosclerotic lesion area and the cumulative plasma cholesterol exposure in the 
control E3L mice (Supplemental Fig. 9A; r2=0.757, P=0.002). However, we did not observe such 
a correlation in the E3L.LIKK mice (Supplemental Fig. 9B; r2=-0.250, P=0.369), indicating that in 
addition to the transient increase in plasma TC levels in E3L.LIKK mice, additional mechanism(s), 
most likely the increased sensitivity to pro-inflammatory stimuli, contributed to the aggravated 
atherosclerosis development in these mice.
Discussion
NF-κB is regarded as a potential therapeutic target in atherosclerosis3, 4 and studying tissue- and 
cell-specific effects of NF-κB in atherogenesis will expand our knowledge in the comprehensive 
actions of NF-κB on atherosclerosis development. The present study demonstrates for the first 
time that chronic, hepatocyte-specific expression of IKKβ (LIKK) and subsequent activation of 
NF-κB aggravates atherosclerosis development in E3L mice. In addition, the atherosclerotic 
lesion composition with respect to the macrophage and collagen content was not affected by 
LIKK, but in line with the presence of more advanced lesions, the smooth muscle cell content 
was increased. Expression of LIKK resulted in transiently increased plasma cholesterol levels and 
an enhanced sensitivity to pro-inflammatory triggers, which both are likely to have contributed 
to the increased atherosclerotic lesion size and severity. Since lesion size and severity are often 
correlated in atherosclerosis studies with different murine models,13,  25 the increased lesion 
severity in E3L.LIKK mice is likely to be mainly attributed to the larger size of the lesions. 
Expression of LIKK in E3L mice increased the activation of the NF-κB pathway in the liver, 
in line with our previous report.15 In addition, hepatic mRNA expression of inflammatory 
parameters was increased or tended to be increased in E3L.LIKK mice, indicating that 
inflammatory mediators at local tissue level were enhanced in E3L.LIKK mice. This enhanced 
activation of hepatocyte-specific NF-κB in E3L.LIKK mice, however, did not result in a significant 
increased systemic pro-inflammatory state under basal conditions as compared to their E3L 
littermates. Importantly, Cai et al.12 demonstrated that in LIKK mice on a wild-type background, 
systemic levels of IL-6 were only mildly elevated, while IL-1β and TNFα levels were similar as 
in wild-type mice. Our results show that LIKK expression on an E3L background resulted in a 
less pronounced hepatic inflammatory state as compared to LIKK expression on a wild-type 
background as described by Cai et al.,12 as reflected in a smaller increase in active NF-κB (1.4- vs. 
2.2-fold) and mRNA levels of pro-inflammatory cytokines levels in the liver. Furthermore, under 
basal conditions E3L mice have lower levels of active NF-κB present in the liver as compared to 
wild-type mice (unpublished data, J.A. van Diepen, M.C. Wong, P.J. Voshol). This implies that 
E3L mice have a lower chronic inflammatory state than wild-type mice, which could interfere 
with the pro-inflammatory effects caused by expression of LIKK in the present study. Also, in 
comparison with other murine atherosclerosis models, e.g. the apoe-/- and ldlr-/- mice, E3L mice 
display a milder phenotype with respect to hyperlipidemia and increased inflammation.26, 27 In 
the current study, basal circulating levels of some cytokines were at borderline of the detection 
limit of current assays (Supplemental Fig. 3) and, as expected, the cytokine levels increased 
approximately 5- to 3700-fold after LPS injection (Fig. 2). Furthermore, after stimulation with 
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LPS, E3L.LIKK mice showed a tendency towards a higher systemic inflammatory state than E3L 
mice.
There is a strong interaction between inflammation and lipid metabolism.28 For example, 
lowering inflammation using salicylate did not only reduced NF-κB activation, but concomitantly 
also reduced circulating cholesterol levels in E3L mice.29 In line with this observation, in the 
present study we found higher plasma lipid levels at 8 weeks of Western-type diet feeding in 
female E3L.LIKK compared to E3L mice, which were confined to (V)LDL. We hypothesize that the 
increased lipid levels at this time point are accompanied by increased systemic inflammation, 
which is in line with previous findings showing that  lipid metabolism and inflammation strongly 
influence each other.28 A possible cause for the increased plasma lipid levels at 8 weeks of diet 
is therefore a more enhanced inflammation in the liver, possibly due to an increased activation 
of the NF-κB pathway in the liver.  
We recently reported that male E3L.LIKK mice on chow diet also showed enhanced (V)LDL 
levels as a result of an increased hepatic VLDL-TG production rate,15 and found in the current 
study a trend towards an enhanced VLDL-apoB production in female E3L.LIKK mice on Western-
type diet, with a similar effect-size. Possible reasons for the less apparent increase of VLDL-TG 
production in females compared to males are differences in gender and/or diet. Although the 
increase in VLDL-TG production is more apparent in male E3L.LIKK mice, we used female mice 
in the present study. The main reason for this is that female E3L mice are more susceptible 
to develop atherosclerosis. In order for male E3L mice to become similarly atherosclerosis-
prone they need to be fed Western-type diets not only with higher percentages of cholesterol, 
but also containing cholate. In addition, fructose was added to the drinking water to further 
raise their (V)LDL-cholesterol levels.30 The increase in (V)LDL levels in females in the current 
study was only transient at 8 weeks of Western-type diet feeding and disappeared at 16 weeks. 
Since no differences in plasma lipid levels and hepatic mRNA expression of genes involved 
in lipid metabolism were detected between both groups at 24 weeks of diet, the increased 
VLDL-TG production at 8 weeks of diet is likely to be transient. At present, we cannot explain 
the transient nature of this increase in (V)LDL levels, but it may be the result of a progressive 
negative feedback mechanism to reduce the hepatic VLDL production which takes place during 
long-term Western-type diet feeding. 
Dyslipidemia is regarded as the classical risk factor for atherosclerosis development. The 
transiently enhanced total cholesterol levels, resulting in a modest increase (+17%) in cumulative 
total cholesterol exposure upon LIKK expression, thus likely contributed to the enhanced 
atherosclerosis development. Previous diet-induced atherosclerosis studies in E3L mice have 
consistently demonstrated that there is a positive logarithmic relation between the cumulative 
cholesterol exposure during the study and the atherosclerotic lesion area (J.F.P. Berbée, P.C.N. 
Rensen, unpublished data). In agreement with these previous observations, we did observe 
such a significant logarithmic relation in E3L mice but not in E3L.LIKK mice. This suggests that 
the increase in atherosclerotic lesion area in E3L.LIKK mice can only partly be attributed to the 
transiently enhanced plasma cholesterol levels and that additional mechanisms are involved.
Inflammation is the second main risk factor for atherosclerosis. Enhanced extravascular or 
systemic inflammation, by the periodontal pathogen Porphyromonas gingivalis31 or by repeated 
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administration of LPS,21 respectively, promotes atherosclerosis development. In addition, 
in humans, low-grade systemic inflammation is associated with enhanced risk of coronary 
artery disease.32,33 It is thus likely that, as discussed above, the increased sensitivity for pro-
inflammatory triggers such as LPS in E3L.LIKK mice also directly contributed to the enhanced 
atherosclerotic lesion formation.
We excluded higher circulating levels of pro-inflammatory Ly6C-hi monocytes as being 
another possible contributor to the aggravated atherosclerosis development in E3L.LIKK mice. 
Adhesion of monocytes to endothelial cells and subsequent migration into the vessel wall is 
one of the crucial steps in atherosclerotic lesion formation. Ly6C-hi monocytes are more prone 
to adhere to activated endothelium than Ly6C-lo monocytes and are, therefore, associated 
with enhanced atherosclerosis development.34 We found that E3L.LIKK mice had similar levels 
of circulating subsets of monocytes as compared to their E3L controls, which is consistent with 
the observed similar number of adhering monocytes to the vascular wall. 
In line with the enhanced atherosclerosis development that we observed in E3L.LIKK 
mice, Luchtefeld et al.11 have reported that gp130-deficient mice with defective IL-6 signaling 
specifically in hepatocytes, develop less atherosclerosis, indicating that modulation of hepatic 
inflammation can have profound effects on atherogenesis. These studies also underscore that 
enhanced inflammation in the liver, e.g. due to viral hepatitis or steatohepatitis, may augment 
atherosclerosis development. Indeed, in several clinical studies, such hepatic pathological 
conditions are associated with an elevated occurrence of CVD.35, 36, 37 Even after adjustment for 
classical risk factors for CVD, such as LDL cholesterol levels, chronic hepatitis C infection was 
still significantly associated with increased atherosclerosis in a cross-sectional study.37 Together, 
these findings suggest that there is a direct effect of hepatic inflammation on atherosclerosis 
development, independent of systemic lipid levels. Moreover, they suggest that in addition to 
the currently used lipid-targeted drugs such as statins, reducing NF-κB activity in the liver may 
be a promising additive therapeutic strategy against atherosclerosis development.
In conclusion, we have shown that hepatocyte-specific activation of NF-κB leads to larger 
and more advanced atherosclerotic lesions. Our studies furthermore suggest that both 
the transient elevated (V)LDL cholesterol levels as well as the increased sensitivity to pro-
inflammatory stimuli are most likely responsible for this aggravating effect on atherosclerosis. 
These findings contribute to the present understanding of the role of the liver, and more 
specifically the role of hepatic NF-κB, in atherosclerosis development and may help to develop 
new innovative anti-atherosclerotic strategies.
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Supplemental data
Supplemental Table 1. Primers used for RT-PCR.
Human target Forward primer Reverse primer
IKKβ GGAGCTCTGTGGGCGGGAGA GGCCCATGGGGCTCCTCTGT

















IKKβ, IκB kinase-β; Apob, apolipoprotein B; Cd3, marker for (NK)T cells; CD68, marker for macrophages (Kupffer 
cells); Cpt1a, carnitine palmitoyltransferase 1a; Cyclo, cyclophilin; Fas, fatty acid synthase; Gapdh, glyceraldehyde-3-
phosphate dehydrogenase; Hmgcr, HMG-CoA reductase; Hprt, hypoxanthine-guanine phosphoribosyl transferase; 
IL-1β, interleukin-1β; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; Mttp, microsomal triglyceride 
transfer protein; Srebp-1c, sterol-regulatory element binding protein; Va14, marker for NKT cells.
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Supplemental Table 2. Expression of LIKK increases hepatic MCP-1 expression. 
Target E3L E3L.LIKK Significance
Cytokines and chemokines
IL-1β 1.00 ± 0.05 1.24 ± 0.14 P = 0.085
IL-6 1.00 ± 0.13 1.24 ± 0.20 n.s.
MCP-1 1.00 ± 0.27 1.39 ± 0.32* P = 0.049
Inflammatory cells
CD68 1.00 ± 0.29 1.15 ± 0.14 n.s.
CD3 1.00 ± 0.14 0.69 ± 0.30 n.s.
Vα14 1.00 ± 0.08 0.94 ± 0.21 n.s.
VLDL secretion
ApoB 1.00 ± 0.24 1.00 ± 0.33 n.s.
MTTP 1.00 ± 0.13 1.15 ± 0.28 n.s.
Lipogenesis
Srebp-1c 1.00 ± 0.19 1.46 ± 0.49 n.s.
Fas 1.00 ± 0.21 0.83 ± 0.19 n.s.
After 24 weeks of Western-type diet, E3L.LIKK and E3L mice were sacrificed, livers were isolated and mRNA expression 
of indicated targets were quantified by RT-PCR. Data are calculated as fold difference as compared to the control 
group. Values are means ±SEM; n=6-15/group; *P<0.05 compared to the control group; n.s., not significant. IKKβ, IκB 
kinase-β; Apob, apolipoprotein B; Cd3, marker for (NK)T cells; CD68, marker for macrophages (Kupffer cells); Cpt1a, 
carnitine palmitoyltransferase 1a; Cyclo, cyclophilin; Fas, fatty acid synthase; Gapdh, glyceraldehyde-3-phosphate 
dehydrogenase; Hmgcr, HMG-CoA reductase; Hprt, hypoxanthine-guanine phosphoribosyl transferase; IL-1β, 
interleukin-1β; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; Mttp, microsomal triglyceride transfer 
protein; Srebp-1c, sterol-regulatory element binding protein; Vα14, marker for NKT cells.
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Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. E3L.LIKK 
(black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. Body weight 
(A) and food intake (B) were measured weekly. Values are means ±SEM; n=15/group.
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Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. E3L.LIKK 
(black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. Body weight 
(A) and food intake (B) were measured weekly. Values are means ±SEM; n=15/group.
Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. E3L.LIKK (black 
symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. Body weight (A) and 
food intake (B) were measured weekly. Values are means ±SEM; n=15/group.
Supplemental Fig. 2. Expression of LIKK increases hepatic IKKβ mRNA and protein expression, and NF-κB 
protein activity. After 24 weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were 
sacrificed, livers were isolated and hepatic mRNA expression of human IKKβ (A) and murine IKKβ (B) was 
quantified by RT-PCR. Human IKKβ is expressed as fold difference compared to E3L.LIKK mice and murine 
IKKβ to E3L mice. The inserts show representative bands of two mice per group of the qPCR product run on 
a gel. Values are mean ±SEM; n=14-15/group; ****P<0.0001. Hepatic protein expression of IKKβ normalized 
to tubulin (C) and phosphorylated NF-κB p65Ser536 normalized to total NF-κB (D) was assessed in E3L.LIKK 
(black bars) and E3L mice (white bars). Values are mean ±SEM; n=6-7/group; *P<0.05, **P<0.01.
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Supplemental Fig. 2. Expression of LIKK increases hepatic IKKβ mRNA and protein expression, 
and NF-κB protein activity. After 24 weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice 
(white bars) were sacrificed, livers were isolated and hepatic mRNA expression of human IKKß (A) and 
murine IKKβ (B) was quantified by RT-PCR. Human IKKβ is expressed as fold difference compared to 
E3L. IKK mice and murine IKKβ to E3L mice. The inserts show representative bands of two mice per 
gro p of the qPCR product run on a el. Values are mean ±SEM; n=14-15/group; ****P<0.0001. Hepatic 
protein expression of IKKβ normalized to tubulin (C) and phosphorylated NF-κB p65Ser536 normalized 
to total NF-κB (D) was assessed in E3L.LIKK (black bars) and E3L mice (white bars). Values are mean 
±SEM; n=6-7/group; *P<0.05, **P<0.01.
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Supplemental Fig. 3. LIKK does not affect plasma cytokines after 0 and 24 weeks of diet. E3L.LIKK 
(black bars) and E3L (white bars) were fed 24 weeks of Western-type diet. Plasma levels of the indicated 
cytokines were measured at t=0 and 24 weeks of diet. Values are means ±SEM; n=15/group.
Supplemental Fig. 3. LIKK does not affect plasma cytokines after 0 and 24 weeks of diet. E3L.LIKK (black 
bars) and E3L (white bars) were fed 24 weeks of Western-type diet. Plasma levels of the indicated cytokines 
were measured at t=0 and 24 weeks of diet. Values are means ±SEM; n=15/group.
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Supplemental Fig. 4. LIKK does not affect circulating subsets of monocytes. Blood was drawn from 
E3L.LIKK (black circles) and E3L (open circles) mice fed a Western-type diet for 8 weeks. The number of 
monocytes (A) and Ly6C-hi (B), Ly6C-med (C) and Ly6C-lo (D) expressing subsets were determined by 
FACS analysis. n=7-8/group. 
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Supplemental Fig. 4. LIKK does not affect circulating subsets of monocytes. Blood was drawn from 
E3L.LIKK (black circles) and E3L (open circles) mice fed a Western-type diet for 8 weeks. The number 
of monocytes (A) and Ly6C-hi (B), Ly6C-med (C) and Ly6C-lo (D) expressing subsets were determined 
by FACS analysis. n=7-8/group.
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Supplemental Fig. 5. LIKK transiently increases plasma triglycerides and phospholipids. E3L.LIKK 
(black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. Plasma was 
obtained every 4 weeks to determine triglycerides (TG) (A) and phospholipids (PL) (B) concentration 
over time. Values are means ±SEM; n=15/group; *P<0.05, ***P<0.001.
Supplemental Fig. 5. LIKK transiently increases plasma triglycerides and phospholipids. E3L.LIKK (black 
symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. Plasma was obtained 
every 4 weeks to determine triglycerides (TG) (A) and phospholi ids (PL) (B) concentration over time. 
Values are means ±SEM; n=15/group; *P<0.05, ***P<0.001.
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Supplemental Fig. 6. Expression of LIKK tends to increase VLDL-apoB production. After 8 weeks of 
Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 hours and injected with 
Trans35S and tyloxapol, and blood samples were drawn after tyloxapol injection. The rate of TG production 
was calculated from the slopes of the curves from the individual mice (A). After 120 min, the total VLDL-
fraction was isolated by ultracentrifugation, 35S-activity was counted, and the production rate of newly 
synthesized VLDL-35S-apoB was determined (B). Values are means ±SEM; n=5-11/group. 
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Supplemental Fig 6. Expression of LIKK tends to increase VLDL-apoB production. After 8 weeks of 
Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 hours and injected 
with Tr ns35S and tyloxapol, and blood samples were d awn after tyloxapol i jection. The rate of TG 
production was calculated from the slopes of the curves from the individual mice (A). After 120 min, the 
total VLDL-fraction was isolated by ultracentrifugation, 35S-activity was counted, and the production rate 
of newly synthesized VLDL-35S-apoB was determined (B). Values are means ±SEM; n=5-11/group. Hepatic inflammation aggravates atherosclerosis








































































































































































Supplemental Fig. 7. LIKK does not affect liver lipid content. After 24 weeks of Western-type diet, the 
livers of E3L.LIKK (black bars) and E3L mice (white bars) were isolated and triglyceride (TG) (A), 
phospholipid (PL) (B), total cholesterol (TC) (C), free cholesterol (FE) (D), cholesteryl ester (CE) (E) 
content was determined. Values are means ±SEM; n=14-15/group. 
Supplemental Fig. 7. LIKK does not affect liver lipid content. After 24 weeks of Western-type diet, the livers 
of E3L.LIKK (black bars) and E3L mice (white bars) w re isolated and triglyceri e (TG) (A), phospholipid (PL) 
(B), total cholesterol (TC) (C), free cholesterol (FE) (D), cholesteryl ester (CE) (E) content was determined. 
Values are means ±SEM; n=14-15/group. 
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Figures LIKK aggravates atherosclerosis development in E3L mice
Wong et al. 2011
Supplemental table and figures
Supplemental Fig. 8. Representative pictures of HPS-stained segments without 
lesion (A) and type I-V (B-F) atherosclerotic lesions in E3L(.LIKK) mice and 
categorization into mild (type 1-III) and severe (type IV-V) phenotypes. Magnification 
200x.
Suppl Figure 8
A. No lesion B. Type I lesion
C. Type II lesion D. Type III lesion
E. Type IV lesion F. Type V lesion
Supplemental Fig. 8. Representative pictures of HPS-stained segments classified in different severities. 
Atherosclerotic lesions are categorized into mild (type I-III) and severe (type IV-V) phenotypes. 
Magnification 200x. (A). No lesion. (B). Type I, early fatty streak: per section up to 10 foam cells present in 
the intima. (C). Type II, regular fatty streak: more than 10 foam cells pr sent in th  intima. (D). Type III, mild 
plaque: extension of foam cells into t  media and covered by a fibrotic cap. (E). Type IV, moderate plaque: 
a more p ogressive lesion infiltrating into the m dia, fibrosis in the media, without loss of ar hitecture. (F). 
Type V, severe plaque: the media is severely damaged, elastic lamina are broken, presence of cholesterol 
clefts, mineralization and/or necrosis.
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Hepatic inflammation aggravates atherosclerosis


























































Supplemental Fig. 9. Correlation between cumulative plasma TC exposure and atherosclerotic 
lesion area. The correlation between the cumulative plasma TC exposure and atherosclerotic lesion area, 
after log transformation, in E3L (open circles) (A) and the E3L.LIKK mice (closed circles) (B) was 
determined using the Pearson correlation test. n=15/group.
Supplemental Fig. 9. Correlation between cumulative plasma TC exposure and atherosclerotic lesion area. 
The corr lation between the cumulativ  plasma TC exposure and therosclerotic sion area, after log 
transformation, in E3L (open circles) (A) and the E3L.LIKK mice (closed circles) (B) was determined using 
the Pearson correlation test. n=15/group.
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Chronic obstructive pulmonary disease (COPD) is a strong risk factor for cardiovascular 
diseases (CVD), independent of common risk factors such as smoking. The pathophysiological 
mechanism underlying the link between COPD and CVD, however, is incompletely understood. 
The aim of the present study was to investigate whether established emphysema in the absence 
of chronic pulmonary inflammation affects atherosclerosis development in mice. To address 
this, hypercholesterolemic APOE*3-Leiden transgenic mice were intratracheally instilled 
with 15 or 30 μg of porcine pancreatic elastase (PPE) to induce emphysema, or vehicle as 
control. After 3 weeks of recovery, mice were fed a diet with 0.4% (w/w) cholesterol to induce 
atherosclerosis. Blood was drawn to assess plasma lipid and inflammatory parameters. After 
20 weeks of diet, mice were sacrificed to analyze the lungs, hearts, and atherosclerosis in the 
aortic root. Our results showed that intratracheal PPE instillation dose-dependently induced 
emphysema and right ventricular hypertrophy development. PPE instillation did not affect 
plasma levels of lipids and acute-phase proteins, but did result in a dose-dependent decrease in 
numbers of circulating monocytes and neutrophils. There was no difference in atherosclerotic 
lesion area, but the atherosclerotic lesion severity was dose-dependently decreased after 
PPE instillation. These data show that PPE-induced emphysema did not affect atherosclerotic 
lesion area and even reduced atherosclerosis severity in hypercholesterolemic APOE*3-Leiden 
transgenic mice. The findings suggest that emphysema, in the absence of (smoking-induced) 




Clinical epidemiological studies have demonstrated a strong positive correlation between 
chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD).1 This 
increased risk of CVD is not entirely explained by traditional shared risk factors, e.g. smoking, 
suggesting that COPD by itself may play a causal role in the pathophysiological mechanisms 
involved in CVD.2 Markers of systemic inflammation are increased in many patients with COPD, 
especially in those with more severe disease and/or exacerbations.3 This systemic inflammation, 
which may in part result from overspill of inflammatory mediators from the inflamed lung, could 
explain this increased risk for CVD.2, 4
Although this enhanced systemic inflammation appears to be a plausible link between 
CVD and COPD, little is known about the origin of these circulating inflammatory mediators. 
Moreover, the evidence for a prominent role of systemic inflammation in the association 
between COPD and extrapulmonary manifestations of COPD such as CVD is circumstantial.3 
Emphysema severity is associated with arterial stiffness independent of C-reactive protein 
(CRP).5 Anti-inflammatory therapies in COPD, e.g. inhaled corticosteroids and tiotropium, 
have not been consistently shown to modify serum levels of CRP or IL-6, nor the long-term 
cardiovascular complications.6,7 This suggests that while local delivery of anti-inflammatory 
drugs to the lungs does have a limited effect on lung inflammation, it does not reduce systemic 
inflammation. Furthermore, levels of inflammatory mediators (i.e. TNFα, IL-6 and IL-8) in 
induced sputum do not correlate with the values in blood in COPD patients.8 Therefore, it is 
likely that other mechanisms than inflammation are also involved in the interaction between 
COPD and CVD. 
Pulmonary emphysema is a major component of COPD and defined as abnormal airspace 
enlargement distal to the terminal bronchioles.9 Recently, it was demonstrated in a study with 
current, ex- and never-smokers with or without COPD that the occurrence of atherosclerotic 
plaques in the internal carotid arteries is positively associated with two function parameters that 
are associated with pulmonary emphysema, i.e. a low diffusing capacity for carbon monoxide 
and a high residual volume.10 These associations still remained significant after correction for 
established risk factors for atherosclerosis, such as older age, blood pressure, total cholesterol 
and smoking. Interestingly, after multivariate analysis, the extent of atherosclerosis was not 
associated with variables such as forced expiratory volume in one second (FEV
1
) and CRP. These 
results suggest that in addition to airflow obstruction and low-grade systemic inflammation, 
other features of COPD (i.e. reduced diffusing capacity and increased residual volume) may 
contribute to the association between reduced lung function and CVD.
Intratracheal administration of porcine pancreatic elastase (PPE) in animals reproduces key 
features of emphysema.11 When compared to other emphysema models, e.g. chronic smoke 
exposure or intrapulmonary lipopolysaccharide instillation,11 the PPE model is not characterized 
by chronic inflammation. This allows a separate analysis of the contribution of emphysema 
in absence of chronic inflammation alone to atherosclerosis development. This is important 
since it is unknown whether the main characteristic of emphysema, i.e. alveolar destruction,12 
in the absence of pulmonary inflammation can enhance atherosclerosis.13 Intratracheal PPE 
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instillation induces a transient acute inflammatory response in the lung and, subsequently, 
alveolar destruction.14 PPE-induced emphysema is thus a suitable model to investigate the 
role of alveolar destruction, in the absence of smoke-induced chronic inflammation, on 
atherosclerosis development. 
The aim of this study was to assess whether emphysema per se, without concomitant 
pulmonary inflammation, enhances atherosclerosis development in atherosclerosis-prone 
APOE*3-Leiden (E3L) mice.15 We found that mice with PPE-induced emphysema had similar 
plasma levels of lipids and inflammatory markers, but lower circulating monocyte and neutrophil 
levels. In line with these findings, their atherosclerotic lesion size was not different, while their 
atherosclerosis severity was reduced compared to the control mice without emphysema.
Materials and methods
Animals
Female APOE*3-Leiden (E3L) mice15 of 10-12 weeks of age were housed under standard 
conditions with a 12-hour light/dark cycle and had free access to food and water. E3L mice 
represent a well-established model for human-like lipoprotein metabolism and develop 
atherosclerosis when fed a Western-type diet. All mice were fed a synthetic diet containing 15% 
(w/w) cacao butter (diet T, Hope Farms, Woerden, The Netherlands) for 3 weeks. Subsequently, 
mice were divided into 3 groups after matching for plasma cholesterol levels, age and body 
weight. To induce pulmonary emphysema, porcine pancreatic elastase (PPE) (E7885, Sigma-
Aldrich, Schnelldorff, Germany) was administered intratracheally (15 μg or 30 μg in 40 μL 
PBS).16, 17 Control mice received 40 μL sterile PBS (vehicle). After 3 weeks of recovery, all mice 
were fed a Western-type diet (i.e. diet T supplemented with 0.4% (w/w) cholesterol) to induce 
atherosclerosis development. All mice were weighed weekly and food intake was assessed for 
one week at 12 weeks after instillation of vehicle or PPE.
At baseline (before intratracheal PPE instillation) and every 4 weeks thereafter, blood was 
drawn in EDTA-coated tubes (Sarstedt, Numbrecht, Germany) by tail bleeding after 4 hours 
of fasting, and plasma was isolated by centrifugation. All animal experiments were approved 
by the Institutional Ethical Committee on Animal Care and Experimentation of the Leiden 
University Medical Center (Leiden, The Netherlands). 
Pulmonary function measurements
Total respiratory amplitude and respiratory rate were assessed 13 weeks after vehicle or PPE 
instillation with non-invasive whole body plethysmography (RM-80, Columbus Instruments, 
Columbus, OH, USA) as described previously.18 The total respiratory amplitude was calculated 
from the measured peak-to-peak signals and reflects the tidal volume. Flow derived parameters 
of breath amplitude and frequency were collected for and averaged over 2 minutes per mouse. 
The signal was digitized using a Digidata 1440A interface (Axon Instruments/Molecular 




Plasma lipids and inflammatory markers
Plasma total cholesterol, triglyceride and phospholipid levels were determined using 
enzymatic kits from Roche Molecular Biochemicals (Woerden, The Netherlands) according 
to the manufacturer’s protocols. The cholesterol distribution over plasma lipoproteins was 
determined after size-fractionation of pooled plasma samples using an ÄKTA fast performance 
liquid chromatography (FPLC) system (Pharmacia, Roosendaal, The Netherlands).19
Plasma levels of serum amyloid A (SAA) and soluble E-selectin (sE-selectin) were determined 
at 24 weeks after intratracheal PPE instillation using the murine SAA assay kit (Tridelta, County 
Kildare, Ireland) and murine E-selectin ELISA kit (R&D, Minneapolis, MN), respectively, 
according to manufacturer’s instructions.
Blood count analysis
Eight weeks after intratracheal vehicle or PPE instillation, unfasted blood was collected in 
EDTA-coated tubes (Sarstedt, Numbrecht, Germany) by tail bleeding of mice. Complete blood 
cell count and hematological analysis was performed in whole blood using a Sysmex XT-2000iV 
veterinary hematology analyzer (Sysmex Corporation, Kobe, Japan), as described previously.20 
The XT-2000iV employs a fluorescent flow cytometry method using a fluorescent dye to stain 
cellular DNA and RNA and a semiconductor laser to detect forward-, side-scattered, and 
fluorescent light.
Arterial blood and tissue collection 
Mice were anesthetized by intraperitoneal injection of 6.25 mg/kg acepromazine (Alfasan, 
Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), and 
0.31 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands) 24 weeks after intratracheal PPE 
instillation. Blood was obtained by cardiac puncture. Subsequently, the mice were sacrificed 
by cervical dislocation and the pulmonary and systemic circulation was rinsed with ice-cold 
PBS. The lungs were fixated in situ by gentle infusion of fixative (phosphate-buffered 4% 
formaldehyde) by a continuous-release pump under constant pressure (12 mL/hour; 8 min) 
through a tracheal cannula. After excision, the lungs and heart were immersed in fresh fixative 
for a period of 24 hours at 4°C. 
Histological analysis of the lungs
Lungs were processed for paraffin embedding and cut in 5 µm coronal sections. Tissue 
samples were stained with hematoxylin-eosin (HE). To assess air space enlargement, the 
mean linear intercept (MLI) and air/tissue ratio was quantified by one observer in a blinded 
fashion by superimposing a line grid with 21 lines and 42 points on the images of lung sections 
at a magnification of 200x as described previously.21 To calculate the MLI, the number of 
intersections between the lines of the grid and the alveolar walls was quantified for each mouse 
in 10 non-overlapping fields. To determine the air/tissue ratio, the number of points in alveolar 
space was counted. 
For immunohistochemical staining of macrophages and neutrophils in the lungs, rat 
anti-mouse MAC-3 antibody (1:50, BD Pharmingen, Breda, The Netherlands)22 and anti-
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myeloperoxidase (MPO) (1:1500, Thermo Fisher scientific, Runcorn, United Kingdom)21 were 
used as described previously.  Results of MAC-3- and MPO-positive cells are represented as 
the average count from 10 non-overlapping fields per mouse (400x magnification) corrected 
for tissue density by calculating the ratio between the number of cells and the average area of 
tissue per field. To determine the average area of tissue, the number of points superimposed 
on alveolar tissue was counted (400x magnification), using the same line grid for assessment of 
air space enlargement, as described above. 
Histological analysis of the heart and aorta
Hearts were isolated and fixed in phosphate-buffered 4% formaldehyde, dehydrated and 
embedded in paraffin. A 5 μm transversal section of the heart halfway in the long axis was 
stained with HE. Thickness of the right and left ventricular free walls was assessed at a 40x 
magnification by averaging 6 measurements per structure with the NIH Image J program.
For quantification and classification of atherosclerosis, the hearts were cross-sectioned (5 μm) 
throughout the entire aortic root area. Per mouse, 4 sections with 40-μm intervals were used 
for quantification of atherosclerotic lesion area and characterization of lesion severity. Sections 
were stained with hematoxylin-phloxine-saffron. According to the guidelines of the American 
Heart Association, adapted for mice,23, 24 atherosclerotic lesions were categorized for severity 
as follows:
– Type I: early fatty streak: per section up to 10 foam cells present in the intima.
– Type II: regular fatty streak: more than 10 foam cells present in the intima.
– Type III: mild plaque: extension of foam cells into the media and covered by a fibrotic cap.
– Type IV: moderate plaque: a more progressive lesion infiltrating into the media, fibrosis in 
the media, without loss of architecture.
– Type V: severe plaque: the media is severely damaged, elastic lamina are broken, presence 
of cholesterol clefts, mineralization and/or necrosis.
All segments were categorized into: 1) no lesions (undiseased) 2) mild (type I-III) and 3) severe 
(type IV-V) lesions. The percentage of lesion-free segments and the percentages of lesions 
belonging to the respective lesion categories were calculated. 
AIA31240 rabbit antiserum (1:1000, Accurate Chemical and Scientific, Westbury, NY) was used 
for determination of adhering monocytes and macrophage- and  mouse monoclonal antibody 
M0851 (1:800, Dako, Carpinteria, CA) for quantification of smooth muscle cell content in the 
lesions, described previously.25 Sirius red (Chroma, Stuttgart, Germany) was used to stain for 
collagen in the lesions.
Total lesion area, macrophage -, smooth muscle cell - and collagen content were quantified 
using Cell^D image analysis software (Olympus Soft Imaging Solutions, Münster, Germany).
Statistical analysis
Statistical differences were assessed with one-way ANOVA analysis, followed by post-hoc 
analysis using Fisher’s LSD multiple comparison test. For lesion typing, differences were 
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assessed by the χ2 test. SPSS 16.0 for Windows (SPSS, Chicago, Ill) was used for statistical 
analysis. Differences at P<0.05 were regarded as statistically significant. Data are presented as 
mean ± SEM.
Results
Intratracheal administration of PPE induces emphysema and increases the total 
respiratory amplitude 
To investigate whether PPE-induced emphysema results in changes in respiration pattern, we 
used non-invasive whole body plethysmography. PPE instillation dose-dependently increased 
the total respiratory amplitude of the measured signal, reflecting an increased tidal volume 
(Fig. 1A). The respiration rate was not different between the groups (Fig. 1B).
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Fig. 1. Intratracheal PPE instillation dose-dependently increases total respiratory amplitude, mean linear 
intercept (MLI) and air/tissue ratio. Thirteen weeks after instillation of vehicle or PPE, total respiratory 
amplitude (A) and respiration rate (B) were analyzed by non-invasive whole body plethysmography. 
Twenty-four weeks after instillation E3L mice were sacrificed. The lungs were isolated and sections were 
HE-stained (C) to determine MLI (D) and air/tissue ratio (E). Values are means ± SEM; n=13-18; *P<0.05, 
**P<0.01, ***P<0.001.
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To determine the extent of emphysema development after intratracheal PPE instillation, the 
lungs were perfused under continuous pressure at 24 weeks after PPE instillation and analyzed 
by morphometry (Fig. 1C). PPE instillation caused a significant dose-dependent increase in 
mean linear intercept (MLI) (Fig. 1D) and air/tissue ratio (Fig. 1E) as compared to instillation 
of vehicle, indicating destruction and enlargement of alveolar space. To assess whether PPE 
instillation generates prolonged inflammatory cell influx into the lungs, we also quantified the 
number of macrophages and neutrophils by immunohistochemistry. No differences in the 
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Fig. 2. Intratracheal instillation of PPE does not affect number of macrophages and neutrophils in the lungs. 
Twenty-four weeks after instillation of vehicle or PPE, E3L mice were sacrificed and the lungs were isolated 
to deter ine the number of macrophages (A) and neutrophils (B) by immunohistochemistry. Values are 
means ± SEM; n=13-16. 
Intratracheal administration of PPE induces right ventricular hypertrophy
In a previous study in which mice were treated repetitively with PPE, right ventricular hypertrophy 
was observed.17 Therefore, we determined whether the development of emphysema also 
affected the pulmonary circulation and the heart in this study. We found a dose-dependent 
increase in right ventricular hypertrophy with a single dose of PPE (Table 1 and Fig. 3A-B), which 
was also reflected by a significantly higher total heart weight/body weight ratio in the mice 
treated with the highest dose of PPE (Table 1).
Table 1. Intratracheal PPE instillation increases heart weight and induces right ventricular hypertrophy.
Group RV free wall thickness (mm) LV free wall thickness (mm)
Heart weight / body weight 
(x10-3)
Vehicle 0.21 ± 0.009 0.96 ± 0.02 4.9 ± 0.1
15 μg PPE 0.25 ± 0.020** 0.97 ± 0.04 4.8 ± 0.1
30 μg PPE 0.30 ± 0.008***∆∆ 1.00 ± 0.03 5.1 ± 0.1∆
Twenty-four weeks after intratracheal vehicle or PPE instillation, mice were weighed and sacrificed. The hearts were 
isolated, weighed and processed for histological analysis. Values are means ± SEM; n=11-18; **P<0.01, ***P<0.001 
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Intratracheal administration of PPE reduces circulating monocytes and neutrophils
To evaluate whether PPE instillation affected systemic inflammation, we measured leukocytes 
concentration in whole blood and plasma levels of the acute-phase proteins SAA and sE-
selectin. Circulating levels of monocytes and of neutrophils were dose-dependently decreased 
in the PPE-treated groups. Despite this decrease, the concentration of total leukocytes was 
similar between the groups, since the majority (86%) of leukocytes consisted of lymphocytes, 
which was unaffected by PPE treatment (Fig. 4A-D). Plasma levels of SAA and sE-selectin were 
not different between groups (not shown). 
As a measure for chronic hypoxia, erythrocyte count, hemoglobin and hematocrit were 
determined. The total number of erythrocytes, the hemoglobin concentration and hematocrit 
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Fig. 3. Intratracheal PPE instillation dose-dependently induces right ventricular hypertrophy. Twenty-four weeks 
after intratracheal instillation of vehicle or PPE, E3L mice were sacrificed and the hearts were isolated. Transversal 
sections of the hearts were HE-stained (A). Right ventricular (RV) and left ventricular (LV) wall thickness was 
determined and the RV/LV was calculated (B). Values are means ± SEM; n=11-18; *P<0.05, ***P<0.001.
Table 2. Intratracheal PPE instillation increases number of erythrocytes, hemoglobin concentration and 
hematocrit. 
Group Erythrocytes (x106/μL) Hemoglobin (mmol/L) Hematocrit (vol%)
Vehicle 8.7 ± 0.5 8.2 ± 0.4 40.1 ± 2.1
15 μg PPE 8.5 ± 0.6 8.4 ± 0.4 39.4 ± 2.5
30 μg PPE 9.9 ± 0.3∆ 9.2 ± 0.1* 45.2 ± 1.0*∆
Eight weeks after intratracheal vehicle or PPE instillation, blood was collected to determine the number of erythrocytes, 
hemoglobin concentration and hematocrit. Values are means ± SEM; n=13-18; *P<0.05 compared to vehicle, ∆P<0.05 
compared to 15 μg PPE.
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Intratracheal administration of PPE does not affect plasma lipids
PPE treatment did not affect body weight gain (Table 3) and food intake (2.8 ± 0.15 g/mouse/
day for vehicle; 2.7 ± 0.11 for 15 μg PPE; 2.3 ± 0.07 for 30 μg PPE). Since dyslipidemia is a major 
contributor to atherosclerosis development, we next assessed the possibility that PPE-induced 
emphysema affects plasma lipid levels. After PPE or vehicle instillation, mice had a recovery period 
of 3 weeks before the mice were fed the Western-type diet (containing 0.4% cholesterol, w/w). 
By using this design, PPE activity and the accompanying inflammatory response had resolved26,27 
before atherosclerosis development was initiated. Plasma total cholesterol levels (Fig. 5A), as 
well as triglycerides and phospholipids levels (not shown) were similar in all groups throughout 
the study. In addition, the plasma lipoprotein distribution was not different (not shown).
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Fig. 4. PPE-induced emphysema dose-dependently reduces circulating monocytes and neutrophils. Eight 
weeks after intratracheal instillation of vehicle or PPE, blood was drawn to determine total leukocyte count 
(A), monocytes (B), neutrophils (C) and lymphocytes (D) using an automated veterinary hematology 
analyzer. Values are means ± SEM; n=13-16; *P<0.05, **P<0.01, ***P<0.001. 
Table 3. Intratracheal PPE instillation does not affect body weight. 
Body weight
Group Before instillation (t=0 wks) Before start of diet (t=4 wks) At end of study (t=24 wks)
Vehicle 20.1 ± 0.3 21.3 ± 0.28 36.7 ± 0.44
15 μg PPE 20.2 ± 0.4 21.5 ± 0.40 37.3 ± 0.58
30 μg PPE 20.3 ± 0.3 21.6 ± 0.23 37.2 ± 0.52
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Fig. 5. Intratracheal PPE instillation does not affect atherosclerosis lesion area, but reduces lesion severity. 
Three weeks after intratracheal vehicle or PPE instillation, mice were fed a Western-type diet. Every 
4 weeks thereafter, blood was drawn to assess plasma cholesterol levels (A). After 20 weeks of diet, the 
mice were sacrificed and the total lesion area was determined in the segments between the three aortic 
valves (B). In addition, the percentages of lesion-free segments (C), and with mild and severe lesions (D) 
were assessed. Representative pictures of each group are shown (E). Arrows indicate lesions. Values are 
means ± SEM, n=12-18; *P<0.05, **P<0.01.
Intratracheal administration of PPE reduces atherosclerotic lesion severity
To study whether PPE-induced emphysema enhanced atherosclerosis development in the 
absence of chronic pulmonal inflammation, we determined the atherosclerotic plaque area and 
plaque severity in the aortic root area of the heart. Total lesion area, lesion severity and lesion 
composition were scored in the segments between the three aortic valves. PPE instillation did 
not affect atherosclerotic lesion size and percentage of lesion-free segments as compared 
to vehicle-treated control mice (Fig. 5B-C). However, classification of the segments that 
contained lesions showed a dose-dependent decrease in severity in the PPE-treated groups, 
as is demonstrated by an increased percentage of mild lesions and a decreased percentage of 
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severe lesions (Fig. 5D-E). With respect to the lesion composition, no differences in adhering 
monocytes to the vessel wall and lesion content of macrophages and smooth muscle actin was 
observed (Fig. 6A-C). The group treated with 15 µg of PPE had a significantly higher collagen 
content in the lesions (Fig. 6D) compared to the control group, but no difference was observed 
between the 30 µg PPE group and the control or 15 µg PPE groups.
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Fig. 6. Intratracheal PPE instillation does not affect adhering monocytes and tends to increase collagen 
content. Twenty-four weeks after intratracheal vehicle or PPE instillation, mice were sacrificed and the number 
of adhering monocytes (A), macrophage content (B), smooth muscle content (C) and collagen content (D) in 
the atherosclerotic lesions in the aortic root was determined. Values are means ± SEM; n=12-18; *P<0.05. 
Discussion
There is ample clinical evidence that a poor lung function, most commonly caused by COPD, 
is an independent predictor of CVD.28,29,30 Since smoking is the leading cause of COPD, smoke 
models have been utilized to investigate the relationship between pulmonary emphysema and 
atherosclerosis.31, 32 Smoking itself, however, has a direct effect on atherogenesis, i.e. through 
induction of a systemic inflammatory response and dyslipidemia, and therefore interferes with 
the elucidation of the role of the different aspects of COPD in atherosclerosis development. 
Furthermore, although the majority of COPD patients are current or former smokers (~90%), 
the disease also occurs in patients who have never smoked.33 Emphysema, characterized by 
alveolar tissue destruction, is a common manifestation of COPD, but its role in atherosclerosis 
development independent of systemic inflammation has never been studied. Therefore, in 
the present study we investigated whether emphysema in the absence of smoke-induced 
pulmonary inflammation would affect atherosclerosis development.
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For the first time we show that PPE-induced emphysema per se does not worsen 
atherosclerosis development. Atherosclerotic lesion size and composition were not different 
between the groups. Thus, our results indicate that alveolar destruction alone cannot 
explain the increased incidence of CVD in COPD patients. Systemic inflammation has been 
regarded as a possible mediator between COPD and CVD,4,34 although the evidence for this 
link is circumstantial.3 Nevertheless, because of the known role of systemic inflammation in 
aggravating CVD, the absence of enhanced systemic inflammation in the current study may 
explain why atherosclerosis was not affected by the presence of emphysema in our study. Our 
results are in line with a study showing that allergic airways inflammation induced by Aspergillus 
fumigatus, resulted in marked increase in pulmonary cytokine levels and inflammatory cell influx 
and mild increased plasma SAA levels, but did not affect atherosclerosis development in apoe-/- 
mice.35 This indicates that an increase in pulmonary (and subsequent systemic) inflammation 
does not necessarily affect atherosclerosis development. In our study, emphysema was 
developed before the induction of atherosclerosis, whereas in humans these diseases often 
develop concomitantly. The reason for this study design is that we aimed to study the effect of 
alveolar destruction separate from the effect of lung inflammation and spill over in the systemic 
circulation. Therefore, the study was designed to make sure that during development of 
atherosclerosis, which was started 3 weeks after PPE instillation to induce emphysema, systemic 
inflammation due to a spillover from the lung is no longer a contributing factor. Future studies 
using a different study design and other experimental COPD models should therefore focus on 
whether pulmonary inflammation by itself, or synergistically with alveolar destruction affects 
atherosclerosis development. 
Unexpectedly, we found a dose-dependent decrease in lesion severity in the PPE-treated 
groups. We therefore considered the possibility that PPE treatment affected mechanisms 
involved in atherosclerosis development. First, dyslipidemia is one of the main contributors 
to atherosclerosis development. We found however, that intratracheal PPE instillation did not 
affect plasma lipid levels nor the lipoprotein profile. Therefore, the moderating effect of PPE-
induced emphysema on atherosclerosis severity in our mouse model cannot be explained by a 
reduction in lipid levels. Second, inflammation is another well-known player in atherogenesis 
and may be decreased in experimental emphysema. A reduction of inflammation in the 
lungs and accompanying decrease in systemic inflammation in the PPE-treated mice may 
explain the observed decrease in atherosclerosis severity. However, at the same time point of 
determination of atherosclerosis development, i.e. 24 weeks after intratracheal PPE instillation, 
no differences in the number of macrophages and neutrophils in the lungs were found, making 
this mechanism unlikely. On the other hand, we found a reduction in circulating monocytes 
and neutrophils after intratracheal PPE instillation, which may have contributed to the reduced 
atherosclerotic lesion severity in these mice. 
How do we explain the observed decrease in the number of circulating monocytes and 
neutrophils? Recruitment of monocytes and neutrophils towards the lung during the acute 
phase of inflammation due to PPE-induced damage could be a mechanism.36 This is however an 
unlikely explanation, since the acute inflammatory reaction after intratracheal administration 
of PPE to rodents is resolved within 3 weeks,37,38 and we found that the number of macrophages 
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and neutrophils in lung tissue at the end of the study was not affected by PPE treatment. A 
second potential mechanism for the decrease in circulating monocytes and neutrophils in the 
PPE-treated animals is that it is part of a resolution process. Resolution after inflammation is 
programmed within the normal inflammatory response itself after an acute injury to minimize 
tissue and organ damage.39 Possibly, this resolution of inflammation reduces systemic 
inflammation involved in atherosclerosis. Failure of effective resolution has been suggested to 
be a contributor to the dysregulated inflammatory process in atherosclerosis development.40 
In addition, the decrease in circulating monocytes and neutrophils may be the result of a 
progressive negative feedback mechanism for the production of inflammatory cells, after the 
acute inflammation induced by PPE instillation. In view of the time span of 8 weeks between 
the intratracheal PPE instillation and the observed reduction in circulating monocytes and 
neutrophils, this possibility is not presumable. It is likely that there are other causes for this 
reduction which are currently unknown to us.
Another potential mechanism linking COPD to enhanced CVD is chronic hypoxia.2 PPE-
treated mice also showed signs of chronic hypoxia, indicated by a significantly higher number 
of circulating erythrocytes, hemoglobin and hematocrit levels. As it is known that hypoxia can 
promote atherogenesis,41 it seems contradictory that the mice treated with PPE in our study 
showed less severe atherosclerotic lesions. However, the magnitude of hypoxia in the PPE-
treated mice was likely compensated by several mechanisms. First, the respiration amplitude 
was increased, probably as a compensation mechanism for the reduction in diffusion area 
caused by PPE instillation. This compensating mechanism may have sufficed to prevent hypoxia 
to some degree, since the respiratory rate did not differ between the groups. In addition, 
hypoxia was probably at least partly compensated by the increase in the number of circulating 
erythrocytes. Moreover, the development of right ventricular hypertrophy as observed in the 
present study, and reported in COPD patients by others42 may also have acted as a compensation 
mechanism. Therefore, in the PPE-treated mice several compensatory mechanisms are likely to 
have developed in order to minimize the level of hypoxia. Finally, the possibility that hypoxia 
does increase atherosclerosis only in presence of nicotine needs to be considered. Previous 
studies have shown that nicotine increases growth of atherosclerotic lesions in mice.43 Since this 
effect was subsequently shown to be mediated by the α7-non-neuronal nicotinic acetylcholine 
receptor, and because the endothelial expression of this receptor is increased by hypoxia,44 
which may have resulted from emphysema in the present study, it is possible that nicotine-
mediated effects on atherosclerotic plaque growth are increased in PPE-treated mice. 
Finally, physical inactivity and obesity are risk factors for the development of atherosclerosis.45 
In the present study, PPE treatment did not affect body weight gain and food intake. Therefore, 
it is unlikely that these factors have influenced atherosclerosis development. Although we did 
not measure the physical activity of the mice, there was no evident difference in appearance 
and behavior between the groups, but we cannot formally exclude this. 
In summary, our results indicate that in atherosclerosis-prone E3L mice, emphysema per 
se, in the absence of inflammation, does not aggravate the development of atherosclerosis size 
and even diminishes its severity. Thereby, this study has provided more mechanistic insight into 
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Abstract
Resveratrol is a major constituent of traditional Asian medicinal herbs and red wine and is 
suggested to be a potential anti-atherosclerotic drug, due to its proposed hypolipidemic, 
anti-inflammatory and anti-oxidative properties. The aim of this study was to evaluate whether 
resveratrol protects against atherosclerosis development in APOE*3-Leiden.CETP (E3L.CETP) 
mice, and adds to the anti-atherogenic effect of mild statin treatment, currently the most 
widely used anti-atherogenic therapy. E3L.CETP mice were fed a cholesterol-rich diet without 
(control) or with resveratrol (0.01% w/w), atorvastatin (0.0027% w/w), or both for 14 weeks. 
During the study plasma lipid, inflammatory and oxidative stress parameters were determined. 
Resveratrol reduced atherosclerotic lesion area (-52%) in the aortic root, comparable to 
atorvastatin (-40%) and the combination of both drugs (-47%). The collagen/macrophage 
ratio in the atherosclerotic lesion, a marker of plaque stability, was increased by resveratrol 
(+108%), atorvastatin (+124%) and the combination (+154%). Resveratrol decreased plasma 
cholesterol levels (-19%) comparable to atorvastatin (-19%) and the combination (-22%), which 
was completely confined to (V)LDL-cholesterol levels in all groups. Posthoc analyses showed 
that the anti-atherogenic effect of atorvastatin could be explained by cholesterol lowering, 
while the anti-atherosclerotic effect of resveratrol could be attributed to factors additional 
to cholesterol lowering. Markers of inflammation and oxidative stress were not different, but 
resveratrol improved macrophage function. We conclude that resveratrol potently reduces 
atherosclerosis development and induces a more stable lesion phenotype in E3L.CETP mice. 
However, under the experimental conditions tested, resveratrol does not add to the anti-




Dyslipidemia, characterized by high plasma levels of VLDL and LDL, and low plasma levels of 
HDL, is a well recognized risk factor for atherosclerosis, the main cause for cardiovascular 
events. Current treatment of atherogenic dyslipidemia mainly aims at reducing plasma 
(V)LDL-cholesterol levels, for example by using statins, which effectively inhibit 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase. However, statin use prevents only 15-30% 
of all cardiovascular events.1
Atherosclerosis is considered to be a multifactorial inflammatory disease and optimal 
therapeutic treatment of atherosclerosis should thus encompass different approaches. In 
addition to dyslipidemia, oxidative stress, inflammation and macrophage foam cell formation 
are crucial processes in the development of atherosclerotic plaques.2 (V)LDL particles are 
oxidized locally within the vascular wall, but also circulating oxidized (V)LDL can enter the 
vascular wall, and can trigger an inflammatory reaction by resident macrophages. This 
inflammatory reaction includes the production of cytokines, chemokines and reactive oxygen 
species (ROS), and results in upregulation of adhesion receptors on endothelial cells and 
recruitment of monocytes from the circulation.
Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a phytoalexin produced in plants in 
response to stress, and is present in large amounts in some nuts, Polygonum cuspidatum 
(Japanese knotweed) and in the skin of red grapes. Consequently, resveratrol is a major 
constituent of traditional Asian medicinal herbs and red wine. Resveratrol has been shown to 
extend the life span of yeast3 and mice,4 to improve insulin sensitivity4 and to prevent cancer 
development5 in experimental models. Importantly, resveratrol has also been recognized to 
possess various anti-atherosclerotic activities, including hypolipidemic,6-8, anti-oxidative9-12 and 
anti-inflammatory9,11,13,14 properties.
Despite these promising and diverse anti-atherosclerotic actions, studies addressing 
the effect of resveratrol on atherosclerosis are scarce. Recent preliminary reports suggest 
that resveratrol indeed reduces atherosclerosis development.6,15,16 In the current study we 
investigated whether resveratrol protects against atherosclerosis development in APOE*3-
Leiden.CETP (E3L.CETP) transgenic mice and whether resveratrol adds to mild atorvastatin 
treatment because of its proposed diverse anti-atherosclerotic properties. To address this, we 
used a dose of resveratrol (i.e. 11 mg/kg/day) similar to dosages in other experimental models 
(i.e. 2-20 mg/kg/day) in which resveratrol effectively reduced atherosclerosis.6,15,16 To study a 
potential modulating effect of resveratrol on top of atorvastatin treatment, we used a mild 
atorvastatin dose (i.e. 2 mg/kg/day) aiming at a reduction in plasma cholesterol of 25%, which 
is approximately half of the maximal cholesterol-lowering effect of atorvastatin in this mouse 
model,17,18 and similar to the reduction of plasma cholesterol in men. By using this strategy a 
(potentially) relevant additive effect of resveratrol could be better detected. E3L.CETP mice 
represent a unique murine atherosclerosis model for human-like lipoprotein metabolism that 
shows a similar response to lipid-lowering drugs including statins19 and HDL-raising drugs19,20 as 
humans. In contrast, classical atherosclerosis models have no human-like response to statins 
with respect to cholesterol lowering (apoe-/-) or a variable response with respect to cholesterol 
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lowering and atherosclerosis development (ldlr-/-).21 In addition, ldlr-/- mice are unable to 
upregulate the LDLr after statin treatment, an important additional cholesterol-lowering 
characteristic of statin treatment. Therefore, the E3L.CETP model is thus a more suitable 
model than these classical models to study whether resveratrol is atheroprotective on top of 
atorvastatin treatment. Our results show that resveratrol markedly reduces atherosclerosis 
development, but does not add to the anti-atherogenic effect of atorvastatin.
Methods and materials
Animals
E3L mice were crossbred with mice expressing human cholesteryl ester transfer protein 
(CETP) under control of its natural flanking regions to generate heterozygous E3L.CETP mice.19 
Female E3L.CETP mice of 10-12 weeks of age were used for all studies. Mice were housed under 
standard conditions with a 12-h light/dark cycle and had free access to food and water. They 
were fed regular chow (Ssniff, Soest, Germany) or a Western-type diet (WTD) containing 15% 
(w/w) cacao butter (diet T, HopeFarms, Woerden, The Netherlands) supplemented with 0.15% 
(w/w) cholesterol (Sigma-Aldrich, Zwijndrecht, The Netherlands) with or without resveratrol 










Pfizer, Capelle a/d IJssel, The Netherlands). Body weight and food intake were monitored 
during the study. Food intake was monitored twice per week by determining the amount of diet 
consumed by the mice of each cage (each cage housed 3-5 mice), divided by the number of 
mice per cage. Unless indicated otherwise, blood was drawn after a 4-h fast in EDTA-containing 
cups by tail bleeding, and plasma was isolated by centrifugation and stored frozen at -80°C until 
further analyses. All animal experiments were approved by the Institutional Ethics Committee 
on Animal Care and Experimentation.
Atherosclerosis study and atherosclerosis quantification
During a run-in period of 5 weeks, all female E3L.CETP mice received the WTD (containing 
0.15% w/w cholesterol). After matching into 4 groups based on age, body weight, and 
plasma cholesterol and triglyceride levels, the mice received the WTD either alone (control) 
or supplemented with resveratrol (0.01% w/w; 11 mg/kg/day), atorvastatin (0.0018% w/w; 
2 mg/kg/day) or both, as described above. Since after 4 weeks of drug intervention the dose 
of atorvastatin did not result in an anticipated 25% reduction in plasma cholesterol levels, the 
dose of atorvastatin was adjusted to 0.0027% (w/w; 3 mg/kg/day) in the atorvastatin only group 
and in the combination group.
After 14 weeks of drug intervention, mice were killed by CO
2
 inhalation. Blood was drawn via 
cardiac puncture for serum isolation and hearts were collected. Hearts were fixed in phosphate-
buffered 4% formaldehyde, dehydrated, embedded in paraffin, and perpendicular to the axis of 
the aorta cross-sectioned (5 µm) throughout the aortic root area starting from the appearance of 
open aortic valve leaflets. Per mouse, 4 sections with 50 µm intervals were used for atherosclerosis 
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measurements. Sections were stained with hematoxylin-phloxin-saffron for histological analysis. 
Lesions were categorized for severity according to the guidelines of the American Heart 
Association adapted for mice.22 Various types of lesions were discerned; no lesions, mild lesions 
(types 1-3) and severe lesions (types 4-5). Lesion area was determined using Cell D imaging 
software (Olympus Soft Imaging Solutions, Münster, Germany). Immunohistochemistry for 
determination of lesion composition was performed as described previously.22 Rabbit anti-mouse 
antibody AIA 31240 (1:3000; Accurate Chemical and Scientific, Westbury, NY) was used to quantify 
macrophage area and the number of monocytes adhering to the lesions.23 Monoclonal mouse 
antibody M0851 (1:800; Dako, Heverlee, The Netherlands) against smooth muscle cell actin was 
used to quantify smooth muscle cell area. Sirius Red was used to quantify collagen area.
Plasma lipid, lipoprotein, and inflammatory marker analysis
Plasma was assayed for total cholesterol (TC) and triglycerides (TG) using commercially 
available enzymatic kits according to the manufacturer’s protocols (236691 and 1488872, Roche 
Molecular Biochemicals, Indianapolis, IN). The cholesterol distribution over plasma lipoproteins 
was determined by fast performance liquid chromatography using pooled plasma (14-15 mice 
per pool).24
Plasma cytokine levels (i.e. IL-1ß, IL-6, IL-10, IL-12p70, TNFα, CXCL1) were assessed using a 
multiplex murine inflammatory cytokine profile immunoassay from Meso Scale Discovery (MSD) 
on a MSD 2400 plate reader according to the manufacturer’s protocol (MSD, Gaithersburg, 
MD). Plasma levels of soluble E-selectin (sE-selectin; R&D systems, Abingdon, United Kingdom) 
and monocyte chemoattractant protein-1 (MCP-1; R&D systems) were determined according 
the manufacturers’ instructions. Plasma levels of MCP-1 were determined in pooled plasma 
(7 pools per group with 2 mice per pool).
Hepatic and macrophage gene expression analysis
Total RNA from livers or from peritoneal macrophages was isolated using the Nucleospin 
RNA II kit (Macherey-Nagel, Düren, Germany) according to manufacturer’s instructions. RNA 
quality of each sample was checked with the lab-on-a-chip technology using Experion Std 
Sens analysis kit (Biorad, Hercules, CA). One microgram of total RNA was converted to cDNA 
with iScript cDNA Synthesis kit (Biorad) and purified with Nucleospin Extract II kit (Macherey-
Nagel). Real-Time PCR (RT-PCR) was conducted on the IQ5 PCR machine (Biorad) using the 
Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). mRNA levels were normalized to 
mRNA levels of hypoxanthine phosphoribosyltransferase (hprt) and cyclophilin (cyclo). Primer 
sequences are listed in Supplemental Table S1.
Analyses of oxidative stress markers
Serum levels of IgG1, IgG2a and IgM against oxidized LDL (oxLDL) were determined using the 
Mouse MonoAb ID kit (HRP) (Zymed Laboratories Inc, San Francisco, CA). Oxidized human 
LDL (5 µg/ml) dissolved in a NaHCO
3
 buffer (pH 9.0) was coated overnight onto a flat-bottom 
96-well high binding plate (Corning, NY). Subsequently, levels of IgG1, IgG2a and IgM in serum 
(dilution 1:3) were detected according to the manufacturer’s instructions.
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Urine from spontaneous urination upon handling of mice was collected in Eppendorf tubes 





α) was determined in pooled urine samples (7 pools per group with 2 mice per pool) 
by GC-MS/MS after immunoaffinity column chromatography from Cayman Chemicals (Ann 
Arbor, MI) as described previously.25 Values were corrected for urinary creatinine excretion, 
which was measured by GC-MS as described.25
Analyses of peritoneal macrophage function in vitro
Thioglycollate-elicited peritoneal macrophages from E3L.CETP mice were isolated and 
cholesterol efflux assay was performed as described previously.26 Macrophages were loaded 
with [3H]cholesterol-labeled acetylated LDL (AcLDL; 50 µg/ml) for 32 h and subsequently 
incubated overnight without or with the indicated concentrations of resveratrol. The next day 
these cholesterol-laden macrophages were incubated with lipid-free apoAI (10 µg protein/ml) 
or HDL (50 µg/ml) for 6 h and radioactivity was determined in the medium and cell lysates to 
determine the percentage of cholesterol efflux.
To study the effect of resveratrol on the uptake of AcLDL isolated peritoneal macrophages 
were incubated overnight without or with the indicated concentrations of resveratrol. The 
next day, the macrophages were incubated with [3H]cholesteryl oleoyl ether-labeled AcLDL 
(10 µg protein/ml) for 6 h and radioactivity was measured in the cell lysates to determined the 
percentage of AcLDL uptake.
To determine the lipopolysaccharide (LPS)-induced TNFα response27 peritoneal 
macrophages were incubated overnight with resveratrol (10 µM) and, subsequently, incubated 
for 4 h with the indicated concentrations of LPS (Salmonella minnesota Re595 LPS; Sigma). 
TNFα was determined in the medium by ELISA (OptEIATM ELISA, BD Biosciences Pharmingen). 
For the macrophage assays, values were corrected for the cellular protein content.
Statistical analysis
Data are presented as mean ±SEM unless indicated otherwise. Differences were assessed by 
one-way ANOVA test followed by the Bonferroni posthoc test. Differences in plasma cholesterol 
levels were tested using the one-way ANOVA test followed by Dunnett’s posthoc test. Two-way 
ANCOVA was performed to test for differences on atherosclerotic lesion area after controlling 
for the cholesterol-lowering capacity of the different treatments. The square root was taken of 
the atherosclerotic lesion area to linearize the relationship with plasma cholesterol exposure. 
A probability level (P) of 0.05 was considered significant. The Student’s T-test was used to 
evaluate differences in the in vitro macrophage studies. SPSS 17.0 for Windows (SPSS, Chicago, 
IL) was used for statistical analysis.
Results
Resveratrol attenuates atherosclerosis development to a similar extent as atorvastatin
To study the effect of resveratrol on atherosclerosis development, E3L.CETP mice were fed a 
Western-type diet (WTD) without or with resveratrol, atorvastatin, or the combination of both 
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drugs. Neither of the treatments affected food intake and body weight during the study (not 
shown). Mice were sacrificed after 14 weeks of treatment and lesion size and lesion severity 
were determined in the valve area of the aortic root. Treatment with resveratrol reduced total 
atherosclerotic lesion area by -52% (P<0.01), whereas atorvastatin reduced this by -40% (P<0.05) 
as compared to control treated mice (Figure 1A). The combination of resveratrol and atorvastatin 
did not further reduce atherosclerotic lesion area (-47% as compared to the control group; P<0.01) 
as compared to single treatments. This reduction in lesion area was similar over all 4 sections 
of the sampled valve area of the aortic root (Figure 1B). Neither of the treatments significantly 
affected lesion severity as classified as mild (type 1-3) and severe (type 4-5) lesions (Figure 1C).
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Fig. 1. Resveratrol, atorvastatin and the combination comparably reduce atherosclerosis development. 
Slides of the valve area of the aortic root were stained with hematoxylin-phloxin-saffron and total lesion 
area was calculated of 4 sections per mouse starting from the appearance of open aortic valve leaflets as 
described in Methods and Materials (A). Lesion area as a function of distance was determined by calculating 
the lesion area of each cross-section from A (B). The same 4 sections per mouse were categorized according 
to lesion severity (C). Values are means ±SEM (n=14-15). *P<0.05, **P<0.01 vs control group.
Resveratrol and atorvastatin induce stable lesions
Subsequently, we assessed whether the different treatments affected monocyte recruitment 
and lesion composition. With respect to lesion composition we characterized macrophage 
content, a destabilizing component in the lesions, and collagen and smooth muscle cell content, 
both stabilizing components in the lesions.2 As shown in Figure 2, neither of the treatments 
affected the number of adhering monocytes to the endothelium. However, resveratrol tended 
to decrease macrophage content, whereas atorvastatin significantly decreased it (Figure 2B). 
Resveratrol enhanced smooth muscle cell and collagen content to a similar extent as 
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Fig. 2. Resveratrol, atorvastatin and the combination induce more stable lesions. The adhesion of 
monocytes to the lesions in the aortic root was determined (A) as were the macrophage content (B), 
collagen content (C), smooth muscle cell (SMC) content (D) and collagen/macrophage ratio (E) of the 
lesions. Values are means ±SEM (n=14-15). *P<0.05, **P<0.01, ***P<0.001 vs control group.
atorvastatin (Figure 2C+D). Both resveratrol and atorvastatin thus induced more stable lesions 
as indicated by an enhanced collagen/macrophage ratio (2.2-fold and 2.4-fold, respectively) 
(Figure 2E). The combination treatment did not have a significant additional effect on lesion 
composition as compared to the single treatments.
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Resveratrol and atorvastatin reduce (V)LDL levels to a similar extent
To study whether the anti-atherogenic effect of the different treatments could be the result 
of hypolipidemic, anti-inflammatory and/or anti-oxidant properties of resveratrol and 
atorvastatin, we first determined the effect of the different treatments on plasma lipid levels. 
Plasma cholesterol levels were similarly reduced by resveratrol (-19%; P=0.077) and atorvastatin 
(-22%; P<0.05) as compared to the control group (Figure 3A). The combination treatment 
did not further reduce plasma cholesterol levels (-21% as compared to control-treated mice; 
P<0.05). Lipoprotein fractionation showed that for all treatments the reduction in plasma 
cholesterol levels was confined to the (V)LDL fraction, while HDL-cholesterol levels were not 
affected (Figure 3B).
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Fig. 3. Resveratrol, atorvastatin and the combination similarly lower plasma (V)LDL-cholesterol levels. 
Plasma cholesterol was determined after 8 weeks of treatment (A). The cholesterol distribution over 
lipoproteins was determined in pooled plasma (B). Values are means ±SEM (n=14-15). *P<0.05 vs control 
group.
To investigate whether this reduction in (V)LDL could be caused by reduced hepatic 
production of VLDL and/or increased clearance of (V)LDL from plasma, we subsequently 
determined the expression of hepatic genes involved in cholesterol and TG metabolism 
(Supplemental Table S2). Resveratrol treatment did not affect hepatic mRNA expression of 
genes involved in cholesterol metabolism (i.e. ldlr, sr-b1, abca1 and abcg1) and VLDL metabolism 
(i.e. apob, mttp, fasn and lpl). Treatment with atorvastatin and/or the combination altered the 
expression of genes involved in cholesterol metabolism (i.e. increased: ldlr; decreased: abca1, 
abcg1 and sr-b1), but not those involved in VLDL metabolism, with the exception of a decreased 
expression of lpl.
Unlike for atorvastatin, the anti-atherogenic effect of resveratrol may not be solely 
explained by its plasma cholesterol-lowering capacity
Since our collective data suggest that the anti-atherogenic effect of resveratrol and atorvastatin 
may mainly depend on their ability to reduce plasma cholesterol, we performed 2-way 
ANCOVA analyses in which we controlled for the cholesterol-lowering effect of the treatments 
by using the cumulative plasma cholesterol exposure during the study (i.e. area under the 
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curve). The effect of resveratrol on atherosclerotic lesion area reduction remained significant 
(F = 5.34; P<0.05), whereas for atorvastatin treatment significance was lost (F = 0.88; P=0.36). 
This indicates that the reduction in atherosclerosis development upon atorvastatin treatment 
can be explained by its cholesterol lowering effect, while additional mechanism(s) could be 
involved in the anti-atherogenic effect of resveratrol.
Resveratrol and atorvastatin do not affect inflammatory parameters
To elucidate by which additional mechanism(s) resveratrol may be atheroprotective, we 
assessed the effect of the different treatments on inflammatory parameters in liver and plasma. 
Neither of the treatments affected hepatic mRNA levels of il-1ß and il-6 (Supplemental Table S2) 
or a panel of plasma cytokine levels (i.e. IL-1ß, IL-6, IL-10, IL-12p70, TNFα and CXCL1, the murine 
homologue of IL-8), with the exception that the combination treatment reduced CXCL1 levels 
by -33% (P<0.05; not shown). Similarly, resveratrol and atorvastatin did not affect plasma levels 
of the acute-phase proteins soluble E-selectin (sE-selectin) and MCP-1, but the combination 
reduced plasma MCP-1 by -30% (P<0.05; not shown). These findings indicate that both 
resveratrol and atorvastatin do not substantially affect the hepatic and systemic inflammatory 
status of E3L.CETP mice.
Resveratrol and atorvastatin do not affect oxidative stress parameters
We next investigated the effect of resveratrol, atorvastatin and their combination on markers 
of oxidative stress. Resveratrol did not affect hepatic mRNA expression of enzymes involved 
in oxidative stress (i.e. mnsod, pon1, cox1, cox2, lox1) (Supplemental Table S2). Treatment 
with atorvastatin and/or the combination decreased the expression of cox2, lox1 and mnsod, 
but did not affect expression of pon1 and cox1. Furthermore, circulating levels of IgG1, IgG2a 
and IgM directed against oxLDL were not different between the four groups (not shown). 





α) (not shown), a biomarker of lipid peroxidation.28
Resveratrol beneficially influences macrophage function
Since macrophages are the most prominent inflammatory cells in the atherosclerotic lesion 
and involved in both the initiation, progression and regression of the atherosclerotic lesion,2 
we assessed the effect of resveratrol on macrophage function, i.e. cholesterol efflux and release 
of proinflammatory mediators. Resveratrol enhanced the cholesterol efflux from primary 
macrophages from E3L.CETP mice to apoAI in a dose-dependent manner up to +243% (P<0.05), 
but not to HDL (Figure 4). Moreover, resveratrol reduced the uptake of AcLDL up to -24% 
(P<0.05) as compared to vehicle-treated primary macrophages (Figure 5), without affecting the 
expression of genes involved in cholesterol efflux and/or uptake (i.e. abca1, abcg1, sr-b1, sr-a1, 
cd36, lpl) (not shown). In addition, resveratrol reduced the lipopolysaccharide (LPS)-induced 
TNFα secretion up to -63% (P<0.05) as compared to untreated primary macrophages (Figure 6). 
These data show that resveratrol beneficially influences macrophage function, indicating that 
resveratrol may have local anti-atherosclerotic effects in the vessel wall, which may explain its 



















































































































































































































Fig. 4. Resveratrol enhances the cholesterol efflux from macrophages. [3H]cholesterol-laden peritoneal 
macrophages from E3L.CETP mice were equilibrated overnight without or with the indicated concentrations 
resveratrol. The cholesterol efflux was determined after incubation without or with lipid-free apoAI 
(10 µg/ml) (A) and HDL (50 µg protein/ml) (B) as percentage of 3H-activity released into the medium per µg 
cell protein. The data of 2 separate experiments were combined and expressed as percentage relative to the 
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Fig. 6. Resveratrol reduces the LPS-induced inflammatory response of macrophages. Peritoneal macrophages 
from E3L.CETP mice were equilibrated overnight without or with resveratrol (10 µM). Subsequently, cells were 
incubated for 4 h with the indicated concentrations LPS, and TNFα secretion into the medium was determined. 
Values are expressed as means per mg cell protein ±SEM (n=4). *P<0.05 vs without resveratrol.
Fig. 5. Resveratrol reduces the uptake of AcLDL by macrophages. Peritoneal macrophages from E3L.CETP 
mice were equilibrated overnight without or with the indicated concentrations of resveratrol. The uptake of 
[3H]cholesteryl oleoyl ether-labeled AcLDL ([3H]COEth AcLDL; 10 µg protein/ml) was determined after 6 h. 
Values are expressed as the mean percentage of 3H-activity per µg cell protein ±SEM (n=4). *P<0.05 vs control.
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Discussion
In the present study we assessed the anti-atherosclerotic potential of resveratrol, either alone 
or in combination with atorvastatin. We showed that resveratrol reduces atherosclerosis 
development and improves plaque stability to a similar extent as atorvastatin in E3L.CETP mice. 
Whereas the anti-atherogenic effect of atorvastatin could be explained by its cholesterol-
lowering effect, additional mechanisms may be involved in the anti-atherogenic effect of 
resveratrol, which may involve beneficial modulation of macrophage function. However, the 
combination of resveratrol and atorvastatin did not additively reduce atherosclerosis.
Our finding that resveratrol efficiently reduces atherosclerotic lesion development in 
E3L.CETP mice is in accordance with preliminary reports in literature. The first report suggested 
only qualitatively, that resveratrol reduced atherosclerosis development in the aortas of 
apoE-deficient mice.6 The second report used a very limited number of mice (i.e. n=4-7), but 
nevertheless showed a significant reduction in atherosclerosis development in apoE/LDLr-
double deficient mice.15 The most recent report observed that resveratrol reduced the intima/
media area ratio in New Zealand rabbits fed a 1% cholesterol diet.16 The fact that resveratrol 
reduces atherosclerosis supports the hypothesis that resveratrol contributes to the “French 
Paradox”, i.e. the notion that moderate and prolonged consumption of red wine is associated 
with decreased cardiovascular morbidity and mortality in the French population despite high 
dietary saturated fat consumption.29 Resveratrol is a major constituent of the skin of red grapes 
and, therefore, abundantly present in red wine with concentrations ranging from 1-12 mg/L 
(i.e. 0.2-2 mg/glass).30
To assess the potential anti-atherosclerotic actions of resveratrol responsible for the 
protection against atherosclerosis, plasma lipid levels as well as inflammatory and oxidative 
stress parameters were studied. We found no relevant effect of resveratrol treatment on 
hepatic and systemic inflammation as indicated by hepatic mRNA expression of cytokines and 
circulating cytokine and acute-phase protein levels, respectively. Similarly, there was no effect 
of resveratrol on oxidative stress, as evidenced by unaltered circulating antibodies against oxLDL 
as well as unaltered urinary excretion of the isoprostane 8-iso-PGF
2
α. The latter is a biomarker 
of lipid peroxidation28 and as such has been associated with coronary heart disease.31 The fact 
that in our studies resveratrol treatment did not affect systemic inflammatory and oxidative 
stress parameters may be the result of the mild treatment strategy as compared to most other 
studies in which a reducing effect of resveratrol on these parameters was observed. We treated 
the mice chronically with 0.01% (w/w) resveratrol in the diet, comparable to 11 mg/kg/day, 
whereas most other acute or chronic experimental studies used at least 2.5- to 10-fold higher 
dosages.6,9,10,13 We chose for this mild treatment strategy since comparable dosages (2-20 mg/
kg/day) effectively reduced atherosclerosis development in the above mentioned preliminary 
reports.6,15,16 Furthermore, this dose is similar to the recommended dosage of resveratrol 
supplementation in humans (ranging from 1-20 mg/kg/day; e.g. www.resveratrol.info; www.
resveratrolreference.com). The anti-inflammatory and anti-oxidative effect of resveratrol in 
vivo may in particular be apparent after challenging the mice with inflammatory stimuli, since 
various reports describing the anti-inflammatory effect of resveratrol in vivo used such a 
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experimental set-up, e.g. by lipopolysaccharide (LPS) injection13 or by inducing experimental 
colitis.11
Resveratrol treatment reduced plasma (V)LDL-cholesterol levels similarly as atorvastatin 
treatment. This hypolipidemic effect of resveratrol is in accordance with previous reports,6-8 
and can result from several mechanisms. First, resveratrol could reduce hepatic VLDL 
secretion, since resveratrol reduced apoB secretion in human HepG2 cells.32 However, we did 
not observe differences in expression of several hepatic genes involved in VLDL biogenesis 
(i.e.  fasn, mttp, apob), suggesting that resveratrol did not lower plasma lipids by reducing 
hepatic VLDL production in the present study. Nevertheless, one has to keep in mind that 
this does not exclude a potential effect of resveratrol on posttranslational modification of 
the proteins involved in VLDL biogenesis. Second, resveratrol treatment could enhance VLDL 
catabolism and/or uptake. However, the lack of an effect of resveratrol treatment on key 
hepatic genes involved in VLDL clearance (i.e. ldlr, lpl), the lack of a reduction in plasma TG 
levels (not shown) and the lack of studies in literature, so far do not provide further support 
for this mechanism. Third, resveratrol may inhibit HMG-CoA reductase, possibly via enhancing 
cytochrome P450 27-hydroxylase (CYP27A1) activity which syntheses the HMG-CoA reductase-
inhibitor 27-hydroxycholesterol.33 Resveratrol was shown to attenuate the expression of 
HMG-CoA reductase in hamsters34 and reduce HMG-CoA reductase activity in mice.6 Although 
this could contribute to the hypocholesterolemic effect in the present study, it is unlikely to be 
the prevailing mechanism. Resveratrol treatment did not alter the hepatic cholesterol content 
(i.e. free cholesterol and cholesteryl esters; Supplemental Figure S1), while treatment with the 
HMG-CoA reductase inhibitor atorvastatin did result in the expected reduction of hepatic 
cholesterol. Finally, we speculate that resveratrol treatment may reduce intestinal cholesterol 
absorption, but this has not been studied so far. Therefore, further studies are necessary 
to reveal the prevailing mechanism by which resveratrol lowers plasma cholesterol levels. 
Resveratrol was also suggested to increase plasma HDL-cholesterol levels in apoE-deficient 
mice.6 However, it had no HDL-raising effect in our E3L.CETP model, which is otherwise highly 
responsive to HDL-cholesterol increasing drugs.19,20
The above considerations show that resveratrol mainly reduces atherosclerosis 
development as a result of lowering plasma (V)LDL-cholesterol levels. However, controlling for 
this cholesterol-lowering effect of resveratrol in the statistical analyses showed that additional 
anti-atherogenic mechanism(s) could be involved. If so, it is likely that resveratrol exerts these 
additional mechanism(s) locally in the vessel wall by beneficially altering macrophage function. 
We found that resveratrol improved at least three of the most important characteristics 
of macrophages related to atherosclerosis, i.e. potency to efflux cholesterol, formation of 
foam cells and the release of proinflammatory mediators. These anti-atherogenic actions of 
resveratrol in primary macrophages of E3L.CETP mice together indicate a potential local effect of 
resveratrol at the level of macrophages in the vessel wall in addition to its hypolipidemic effect. 
Our finding that resveratrol enhances the cholesterol efflux from primary macrophages is in 
line with previous findings by others.33,35,36 They reported that resveratrol enhanced cholesterol 
efflux from macrophages via upregulation of the gene and protein expression of ABCA1 and 
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ABCG1. Upregulation of ABCG1 was not consistent in different cell types, which could explain 
the lack of an effect of resveratrol on cholesterol efflux towards HDL in our studies. Moreover, 
Voloshyna et al.33 found that these effects were PPARγ- and adenosine 2A receptor-dependent. 
However, we were unable to observe an increase in ABCA1 expression. Thus, it is likely that 
resveratrol upregulated ABCA1 protein posttranscriptionally. Alternatively, resveratrol could 
have increased CYP27A1 activity,33 which stimulates the efflux of cholesterol to apoAI by a yet 
undefined ABCA1-independent pathway.37
Resveratrol effectively protected against atherosclerosis development. Despite the 
suggested differences in underlying mechanisms, treatment with resveratrol did not add to 
atorvastatin treatment with respect to reducing atherosclerosis in our model. Since resveratrol 
may act on atherosclerosis by mechanism(s) in addition to cholesterol-lowering, these 
mechanistic pathways may become more prominent at higher dosage.
In summary, we have demonstrated that resveratrol potently reduces atherosclerosis 
development and results in more stable lesions in E3L.CETP mice, comparable to atorvastatin 
treatment. This anti-atherogenic effect of resveratrol is mainly explained by its plasma 
(V)LDL-cholesterol-lowering capacity, but may also include local anti-atherogenic effects in 
the vessel wall such as on macrophage function. Nonetheless, in the current experimental 
set-up resveratrol did not add to the effects of atorvastatin with respect to protection against 
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Supplemental Table S1. Primers used for quantitative RT-PCR analysis.




















Abca1/abcg1, ATP-binding cassette transporter a1/g1; Apob, apolipoprotein B; Cox1 / 2, cyclooxygenase-1 / -2; Cyclo, 
cyclophilin; Fasn, fatty acid synthase; Hprt, hypoxanthine phosphoribosyl-transferase; Il-1β / -6, interleukin-1β / -6; 
Ldlr, low-density lipoprotein receptor; Lox-1, lectin-like oxidized low-density lipoprotein receptor-1; Lpl, lipoprotein 
lipase; Mnsod, manganese superoxide dismutase; Mttp, microsomal triglyceride transfer protein; Pon1, paraoxonase-1; 
Sr-a1 / -b1, scavenger receptor-A1 / -B1.
Resveratrol Protects against Atherosclerosis
113
Supplemental Fig. S1. Resveratrol does not reduce the hepatic cholesterol content. The hepatic total 
cholesterol, free cholesterol and cholesteryl ester content were determined according to Wong et al. 
[Wong MC 2012 Atherosclerosis] in livers of E3L.CETP mice that were treated with either no drug (control), 
resveratrol (Resv), atorvastatin (Atorva) or the combination (Resv+Atorva) for 14 weeks. Values are means 
± SEM (n=14-15). Statistical differences were assessed with one-way ANOVA followed by Bonferroni 
posthoc test. **P<0.01 vs control group.
Supplemental Table S2. Effect of resveratrol and atorvastatin on hepatic gene expression.
Gene Control Resv Atorva Resv + Atorva
Lipid metabolism
Abca1 1.00 ± 0.21 0.93 ± 0.19 0.69 ± 0.15* 0.76 ± 0.19
Abcg1 1.00 ± 0.22 0.81 ± 0.24 0.54 ± 0.19** 0.62 ± 0.05**
Apob 1.00 ± 0.28 0.94 ± 0.35 0.92 ± 0.29 1.00 ± 0.23
Fasn 1.00 ± 0.24 1.73 ± 1.14 1.59 ± 0.49 1.49 ± 0.91
Ldlr 1.00 ± 0.24 0.87 ± 0.37 1.36 ± 0.49 1.74 ± 0.55*
Lpl 1.00 ± 0.35 0.83 ± 0.16 0.54 ± 0.09** 0.55 ± 0.24**
Mttp 1.00 ± 0.18 0.94 ± 0.29 1.10 ± 0.26 1.05 ± 0.16
Sr-b1 1.00 ± 0.25 0.92 ± 0.29 0.62 ± 0.18* 0.73 ± 0.14
Inflammation
IL-1β 1.00 ± 0.37 0.61 ± 0.24 0.56 ± 0.24 0.76 ± 0.51
IL-6 1.00 ± 0.34 0.81 ± 0.35 1.04 ± 0.55 1.36 ± 0.47
Oxidative stress
Cox1 1.00 ± 0.32 1.01 ± 0.35 0.78 ± 0.21 0.80 ± 0.40
Cox2 1.00 ± 0.95 0.57 ± 0.45 0.37 ± 0.24 0.38 ± 0.16*
Lox1 1.00 ± 0.72 0.56 ± 0.30 0.42 ± 0.17** 0.36 ± 0.10**
Mnsod 1.00 ± 0.22 0.92 ± 0.26 0.77 ± 0.22 0.67 ± 0.24*
Pon1 1.00 ± 0.15 0.94 ± 0.10 1.21 ± 0.32 1.08 ± 0.32
See the legend of Supplemental Table S1 for explanation of abbreviations. Statistical differences were assessed with 
one-way ANOVA followed by Bonferroni posthoc test. *P<0.05, **P<0.01 vs control group.


















































Supplemental Figure S1. Resveratrol does not reduce the hepatic cholesterol content. 
The hepatic total cholesterol, free cholesterol and cholesteryl ester content were determined 
according to Wong et al. [Wong MC 2012 Atherosclerosis] in livers of E3L.CETP mice that 
were treated with either no drug (control), resveratrol (Resv), atorvastatin (Atorva) or the 
combination (Resv+Atorva) for 14 weeks. Values are means ± SEM (n=14-15). Statistical 
differences were assessed with one-way ANOVA followed by Bonferroni posthoc test. 
**P<0.01 vs control group. 
 
 





General Discussion and Future Perspectives

(Extra)vascular inflammation and lipid metabolism in atherogenesis
Dyslipidemia has been mainly associated with metabolic diseases, and classically regarded as 
the most prominent underlying cause of atherosclerosis. As a consequence, modulation of 
lipids gained most interest in the treatment of cardiovascular diseases (CVDs). Although lipid-
modulating drugs have been studied extensively and applied on large scale in the clinic, two 
thirds of cardiovascular events cannot be prevented by current lipid-modifying strategies, and 
CVD remains to be the leading cause of mortality in the Westernized world.1 While in recent 
decades inflammatory processes have been recognized to contribute largely to atherosclerosis 
development as well, the therapeutic potential of anti-inflammatory drugs in atherosclerosis 
development is less studied and well-defined. 
This disparity can be partly explained by the large role of inflammation in many physiological 
and pathophysiological processes other than CVD. Interference with physiological inflammatory 
processes can impair human host defense and result in life-threatening infections. While a 
healthy immune response includes sporadic bouts of acute inflammation to fight harmful 
stimuli, chronic low-grade inflammation is associated with the development of major diseases 
such as cancer, diabetes, asthma, rheumatoid arthritis, and atherosclerosis.2 
So far, many traditional anti-inflammatory therapies do not improve cardiovascular outcomes, 
and some may even aggravate cardiovascular events. These observations are usually derived 
from post-hoc analyses of clinical studies which may reflect off-target actions of the drugs 
studied, e.g. glucocorticoids, non-steroidal anti-inflammatory drugs, or tumor necrosis factor 
(TNF) inhibitors.3 While general suppression of inflammation is undesirable, selective regulators 
of inflammation that are able to normalize the enhanced inflammation or skew the inflammatory 
response towards the anti-inflammatory side or resolution phase may be beneficial. 
In the past two decades atherosclerosis research has focused primarily on local vascular 
inflammation.4 The crosstalk between dyslipidemia and inflammatory processes within and close 
to the arterial wall has been shown to be the primary cause of atherogenesis. Not only in the 
vessel wall, but also within other organs or tissues there is interaction between lipid metabolism 
and inflammation. This is for example demonstrated in chapter 2, in which increased activity 
of hepatocyte-specific nuclear factor-κB (NF-κB), primarily known as a central regulator of 
inflammatory processes, was shown to increase VLDL production by these hepatocytes. In 
addition, we found that enhanced activation of NF-κB in hepatocytes results in aggravated 
atherosclerosis development in chapter 3. This latter study exemplifies the increasing interest 
in the interaction between different organs and tissues with the vascular wall in the elucidation 
of the underlying processes involved in atherosclerosis development (Figure 1). While changes 
in certain tissues or organs can affect atherogenesis, it is also conceivable that the enhanced 
arterial inflammation and lipid accumulation which is coupled to atherosclerosis development, 
can act on other organs, e.g. by increase of systemic inflammatory mediators. 
This thesis addresses the interaction between lipid metabolism and inflammation and the 
role of two extravascular organs, i.e. the liver and lungs, in atherosclerosis development. In 
this chapter, implications of our findings and future perspectives are discussed, with special 
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emphasis on inflammation, since the possibilities of anti-inflammatory therapy in atherosclerosis 
development have been explored to a lesser extent than lipid-modulating drugs. Furthermore, 
the role of the lungs in atherosclerosis is discussed. Worldwide, chronic obstructive pulmonary 
disease (COPD) is the only major cause of death that still has a rising mortality, and it has been 
estimated that by the year 2020, COPD will be the third leading cause of death. Given the fact that 
COPD patients are at 2-3 times greater risk for CVD,5 a better understanding of the interaction 
between COPD and CVD may help to decrease the burden of these two major killers.
Extravascular inflammation I: liver 
Since NF-κB is one of the most important regulators of inflammation, it is an interesting 
target for the development of new anti-atherogenic agents. However, just like inhibiting all 
inflammatory processes would have adverse effects, e.g. on host defense, full suppression 
of NF-κB would be harmful. Almost all danger-sensing receptors of the innate and adaptive 
immune system activate NF-κB to mediate effector function. In addition, complete NF-κB 
inhibition is undesirable, as NF-κB is involved in many more processes than inflammation, 
including cell proliferation, differentiation, survival and death, and as we show in chapter 2, lipid 
metabolism. This raised the interest for tissue- or cell-specific interference of NF-κB activity 
in atherogenesis.6 The tissue, i.e. endothelium,7 or cells, i.e. macrophages8, 9 that were firstly 
being investigated were obvious choices because of their prominent role in atherosclerosis 
development. These studies demonstrate that dependent on the level and tissue, NF-κB 
activation is not only pro-atherogenic,7, 9 but can also be anti-atherogenic.6, 8





Not only in the vessel wall, but also within other organs or tissues there is interaction 
between lipid metabolism and inflammation. This is for example demonstrated in 
chapter 2, in which increased activity of hepatocyte-specific nuclear factor-κB (NF-κB), 
primarily known as a central regulator of inflammatory processes, was shown to increase 
VLDL production by these hepatocytes. In addition, we found that enhanced activation of 
NF-B in hepatocytes results in aggravated atherosclerosis development in chapter 3. 
This latter study exemplifies the increasing interest in the interaction between different 
organs and tissues with the vascular wall in the elucidation of the underlying processes 
involved in atherosclerosis development (Figure 1). While changes in certain tissues or 
organs can affect atherogenesis, it is also conceivable that the enhanced arterial 
inflammation and lipid accumulation which is coupled to atherosclerosis development, 
can act on other organs, e.g. by increase of systemic inflammatory mediators.  
 
Figure 1. The relationship between dysregulation of lipid metabolism and inflammatory 
processes in extravascular tissue and atherosclerosis.  In addition to endogenous, e.g. 
hereditary characteristics, environmental factors can affect lipid metabolism and the inflammatory 
state of different organs and tissues. Disturbances in lipid metabolism and inflammation in these 
organs can ‘spill over’ to the systemic compartment and result in lipid accumulation and 
increased inflammation in the arterial wall, contributing to atherosclerosis development. The 
Extravascular tissue Blood vessel
Lipid metabolism and inflammation
Dyslipidemia and increased inflammation 
Environmental factors, e.g. diet,
smoking, microorganisms 
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Fig. 1. The relationship between dysregulation of lipid metabolism and infla matory processes in 
extravascular tissue and atherosclerosis. In addition to endogenous, e.g.  hereditary characteristics, 
environmental factors can affect lipid metabolism and the inflammatory state of different organs and 
tissues. Disturbances in lipid metabolism and inflammation in these organs can ‘spill over’ to the systemic 
compartment and result in lipid accumulation and increased inflam ation in the arterial wall, co tributing 
to atherosclerosis development. The inflamed artery in itself also constitutes a source of inflammatory 
mediators for the systemic circulation. 
Chapter 6
120
Going more distant from the endothelium and bearing in mind the two key processes 
involved in atherogenesis, i.e. lipid metabolism and inflammation, our interest was drawn towards 
the role of the liver in atherosclerosis development. Different factors, e.g. dietary cholesterol and 
saturated fatty acids (FAs) can activate the NF-κB pathway in the liver.10 By utilizing a hepatocyte-
specific transgenic murine model, we found that increased hepatocyte-specific NF-κB 
activity increases very-low-density lipoprotein (VLDL) production (chapter 2) and aggravates 
atherosclerosis development (chapter 3) (Figure 2). High concentrations of apolipoprotein (apo)
B-containing lipoproteins result in elevated levels of triglycerides (TGs), which can accumulate in 
the liver, leading to nonalcoholic fatty liver disease (NAFLD).11 NAFLD affects 20-30% of the general 
population and is associated with an increased risk for CVD. The term NAFLD spans a spectrum of 
conditions ranging from accumulation of fat in the liver, i.e. steatosis, to progressive nonalcoholic 
steatohepatitis (NASH), when the liver also exhibits increased inflammation. Patients with NASH 
display increased hepatic NF-κB activation12 and are more prone to develop CVD than patients with 
simple hepatosteatosis.13 In line with this, our findings that an increased activity of hepatocyte-
specific NF-κB aggravates atherosclerosis (chapter 3), provide a pathophysiological explanation 
for the observed association between NASH and CVD. Apart from giving molecular insight into 
the role of hepatic inflammation in atherosclerosis development, these results also implicate that 
targeting the NF-κB in the liver would be an interesting anti-atherogenic therapeutic approach 
avoiding the major obstacle of adverse effects that may arise with broad-spectrum anti-NF-κB 
therapy. In addition, it is likely that not only patients with liver steatosis, but also hepatitis, due to 
endogenous or exogenous agents, are at higher risk for increased atherosclerosis. Treatment of 
these hepatic disorders may therefore not only improve the condition of the liver, but may also 
slow down the development of CVD. 







Figure 2. The role of hepatic NF-B activation in atherosclerosis. Various environmental 
factors such as a high dietary intake of cholesterol and saturated fatty acids can activate the NF-
B pathway in the liver. Increased activation of this pathway in hepatocytes enhances VLDL 
production (chapter 2) and aggravates atherosclerosis development (chapter 3) in APOE*3-
Leiden (E3L) mice.   
Interestingly, smoking increases the risk of developing NAFLD through oxidative stress 
and the unfavorable metabolic action of tobacco, e.g. causing dyslipidemia.14, 15 It also 
directly promotes insulin resistance.16 It is thus likely that smoking increases the hepatic 
NF-B activity (Figure 2). In view of our results of chapter 3, in which we found that an 
increased hepatic NF-B activity aggravates atherosclerosis development, another way 
by which smoking promotes atherogenesis may be through the liver. Alternatively, 
smoking may be a contributor to NAFLD and atherosclerosis development independently. 
In COPD, the NF-B pathway is activated and cigarette smoking is a strong activator of 
the pathway.17 Since an exaggerated inflammatory response to inhaled stimuli (in the 
Westernized world mainly cigarette smoking) is thought to be central to the pathogenesis 
of COPD, this may also provide clues to help understand why COPD patients are at 
increased risk for developing CVD compared to smokers without COPD. In the following 
part, we will focus on the role of COPD in atherosclerosis development. 
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Fig. 2. The role of hepatic NF-kB activation in atherosclerosis. Various environmental factors such as a 
high dietary intake of cholesterol and saturated fatty acids can activate the NF-κB pathway in the liver. 
Increased activation of this pathway in hepatocytes enhances VLDL production (chapter 2) and aggravates 
atherosclerosis development (chapter 3) in APOE*3-Leiden (E3L) mice.  
General Discussion and Future Perspectives
121
Interestingly, smoking increases the risk of developing NAFLD through oxidative stress and 
the unfavorable metabolic action of tobacco, e.g. causing dyslipidemia.14, 15 It also directly 
promotes insulin resistance.16 It is thus likely that smoking increases the hepatic NF-κB activity 
(Figure 2). In view of our results of chapter 3, in which we found that an increased hepatic NF-κB 
activity aggravates atherosclerosis development, another way by which smoking promotes 
atherogenesis may be through the liver. Alternatively, smoking may be a contributor to NAFLD 
and atherosclerosis development independently. In COPD, the NF-κB pathway is activated and 
cigarette smoking is a strong activator of the pathway.17 Since an exaggerated inflammatory 
response to inhaled stimuli (in the Westernized world mainly cigarette smoking) is thought to 
be central to the pathogenesis of COPD, this may also provide clues to help understand why 
COPD patients are at increased risk for developing CVD compared to smokers without COPD. In 
the following part, we will focus on the role of COPD in atherosclerosis development.
Extravascular inflammation II: lungs
The respiratory system is anatomically as well as functionally closely related to the cardiovascular 
system. Although many epidemiological studies demonstrate that COPD is a strong risk factor 
for the development of CVD, the causal link and underlying mechanisms are unclear.18 These 
two diseases share a couple of risk factors, such as smoking, aging and increased inflammation, 
which can explain the observed relation. However, studies also indicate that COPD is associated 
with CVD, independent of these risk factors.19, 20 
As alveolar destruction is a prevalent manifestation in COPD and the major characteristic of 
emphysema, the effects of alveolar destruction without the presence of pulmonary inflammation 
in atherosclerosis development was studied in chapter 4. We found that elastase-induced 
emphysema did not enhance atherosclerosis, and even reduced atherosclerosis severity. This 
implies that other aspects of COPD than alveolar destruction are involved in the increased risk 
of atherosclerosis. Notably, consequences of COPD, such as hypoxia and physical inactivity also 
predispose to atherosclerosis development (Figure 3). It has been shown that after correction 
for physical activity, COPD remains an independent risk factor for CVD.5 In experimental animal 
models, hypoxia, which occurs in COPD, is likely to contribute to atherosclerosis development.21 
In our study, hypoxia and physical inactivity resulting from elastase-induced emphysema were 
not likely to have played a significant role on atherosclerosis development. The duration and 
level of hypoxia was at least partly compensated by an increase in respiration amplitude, right 
ventricular hypertrophy and an increase in number of erythrocytes.
Numerous mechanisms have been proposed to explain the observed link between COPD 
and CVD,22 including systemic oxidative stress, hypoxia, physical (in)activity, activation of 
the sympathetic nervous system, vascular dysfunction, accelerated aging, microbial airway 
colonization and infections, and probably the most advocated one: increased (low-grade) 
systemic inflammation (Figure 3). COPD is characterized by pulmonary inflammation, and 
systemic inflammation has been established as a major pathophysiological factor not only for 
CVD, but also for COPD.23 It is thus likely that the presence of increased inflammation explains 
(part of) the pathophysiological link between COPD and CVD. As mentioned before, increased 
inflammation in any organ can ‘spill over’ to the systemic compartment, thereby affecting the 
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vasculature. To dissect the contributions of two main features of COPD, alveolar destruction 
and pulmonary inflammation on atherosclerosis development, these two aspects have to be 
investigated in one study. To address this research question, an appropriate COPD model has to 
be chosen. In the following section, three commonly used COPD models and their advantages 
and limitations are described.   
Fig. 3. Potential pathophysiological mechanisms for increased atherosclerosis development in patients 
with COPD. COPD is characterized by alveolar destruction and increased airway and parenchymal 
inflammation in the lungs. Possible mechanisms linking the increased CVD risk in COPD are sequelae 
of several of these features, e.g. systemic inflammation, hypoxia. It is hypothesized that the enhanced 
production of inflammatory mediators in the lungs spills over into the systemic compartment and 
thereby contributes to atherosclerosis development. The hallmark of emphysema, a major hallmark of 
COPD, is alveolar destruction and we found that this factor in itself does not explain the increased risk of 
atherosclerosis development observed in COPD (chapter 4). 
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As smoking is the predominant cause of COPD, smoke exposure systems offer the ability to use 
the primary disease-causing agent to model several key features of the disease in small animals. 
Although these models mimic the human COPD development more closely than any other 
in vivo model, an operational smoke exposure system is more laborious to set-up and perform 
experiments with than most other COPD models. Many aspects have to be kept in mind and can 
be crucial in succeeding in setting up a smoke exposure model for animals. Factors concerning 
the choice of smoke exposure machine, set up, dose, frequency, duration, differences in 
branch and batch of cigarettes used, suppliers, strains and gender of mice, techniques to 
quantify emphysema and pulmonary inflammation, can all contribute to variations not only 
between different laboratories, but even within the same laboratory. In addition, because these 
models require a long time, i.e. ~4–6 months, to generate pathologies and functional changes 
consistent to those observed in merely mild COPD, practical application of these smoking 
models for assessing potential therapeutic interventions is more time- and labor-consuming 
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than other COPD models. Smoke exposure induces emphysema in combination with increased 
pulmonary inflammation. It also affects lipid metabolism unfavorably15 and increases systemic 
inflammation,24 which are known to contribute to atherosclerosis development. These 
concurrent effects of smoke hinder the differentiation of the impact of the two major features of 
COPD, i.e. alveolar destruction and pulmonary inflammation, independently on atherosclerosis 
development. However, as smoke exposure models best resemble the natural development 
of COPD, these models are essential, when the pathophysiological processes involved in the 
development of COPD are the subject of investigation. 
Instillation of elastase in the lungs initially causes edema, hemorrhage and inflammation, 
consisting of infiltration by mainly neutrophils and monocytes.25 Once this acute inflammatory 
response has disappeared, destruction of alveolar walls becomes evident which is consistent 
with the anatomical lesions in the lung observed in patients with emphysema.26 One of the 
major drawbacks of this model to use for studying pathophysiology of COPD is the fact that 
inflammation is transient, resolves within a week of elastase administration, and does not reflect 
the progressive, slowly resolving inflammation associated with human COPD. However, the main 
advantages of the elastase models over other in vivo models for COPD are the possibility to easily 
titrate the severity of emphysema development with the dosage of elastase instilled, and the 
rapid onset of the emphysematous destruction of the lung. For this reason, the elastase model is 
ideal for testing therapeutic approaches aimed at reversing or repairing emphysematous damage 
to the lung. Another advantage of this model is that it is suitable to study the effects of alveolar 
destruction without the presence of chronic pulmonary inflammation on the development of 
other diseases, such as comorbidities of COPD (chapter 4).
Lipopolysaccharide (LPS) is a bacterial endotoxin that is present in cigarette smoke and, 
when instilled into the lung, can elicit a pronounced neutrophilic inflammatory response.27 
Because neutrophils are the largest source of neutrophil elastase, it was regarded as the 
central player driving the pathologies associated with COPD for many years. Similar to elastase 
instillation, the dosage of intrapulmonary LPS is more easily controlled than e.g. cigarette smoke 
exposure. In consideration of the research question whether pulmonary inflammation can affect 
atherosclerosis development, intrapulmonary LPS instillation can be adjusted in such way that 
the amount of systemic inflammation is minimized and the effects of pulmonary inflammation 
per se on atherosclerosis development can be investigated. However, the dosage of LPS needs 
to be carefully chosen, as a sufficient high dosage and duration of administration, can induce 
emphysema.28 This may interfere with the distinction of the role of alveolar destruction and 
pulmonary inflammation in atherosclerosis development. In addition, if the LPS dose instilled is too 
high, systemic inflammation may be induced, which directly affects atherosclerosis development. 
Taken together, the best approach to investigate the effects of alveolar destruction and 
pulmonary inflammation on atherosclerosis development, independently and together, seems 
to be the combination of the elastase-induced emphysema model (chapter 4) with chronic 
administration of a low dose of LPS in the lungs. Since smoking by itself induces various pro-
atherogenic triggers, e.g. dyslipidemia, pulmonary and systemic inflammation and oxidative stress, 
a smoke exposure model is less suitable to discern the role of alveolar destruction and pulmonary 
inflammation on atherosclerosis development without the interference by confounding factors. 
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Therapeutical agents for COPD and CVD
COPD is increasingly being recognized as a complex disorder, characterized not only by local 
pulmonary inflammation, but also by systemic inflammation that may have an adverse impact 
on various extrapulmonary organs, such as the blood vessels and the heart among others.29 CVD 
is one of the most important causes of death in COPD patients. Although smoking cessation 
is the cheapest, safest and most effective strategy to treat COPD and CVD, it is a hard task 
to accomplish for the patient and the inflammatory response in many COPD patients persists 
after smoking cessation.30 Therefore, new and more effective therapies that deal with not only 
COPD, but preferably also CVD are needed. Many existing therapeutic options used to treat 
COPD and CVD appear to have other beneficial properties apart from their classical actions. 
This raises the idea whether drugs currently applied for COPD could also be beneficial to treat 
CVD (Table 1), and vice versa (Table 2). 
Application of COPD therapies in CVD
As inhaled corticosteroids (ICSs) are widely prescribed in COPD patients and CVD is a prevalent 
comorbidity of COPD, the effects of ICS on CVD are an interesting subject to explore. Glucocorticoids 
are potent inhibitors of NF-κB activation,31 and thus may be a promising anti-inflammatory agent 
for both COPD and CVD. However, not all studies with COPD patients have demonstrated a clear 
anti-inflammatory and beneficial effect of ICS32, and such effects may be restricted to subgroups 
of COPD patients.33 In a retrospective study it was demonstrated that very low doses of ICSs 
(50-200 μg/day) were associated with a reduced risk of acute myocardial infarction.34 However, 
with higher doses of ICSs, the risk returned to baseline. This lack of benefit at higher doses might 
be due to counterbalancing adverse effects of other risk factors, or the fact that patients with more 
severe disease, which in itself is linked to CVD morbidity, were prescribed the higher doses. In line 
with the latter finding, randomized controlled trials also fail to show any significant effect of ICSs on 
myocardial infarction and cardiovascular mortality.35, 36 A controlled trial of high-dose ICS with or 
without a long acting β-agonist showed no reduction in systemic inflammation in COPD patients, as 
measured by circulating interleukin (IL)-6 and C-reactive protein (CRP) concentrations, indicating 
corticosteroid resistance of systemic, as well as local inflammation in patients with COPD.37 Overall, 
these data suggest that ICSs do not have a significant beneficial effect on CVD. 
Table 1. Possible application of COPD therapies for CVD.
Therapy Main mechanism in COPD Beneficial effect on CVD?
Inhaled corticosteroids Anti-inflammatory? Probably not
β
2
-agonists Bronchodilatory Probably not




Phosphodiesterase 4 inhibitors Anti-inflammatory Probably yes
Supplemental oxygen Restore normal oxygen levels Probably yes
Lung volume reduction surgery Improved lung breathing mechanics If successful probably yes
Surgical risk
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Bronchodilators, i.e. long-acting β
2
-agonists and anticholinergics are useful in COPD, but are 
not known to have marked anti-inflammatory or other anti-atherogenic effects. One trial 
demonstrated that tiotropium, an anticholinergic drug, had no effect on inflammatory markers 
in sputum or in the circulation of COPD patients.38 Whether inhaled or oral β
2
-agonists by 
themselves have any beneficial effects on the systemic inflammatory state of COPD patients has 
not yet been clarified. There has been concern that long-term use of inhaled bronchodilators 
may increase the risk of cardiovascular complications.39 However, in the large Towards a 
Revolution in COPD Health (TORCH) trial, the three-year risk of cardiovascular adverse events 
of the use of salmeterol (a β
2
-agonist), fluticasone (an ICS), both medications combined, or 
placebo in COPD patients was similar in all groups.36 In addition, results from a meta-analysis on 
the occurrence of cardiovascular events and the use of anticholinergic agents to treat COPD in 
trials show that there is no increased risk.40 It is not clear, however, whether this also accounts 
for patients with an increased risk for cardiovascular events, such as those with coronary artery 
disease, heart failure and cardiac arrhythmia, because they are excluded from participation for 
obvious ethical reasons. Furthermore, a poor lung function which is inherent to COPD patients, 
is a marked risk factor for CVD.41 Taken together, although bronchodilators are valuable in the 
treatment of COPD, care must be taken for cardiovascular complications, especially in high-risk 
patients. 
Theophylline seems to be a more promising candidate as a concurrent treatment for 
inflammation in COPD and CVD. It has been shown to reduce neutrophilic inflammation in 
patients with COPD42 and also has the potential to reverse corticosteroid resistance in COPD.43 
However, the molecular mechanism for the anti-inflammatory action of theophylline is currently 
unknown and deserves at least the same priority of exploring its potential as therapeutic agent 
for CVD in COPD patients.  
Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has recently been registered as a novel 
therapy for COPD and thought to be effective through its anti-inflammatory properties.44, 45 
One of the major anti-inflammatory effects of PDE4 inhibitors is their ability to reduce TNFα 
release,46 which supports the potential of these agents for treating systemic inflammation. 
PDE4 inhibitors increase levels of cyclic adenosine monophosphate (cAMP) through inhibition 
of its metabolism. The resulting increase in protein kinase A activation stimulates increased 
protein phosphorylation, with subsequent inhibition of pro-inflammatory cells and mediators. 
Because of their anti-inflammatory properties, PDE4 inhibitors may be beneficial in treating 
CVD. This has not been investigated thus far, but several reports support a protective role of 
cAMP in atherosclerosis.47 Therefore, based on their anti-inflammatory effects, PDE4 inhibitors 
would be an interesting subject for future studies on CVD.
COPD patients are subject to intermittent hypoxia and at a more severe stage of disease 
to sustained hypoxia. Hypoxia can induce increased inflammation and oxidative stress, which 
contribute to atherosclerosis development. Mice subjected to chronic intermittent hypoxia 
have increased atherosclerosis development.21 Long-term use of supplemental oxygen 
improves survival in patients with COPD and severe resting hypoxemia.48 Whether oxygen 
therapy is beneficial in patients suffering from atherosclerosis with a normal lung function has 
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never been investigated, but based on the findings above, oxygen therapy is likely to reduce 
the risk of atherosclerosis in COPD patients, in addition to the relieve of pulmonary symptoms. 
Lung volume reduction surgery in the treatment of properly selected patients with 
COPD, i.e. with severe and predominantly upper-lobe emphysema and low-exercise capacity, 
improves survival and quality of life, including exercise tolerance, dyspnea, oxygen requirement 
and functional status.49 However, this invasive procedure is mostly offered to severely 
impaired emphysema patients as one of the last resorts and accompanied with a high risk on 
cardiopulmonary morbidity (up to 58.7% in the National Emphysema Treatment Trial (NETT)). 
In the same study, cardiovascular morbidity, i.e. myocardial infarction, pulmonary embolus, or 
cardiac arrhythmia requiring treatment within 30 days of surgery occurred in 20% of patients.50 
Although this kind of therapy has proven to be effective in a subgroup of severe emphysema, 
the surgical risk of the procedure is a major barrier withstanding broad application for patients 
with CVD. 
Application of CVD therapies in COPD
The discovery of novel effective treatments for COPD, other than bronchodilators and ICS has 
proven difficult.51 Thus, it is worthwhile to explore whether drugs commonly used in CVD might 
also have beneficial effects in COPD. 
Promising candidates are statins which are primarily prescribed for patients with CVD, but 
nowadays seem to have potential additional benefits in many other diseases, including COPD.52 
It was shown in a retrospective study that the use of statins was associated with a reduced 
mortality in COPD patients, independent of sex, age, smoking, pulmonary function and 
comorbidities.53 In addition, ICS appeared to increase the survival benefit associated with statin 
use. Several possible mechanisms for the beneficial effects of statins have been proposed, 
including their anti-inflammatory property. This feature of statins makes them an attractive 
candidate in the treatment of COPD in which inflammation has a fundamental pathophysiological 
role. In experimental COPD animal models, simvastatin inhibited cigarette smoke-induced 
emphysema, which was associated with a decrease in pulmonary inflammation.54, 55 Moreover, 
in a murine model in which emphysema was already established by elastase instillation in the 
lungs and the acute inflammation after elastase instillation has resolved, simvastatin was even 
able to reverse emphysema.56 Interestingly, in this study the therapeutic effect of simvastatin 
was not ascribed to anti-inflammatory effects, but to a tendency towards an increase of 
vascular endothelial growth factor (VEGF) in bronchoalveolar lavage fluid. A study in apoe-/- 
mice demonstrated that a Western-type diet high in fat and cholesterol content not only 
induced increased systemic, but also pulmonary inflammation in these mice.57 As an enhanced 
pulmonary inflammation is one of the most important pathophysiological causes of COPD, 
these data imply that a Western-type diet can stimulate the development with COPD. The lipid-
lowering action of statins thus may be another mechanism through which they can be useful 
in the treatment of COPD. Taken together, statins seem to be effective in both COPD and CVD, 
which also indicates that COPD and CVD may have a common pathophysiological cause. 
Next to statins, angiotensin converting enzyme (ACE) inhibitors and the more specifically 
acting angiotensin II receptor blockers (ARBs), classically prescribed to treat hypertension, 
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have been shown to reduce the risk of COPD hospitalization, and cardiovascular events and 
death in COPD patients.58 ACE inhibitors reduce pulmonary hypertension, but may have 
other beneficial effects in COPD, e.g. by inhibiting angiotensin II that has pro-inflammatory 
properties.59 Angiotensin II receptors are shown to be expressed in the lung and more highly 
in lungs of COPD patients.60 In mice, treatment with the ARB irbesertan after induction of 
emphysema with elastase, significantly improved the exercise capacity and reduced the 
development of morphological emphysema.61 Therefore, the main action of ACE inhibitors 
and ARBs, i.e. inhibition of the pro-inflammatory angiotensin II, makes them potential valuable 
therapeutic agents in COPD.
Both activators of peroxisome proliferator-activated receptor (PPAR)α and -γ have 
demonstrated anti-inflammatory properties and other anti-atherogenic effects in human and 
mice.62 In fact, part of the anti-inflammatory effects of statins may be explained by activation 
of PPARα and -γ.63 PPARα and -γ agonists have been shown to exert beneficial effects mostly 
in experimental asthma or acute pulmonary inflammation models.64 So far, no studies are 
published on the role of PPARs in animal models of COPD. However, PPARα and -γ inhibit airway 
neutrophil and macrophage influx, as well as cytokine and chemokine production induced by 
LPS in the mouse,65, 66 suggesting that activators of these PPAR subtypes may have a beneficial 
effect on the inflammatory response associated with COPD. 
Accelerated aging may be a characteristic common to COPD and CVD.67 The concept 
of ‘inflamm-aging’ is now gaining attention, with a reduction in adaptive immunity and an 
increase in innate immunity driven by NF-κB activation.68 This suggests that anti-aging drugs 
may be beneficial in CVD and COPD. One of the key players that has gained much interest in 
this field is sirtuin 1 (SIRT1). SIRT1 is an enzyme which deacetylates proteins that contribute to 
cellular regulation, thereby playing an important role in determining lifespan of all organisms.69 
We demonstrated that resveratrol, a moderate SIRT1 activator, protects against atherosclerosis 
(chapter 5). While resveratrol is known to have many pleiotropic effects, we did not find many 
other systemic anti-atherogenic effects, e.g. anti-inflammatory, anti-oxidative, than lipid 
lowering. This can be attributed to the use of a relatively low dose of resveratrol (0.01% (w/w) 
in the diet, compared to other studies.70, 71 Nevertheless, the reported pleiotropic effects of 
resveratol may have therapeutic potential in COPD.72 In fact, resveratrol was found to inhibit 
cigarette smoke extract-mediated pro-inflammatory cytokine release in a human monocyte-
macrophage cell line.73 Furthermore, resveratrol was shown to protect against cigarette 
smoke-mediated oxidative stress in human lung epithelial cells by inducing glutathione 
synthesis.74 Additional studies are required to be able to extrapolate the dosages and effects 
of resveratrol of these in vitro studies and our in vivo study with mice to (clinical) human use 
for CVD and COPD. To address this, experimental studies are needed in which the effects of 
resveratrol on pulmonary damage induced by cigarette smoke are studied in hyperlipidemic 
atherosclerosis models and compared to studies in which pulmonary damage is induced by 
other agents, e.g.  intrapulmonary elastase-instillation, which do not have the diverse direct 
effects of smoke on atherosclerosis. Moreover, as resveratrol is just a moderate SIRT1 activator, 
other more potent SIRT1 activators may have even more beneficial effects, and are possibly 
more effective than resveratrol in the treatment of COPD. In addition, there is clinical evidence 
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that SIRT1 may be an interesting therapeutic target, as its expression is decreased in lungs of 
patients with COPD.72
Table 2. Possible application of CVD therapies for COPD.





Angiotensin converting enzyme 





PPARα agonists Hypolipidemic 
Anti-inflammatory
Possibly; in experimental phase
PPARγ agonists Hypoglycemic
Anti-inflammatory




Possibly; in experimental phase
In summary, COPD has been demonstrated to be an independent predictor of cardiovascular 
death.75 The value of existing drugs that treat both CVD and COPD simultaneously is currently 
extensively being studied. Despite some promising findings, we still do not know whether 
treatment of lung inflammation decreases, for example the progression of atherosclerosis, 
or the risk of acute cardiac events. Alternatively, it is also unclear whether treatment of heart 
disease can reduce the progression of lung disease. There are data suggesting that a Western-
type diet can induce pulmonary inflammation, which is the most important causal factor in 
COPD development.57 Minimizing dyslipidemia thus may be another target to inhibit not only 
CVD but also COPD. In addition, initial data seem to indicate that drugs, originally prescribed for 
CVD such as statins, ARBs and PPAR agonists, also have the potential to benefit COPD patients. 
It can even be hypothesized that one of the ways by which these drugs can inhibit CVD is by 
slowing down progression of the lung disease in COPD patients. Furthermore, since CVD is a 
major cause of mortality in COPD patients and the presence of a poor lung function is proven to 
be an important risk factor for CVD, screening for the presence and treatment of CVD in COPD 
patients is recommended.
Treating infections in CVD and COPD
The clinical course of COPD is punctuated by recurrent episodes of acute increase in both 
airway and systemic inflammation, otherwise known as exacerbations, with a major negative 
impact on the patient’s quality of life, hospital admission and lung function. The increase in 
systemic inflammation and oxidative stress during exacerbations are likely to contribute to 
the inflammatory process underlying atherosclerosis. Furthermore, the peaks of inflammatory 
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activity accompanying COPD exacerbations could precipitate acute exacerbations of the 
atherosclerotic process with increased risk of plaque rupture and thrombotic occlusion.76 
Infection is considered the main cause of acute COPD exacerbations and the standard treatment 
for exacerbations is usually corticosteroids and/or antibiotics.77 
Chlamydophila pneumoniae (C. pneumoniae) has been implicated as an infectious 
trigger for acute exacerbations of COPD78 and postulated to contribute to inflammation in 
atherogenesis,79 making it an interesting candidate in linking the pathophysiology of CVD 
and COPD. Several infectious agents have been associated with an increased risk CVD, but for 
the Gram-negative bacteria C. pneumoniae and Porphorymonas gingivalis (P. gingivalis) most 
compelling evidence is found.80 Many studies demonstrated both an associative and causal 
relation for C. pneumoniae with regard to atherosclerosis formation. C. pneumoniae is an 
obligate intracellular pathogen that infects both epithelial cells and macrophages within the 
lungs and may disseminate outside the lungs through infected monocytes and macrophages.81 
It was the first infectious organism to be found in macrophages and smooth muscle cells of 
human atherosclerotic plaques but rarely within normal (adjacent) arterial cells.82 In addition, 
a number of studies in experimental models showed an acceleration of atherosclerotic lesion 
development following respiratory infection with C. pneumoniae.79 Macrolides are one of 
the first choice antibiotics to treat infections with C. pneumoniae and reported to have anti-
inflammatory properties apart from their antimicrobial activities, making them interesting 
agents to treat sustained infection and low-grade inflammatory states as encountered in 
COPD and CVD.83 Recently, it was demonstrated that erythromycin ameliorates cigarette-
smoke-induced pulmonary inflammation and emphysema in rats.84 Similar to C. pneumoniae, 
P. gingivalis, which colonizes the gingival plaque where it can cause periodontitis, has been 
shown to increase systemic cytokines and acute-phase proteins and increase atherosclerotic 
lesion development in experimental models.85 Although a number of studies have shown that 
treatment of chronic periodontitis results in a reduction in systemic inflammation,86 a direct 
causal link between P. gingivalis with CVD has not been demonstrated so far.
As mentioned before, although a large body of evidence for the role of infection as risk 
factor for atherosclerosis exists, intervention trials with antibiotics until now have ended up with 
disappointing results.80 A few considerations should be taken into account in the interpretation 
of the failed trials. First, it is not clear whether pathogens were effectively cleared by antibiotic 
treatment or chronic (low-grade) infection persisted. This accounts especially for C. pneumoniae 
that replicates intracellularly and exists in a metabolically inactive form, which is not susceptible 
for antibiotics. Second, the participants of the trials had advanced atherosclerosis, and events 
being measured were likely due to plaque destabilization and rupture rather than progression 
of occlusive disease, while the pathophysiological and experimental studies performed so 
far were focused on the initiating process of atherogenesis. Studies focusing on the effects 
of antibiotics in patients with early stage atherosclerosis have not been carried out, and are 
intuitively difficult to design. Furthermore, the beneficial effects of antibiotics in experimental 
studies with C. pneumoniae were only observed when given shortly, i.e. within days rather 
than weeks, after infection,87 and the acute C. pneumoniae infection in humans frequently 
passes clinically unnoticed. Third, there is an emerging concept that not one organism but an 
Chapter 6
130
aggregate of multiple organisms, the infectious or pathogen burden as a whole, is responsible 
for the effects of infection on atherosclerosis development. This is for example supported by 
a study in which it was found that an increased pathogen burden was significantly associated 
with increased coronary artery disease, even after adjustment for traditional cardiovascular risk 
factors.88 The antibiotic treatment in the secondary prevention trials performed thus might be 
ineffective due to the infectious burden of unsusceptible pathogens, allowing these organisms 
to still contribute to the progression of atherosclerosis. 
The failure of antibiotic trials in CVD should therefore not lead to dismissal of the potential 
role of infectious agents in the pathogenesis of atherosclerosis, although considerations to be 
taken into account, such as persistent infection despite antibiotic treatment, emergence of 
antibiotic resistance and requirement of multiple antimicrobial therapies to treat the pathogen 
burden, are not easily overcome. In conclusion, microbial pathogens may form a bridge 
between COPD and CVD in acute exacerbations as well as chronic infections. 
Concluding remarks
The understanding of the pathophysiological processes involved in the local environment 
where atherogenesis takes place has resulted in effective treatment strategies to fight CVD. 
However, the endothelium does not stand by itself, as it is part of a complicated network with 
intricate connections and interactions with other cells, organs and tissues. Therefore, apart 
from investigating the local processes, we have to keep in mind that more distal effectors and 
reactors are present and should broaden our attention when studying the atherosclerotic 
process. 
In this thesis, the role of inflammation in the liver and lungs in atherosclerosis development 
was addressed. Models combining various conditions that are often observed concomitantly in 
clinical practice, such as NASH and CVD or COPD and CVD, represent an exciting new approach 
in order to understand the mechanisms underlying the pathophysiology of these diseases. 
Investigating the interaction between vascular and extravascular changes may expand the 
number of therapeutic options and lead to novel approaches that can be used to help manage 
CVD and associated diseases. 
When considering a role of extravascular inflammation in atherosclerosis, conventional 
therapies used in certain diseases which also seem to be linked to each other, such as CVD and 
COPD, may be applicable for more domains and may even have synergistic beneficial effects. 
Given the complex nature of both COPD and CVD, it seems likely that no single cause of the 
association will be found. However, further studies on the interaction between COPD and 
CVD are expected to improve early identification of patients likely to develop both diseases to 
prompt early intervention, as well as promote stratified medicine and tailored therapy in which 
patients achieve the best possible medicinal care dependent on their individual needs.  
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Cardiovascular diseases (CVDs) are the most important cause of death in the Western world 
and are predominantly caused by atherosclerosis. Dysregulation of lipid metabolism and 
inflammation are the two main risk factors of atherosclerosis development. High levels of (very-)
low-density lipoprotein ((V)LDL) in the blood result in retention of LDL in the intima of the arteries, 
where the particles are modified. Leukocytes such as monocytes are attracted, differentiate 
into macrophages to take up the modified LDL and transform into foam cells. Recruitment of 
more inflammatory cells and production of inflammatory mediators enhance the formation of 
atherosclerotic lesions with a lipid-rich necrotic core, which can be covered by a firm fibrous 
cap that may (partly) obstruct the blood flow in the artery. In a more unfavorable situation an 
unstable lesion is evolved that is prone to rupture which can result in a complete occlusion of the 
blood flow, causing infarction of the supplied tissue.  Apart from the local processes in the vessel 
wall, there is also a marked contribution of other organ systems to atherogenesis. In this thesis, 
the role of the liver and lungs in atherosclerosis development were studied. 
The liver plays an important role in lipid metabolism and the inflammatory response and 
integrates both processes. In chapter 2 the effects of hepatic activation of the transcription 
factor nuclear factor-κB (NF-κB), as a central regulator of inflammation, on lipid metabolism 
were investigated. To this end, mice expressing hepatocyte-specific human IKKβ (Liver-specific 
IKKβ or LIKK mice), which have continuous hepatocyte-specific activation of NF-κB, were 
crossbred with APOE*3-Leiden (E3L) mice to generate E3L.LIKK mice. These mice had increased 
plasma triglyceride levels compared with their E3L littermates. Mechanistic in vitro and in 
vivo experiments demonstrated that this hypertriglyceridemia was not caused by a decrease 
in VLDL clearance, but resulted from an increased VLDL-production by the hepatocytes. As 
dyslipidemia is a well-known contributor to atherosclerosis development and NF-κB activation 
promotes the inflammatory response, we hypothesized that E3L.LIKK mice will have aggravated 
atherosclerosis development as compared to E3L littermates. To study this, we fed these mice a 
Western-type diet for 24 weeks and found that the total atherosclerotic lesion area as well as the 
severity of atherosclerosis was increased in E3L.LIKK mice (chapter 3). This was at least partly 
explained by a transient increase in plasma VLDL-cholesterol levels at 8 weeks after the start of 
the diet. Hepatic expression of monocyte chemoattractant protein 1 (MCP-1) was increased in 
E3L.LIKK mice. While expression of LIKK did not affect basal systemic inflammatory markers, the 
levels of pro-inflammatory cytokines tended to be higher after intravenous lipopolysaccharide 
(LPS) injection. This indicates that E3L.LIKK mice have a higher inflammatory state than E3L 
mice, which likely has contributed to the aggravated atherosclerosis development.  
In addition to the liver, we studied the role of the lungs in atherosclerosis development. 
A considerable amount of epidemiological data indicates that a poor lung function, most 
commonly caused by chronic obstructive pulmonary disease (COPD), is a major risk factor 
for CVD. The exact mechanism underlying this association is unknown. Increased systemic 
inflammation has been postulated as a common risk factor, but has never been proven to be 
the missing link. Enlargement of alveoli due to destruction is a fundamental characteristic of 
emphysema, a major component of COPD. We investigated in chapter 4 whether alveolar wall 
destruction by elastase instillation in the lungs, as a model of emphysema without cigarette 
smoke-induced inflammation, would worsen atherosclerosis development in E3L mice. Two 
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doses, i.e. 15 and 30 μg pancreatic porcine elastase, were used next to the control group to 
detect dose-dependent effects. After feeding the mice an atherogenic Western-type diet for 
20 weeks, we did not observe a difference in the atherosclerotic lesion size between the groups, 
but did find a dose-dependent reduction in lesion severity with elastase treatment. This is 
likely in part due to a dose-dependent decrease in circulating monocytes and neutrophils. The 
number of pulmonary macrophages and neutrophils, as well as the systemic lipid levels were 
similar in all groups. These results indicate that alveolar destruction per se is not responsible for 
the observed increased risk for atherosclerosis in COPD patients. An increased state of systemic 
inflammation has a pathophysiological role in both COPD and atherosclerosis development. 
Thus, increased inflammation may be the missing link explaining the association between these 
diseases. It has been hypothesized that atherosclerosis development is promoted by means 
of a ‘spill over’ of pulmonary inflammatory mediators towards the systemic compartment in 
COPD patients. This concept has yet to be confirmed by future experimental studies.   
The purpose of this kind of experimental studies is to gain more insight in the 
pathophysiological processes involved in order to develop new strategies to fight CVD. One 
of the promising therapeutic candidates is resveratrol, a compound that is naturally present 
in some Asian herbs, nuts and the skin of red grapes and consequently in red wine. It has 
been shown to have various anti-atherogenic, including lipid lowering, anti-inflammatory, 
and anti-oxidative properties. In chapter 5 we studied whether resveratrol can protect 
against atherosclerosis development by itself and secondly, whether it is able to add to the 
anti-atherogenic effects of atorvastatin in E3L.CETP mice, which respond to high-density 
lipoprotein (HDL)-modifying drugs similar to humans, and are therefore used extensively in 
studies in which potential anti-atherogenic therapies are investigated. E3L.CETP mice were fed 
a Western-type diet supplemented without (control) or with resveratrol, atorvastatin, or both 
for 14 weeks. Both size and inflammatory state of the atherosclerotic lesions were reduced to 
a similar extent by resveratrol, atorvastatin and the combination treatment. This is in part due 
to a significant, but comparable lowering of plasma cholesterol levels by the three treatments. 
Inflammatory parameters and markers for oxidative stress were unaffected by the treatments. 
Resveratrol thus protects against atherosclerosis development, but does not add to the anti-
atherogenic effects of atorvastatin. Interestingly, the beneficial effects of resveratrol and statins 
extend beyond the blood vessel, and are also under investigation as a potential treatment for 
other diseases such as COPD.
Taken together, disturbances in organs such as the liver and the lungs can affect 
atherosclerosis development. The clinical implications and future perspectives of these results 
are discussed in chapter 6. While the local processes involved in atherosclerosis development 
have been the primary subject of interest in past decades, the focus is shifting from the artery 
towards the potential role of other (distal) organs, tissues and cells in atherogenesis. This 
exciting trend will shed light on the mechanisms underlying the interactions between different 
organs, and contributes to the discovery of additional effects of existing drugs and new 











Slagaderverkalking of atherosclerose is de belangrijkste onderliggende oorzaak van hart- 
en vaatziekten. Verstoringen in het vetmetabolisme en ontstekingsprocessen zijn de twee 
voornaamste risicofactoren voor de ontwikkeling van atherosclerose. Hoge spiegels van 
zeer-lage-dichtheids lipoproteïne (VLDL) partikels in het bloed leiden tot stapeling van lage-
dichtheids lipoproteïne partikels (LDL) in slagaders, waar het LDL chemische veranderingen 
ondergaat. Afweercellen zoals monocyten worden hierdoor aangetrokken en ontwikkelen 
zich tot macrofagen die het chemisch veranderde LDL opnemen. Hierdoor ontwikkelen deze 
macrofagen zich tot zogenaamde schuimcellen. De aantrekking van meer afweercellen en de 
productie van inflammatoire mediatoren stimuleren de groei van atherosclerotische plaques. 
Naarmate deze groter worden, kunnen ze een deel van de bloedvoorziening blokkeren. Verdere 
ontwikkeling van atherosclerose leidt tot zogenaamde laesies met een kern die voornamelijk 
vet, cholesterol en vergane cellen bevat. De kern wordt van de bloedstroom gescheiden door 
een schil van bindweefsel, dat in het meest gunstige geval stevig en dik is. Enzymen die bij 
ontsteking worden geproduceerd kunnen echter bindweefsel afbreken wat kan resulteren in 
een onderbreking van deze beschermende laag. Dit kan leiden tot de vorming van een stolsel 
dat de volledige bloedvoorziening blokkeert, waardoor het achterliggende weefsel afsterft als 
de bloedvoorziening niet tijdig wordt hersteld. 
Om atherosclerose te bestuderen zijn diverse muismodellen ontwikkeld, zoals het APOE*3-
Leiden (E3L) muismodel. Muizen ontwikkelen van nature geen atherosclerose, omdat ze ten 
opzichte van de mens een veel gunstiger vetmetabolisme hebben. Door de aanwezigheid van 
het E3L eiwit in dit muismodel wordt het vetmetabolisme verstoord, waardoor deze meer op 
die van mensen lijkt met als gevolg dat deze E3L muizen atherosclerose kunnen ontwikkelen. 
In de afgelopen jaren is gebleken dat niet alleen verstoring van deze processen lokaal in 
de slagaders, maar ook stoornissen in andere organen kunnen bijdragen aan atherosclerose 
ontwikkeling. In dit proefschrift wordt de rol van de lever en de longen in de ontwikkeling van 
atherosclerose bestudeerd. 
De lever speelt een prominente rol in zowel het vetmetabolisme als bij ontsteking. In 
hoofdstuk 2 worden de effecten van een centrale regulator van ontstekingsreacties, nuclear 
factor-κB (NF-κB), op het vetmetabolisme onderzocht. Hiervoor werden muizen gebruikt 
waarbij alleen in de levercellen NF-κB overactief was, het zogenaamde LIKK muismodel. Deze 
muizen werden gekruist met E3L muizen, wat resulteerde in E3L.LIKK muizen. Deze muizen 
hadden een toegenomen bloedspiegel van triglyceriden vergeleken met de controle E3L muizen 
(zonder LIKK). In het lichaam wordt vet opgeslagen in de vorm van triglyceriden. Uit nader 
onderzoek bleek dat de toegenomen triglyceriden spiegel in de E3L.LIKK muizen het gevolg 
was een verhoogde productie van de VLDL partikels. VLDL partikels transporteren cholesterol 
en triglyceriden door het lichaam en verhoogde spiegels van VLDL in het bloed leidt tot de 
vorming van atherosclerose. Om direct het effect van LIKK op atherosclerose-ontwikkeling te 
onderzoeken werden E3L.LIKK en E3L muizen op een cholesterolrijk dieet gezet en werd de 
mate en ernst van atherosclerose bepaald na 24 weken (hoofdstuk 3). E3L.LIKK muizen bleken 
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meer en ernstigere atherosclerose te ontwikkelen, wat deels verklaard werd door een tijdelijke 
verhoging in VLDL spiegels. De ontstekingsparameters in het bloed waren niet verschillend 
tussen de twee groepen muizen, maar na stimulatie met lipopolysaccharide, een component 
van bacteriën die vaak wordt gebruikt om een ontstekingrespons teweeg te brengen, waren de 
spiegels van verschillende ontstekingsmediatoren in het bloed sterker verhoogd in de E3L.LIKK 
muizen vergeleken met de E3L muizen. Deze resultaten laten zien dat een verhoogde activiteit 
van NF-κB in levercellen leidt tot meer atherosclerose ontwikkeling door een toename in VLDL 
en ontstekingsmediatoren in het bloed.
Naast de bijdrage van de lever, hebben we de rol van de longen in atherosclerose 
ontwikkeling onderzocht. Roken is een gemeenschappelijke risicofactor voor atherosclerose 
en chronische obstructieve pulmonaire ziekten (COPD). COPD gaat gepaard met een 
achteruitgang in longfunctie en staat nu nog op de zesde plaats van doodsoorzaken, maar 
zal naar verwachting de derde belangrijkste doodsoorzaak wereldwijd worden in 2020 (alleen 
overtroffen door hart- en vaatziekten en beroerte). Uit veel humane studies is gebleken dat 
COPD patiënten een twee tot drie keer verhoogde kans hebben op hart- en vaatziekten dan 
‘gezonde rokers’. Het mechanisme dat hieraan ten grondslag ligt is onduidelijk. De term COPD 
omvat drie aandoeningen die vaak gecombineerd voorkomen in patiënten: aandoening van 
de kleine luchtwegen, chronische bronchitis en longemfyseem. Ontsteking speelt een grote 
rol bij alledrie de aandoeningen. Chronische bronchitis wordt gekenmerkt door chronisch 
hoesten en sputum (slijm uit de diepe luchtwegen) opgeven. Bij longemfyseem is er verlies 
van longweefsel door afbraak van longblaasjes. In hoofdstuk 4 werd onderzocht wat de 
effecten van longemfyseem, oftewel destructie van longblaasjes onafhankelijk van roken, zijn 
op atherosclerose ontwikkeling. Hiervoor werd in de longen van E3L muizen éénmalig elastase 
toegediend. Elastase is een enzym dat elastine, een belangrijk component van longblaasjes, 
afbreekt. Naast de controlegroep waarbij fysiologisch zout werd toegediend, werden twee 
verschillende doses elastase, i.e. 15 en 30 μg, gebruikt om dosisafhankelijke effecten te 
kunnen bestuderen. Na 20 weken cholesterolrijk dieet werd de mate van atherosclerose in 
de drie groepen muizen bepaald. Er werd geen verschil in de hoeveelheid atherosclerose 
gevonden, maar wel een dosisafhankelijke afname in de ernst van atherosclerose in de groepen 
behandeld met elastase. Dit kan deels verklaard worden door een dosisafhankelijke afname 
van ontstekingscellen in het bloed van de muizen die elastase toegediend hebben gekregen. 
De lipidenniveaus in het bloed waren gelijk tussen alle groepen. Deze resultaten wijzen 
erop dat alleen destructie van longblaasjes geen verklaring is voor het verhoogde risico op 
atherosclerose in COPD patiënten. Een verhoogde staat van ontsteking in het lichaam draagt bij 
aan de ontwikkeling van zowel atherosclerose als COPD en kan dus de missende (verklarende) 
link zijn tussen beide aandoeningen. Mogelijk leidt de toegenomen aanwezigheid van 
ontstekingsmediatoren in de longen bij COPD tot lekkage van deze mediatoren in de circulatie 
wat de ontwikkeling van atherosclerose kan stimuleren. 
Door meer inzicht te krijgen in de processen die betrokken zijn bij de vorming van 
atherosclerose kunnen nieuwe strategieën worden ontwikkeld om hart- en vaatziekten tegen te 
gaan. Een veelbelovend middel hiervoor is resveratrol, een bestanddeel dat van nature aanwezig 
is in veel Aziatische kruiden, noten, de schil van rode druiven en in rode wijn. Uit verschillende 
Addendum
146
studies blijkt resveratrol anti-atherosclerotische werkingen te hebben, zoals het verlagen 
van lipiden en het verminderen van ontstekingsreacties. Statines zijn cholesterolverlagende 
middelen die reeds veelvuldig gebruikt worden om de vorming van atherosclerose te remmen 
in patiënten en hebben ook meerdere anti-atherosclerotische werkingen, waaronder het 
remmen van ontstekingsprocessen. In hoofdstuk 5 werd onderzocht of resveratrol de vorming 
van atherosclerose kan tegengaan in muizen én of dit effect van toevoegende waarde is naast 
een statine, i.e. atorvastatine. Hiervoor werden E3L muizen gebruikt die ook het cholesteryl 
ester transfer proteïne (CETP) gen tot expressie brengen, waardoor het vetmetabolisme van de 
mens nog sterker benaderd wordt. Muizen hebben van nature namelijk geen CETP die nodig 
is voor uitwisseling van cholesteryl esters en triglyceriden tussen verschillende vetdeeltjes. 
E3L.CETP muizen werden verdeeld over 4 groepen die elk een ander middel in het dieet kregen: 
1. zonder toevoeging (controlegroep); 2. met resveratrol; 3. met atorvastatine; en 4. met de 
combinatie resveratrol en atorvastatine. Atherosclerose was in dezelfde mate verlaagd in alle 
groepen met toevoeging van resveratrol en/of atorvastatine, wat voornamelijk verklaard kan 
worden door een gelijke verlaging in de VLDL-spiegels in de drie behandelingsgroepen ten 
opzichte van de controlegroep. De niveaus van ontstekingsmediatoren in het bloed was niet 
verschillend tussen de groepen. Resveratrol heeft dus anti-atherosclerotische potenties, maar 
biedt geen aanvullende bescherming naast de werking van atorvastatine. Gezien de gunstige 
effecten van resveratrol en statines op ontstekingsprocessen wordt de effectiviteit van deze 
middelen ook buiten het gebied van de hart- en vaatziekten onderzocht, waaronder voor 
COPD. 
In hoofdstuk 6 worden de implicaties en het toekomstperspectief van de verkregen 
resultaten besproken. Op het gebied van onderzoek naar hart- en vaatziekten is de focus van 
de slagaders, i.e. lokaal, aan het verschuiven naar de bijdrage van distale organen zoals de lever 
en de longen. Aandoeningen van deze organen moeten daarom meegenomen worden om het 
risico op hart- en vaatziekten in kaart te brengen en een behandelplan op te stellen. Door meer 
inzicht te krijgen in de wisselwerking tussen verschillende organen wordt de ontwikkeling 
van nieuwe middelen gestimuleerd en het toepassingsgebied van bestaande therapieën 
uitgebreid. Dit leidt tot meer mogelijkheden om niet alleen hart- en vaatziekten, maar ook 
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en dr.  J.F.P. Berbée. Het promotieonderzoek, waarvan de resultaten zijn beschreven in 
dit proefschrift, werd afgerond in juni 2011. Van september 2007 volgende ze de studies 
Foundations of Chinese Medicine en Acupuncture aan Shenzhou Univerisity in Amsterdam, 
waar ze in juli 2010 cum laude voor slaagde. Vanaf juli 2011 is zij aangesteld als arts-assistent in 





Eindelijk, mijn proefschrift is af. Iedereen die heeft bijgedragen aan het tot stand komen van dit 
proefschrift: dank jullie wel. Een aantal personen wil ik in het bijzonder bedanken.
Copromotor Jimmy: ik heb veel van je mogen leren, van reverse pipetteren, werken met 
proefdieren tot en met het schrijven van rebuttals: teveel om op te noemen. Ik vond het erg fijn 
dat ik altijd langs kon lopen met mijn vragen.  Promotores Pieter en Louis: Pieter, bedankt voor 
al jouw begeleiding. Je kwam altijd weer met nieuwe inzichten en formuleringen waar ik niet 
aan had gedacht. Louis, bedankt voor je input en het concreet en overzichtelijk maken van de 
verschillende lijnen van mijn promotie-onderzoek. 
Patrick: bedankt voor je input. Ik heb veel gehad aan jouw commentaren. Klaus en Hans: 
jullie stonden aan het begin van mijn promotie, dank voor jullie vertrouwen in mij.
Gerry, Yvonne, El Houari, Andreea en Annemarie: jullie hulp was onmisbaar bij het opzetten 
van de analyse van longweefsels en -lavages. Het longlabo van UZ Gent, met name prof. 
Brusselle, Ken en Nele en verder ook Kees Klein van Siemens  en Jerry wil ik bedanken voor 
alle hulp bij het opzetten van het rookmodel. Koen vd Sluijs: dank je wel voor je hulp en uitleg 
bij de intranasale LPS instillatie proeven. Jaap Plomp: dank voor alle hulp bij het meten van 
longfuncties. Miranda: bedankt voor de Sysmex data. Hetty en Annemarie: dank voor de FACS 
data. Alle mensen van het proefdiercentrum in het bijzonder Jan-Bas Prins, Michel, Peter, Piet, 
Silvia en Yasmin wil ik bedanken voor hun samenwerking.
Van Endo/HG/TNO: Amanda, Anita, Bruno, Claudia, Edwin, Hanna, Illi, Irene, Janine, Jitske, 
José, Ko, Lihui, Marieke, Mariëtte, Mattijs, Mieke, Peter, Sam, Silvia, Sjoerd, Susan, Vanessa, 
Willeke, Yanan: dank voor jullie adviezen, medeleven en gezelligheid. Janna: bedankt voor de 
fijne samenwerking in het LIKK project. Alle andere endo-collega’s: Anna, Bang-Wen, Chris, Eric, 
Geertje, Guido, Henny, Henry, Hermine, Hetty, Ineke, Isabel, Ivo, Jan, Janny, Jeroen, Judith, 
Karien, Maggy, Martiene, Razvan, Thomas, Trea, Vicky: bedankt voor jullie hulp en gezelligheid. 
Lianne: dank je wel voor je onmisbare hulp. Erik: bedankt voor je hulp bij het opzetten van 
de athero-analyse op het Endo-lab en alle keren dat ik organen bij je mocht doorvoeren. Ik 
hoop dat je mijn gevulde koeken hebt gewaardeerd; ik waardeer jouw humor. De studenten 
Manoushka, Rowan, Vera en Ebru: bedankt voor jullie enthousiasme en inzet. 
Van het Longlab wil ik bedanken voor alle hulp, steun en gezelligheid: Annemarie, Bram, 
Dennis, Emily, Irene, Jasmijn, Katrien, Letty, Lisette, Marcel, Marianne, Renate, Robert, Suzanne, 
Willemien en Winifred. 
Paranimfen: Padmini (longen): ik ben erg blij met jou als opvolgster. Dank je wel dat je mijn 
paranimf wilt zijn. Wen (liver): unfortunately our high fat diet-emphysema studies were not so 
successful. Thank you for the good times during and after work.
Gimano: ontzettend bedankt voor de prachtige figuren en de tijd en creativiteit die je erin 
hebt gestoken, ondanks alle drukte. Ik bewonder je ijver en ambitie en hoop dat je het ver gaat 
schoppen in de wetenschap. 
Mijn huidige collega’s en met name mijn mede-AIOS, Louis en de andere arts-microbiologen 
van het KML wil ik bedanken voor hun belangstelling.
Dankwoord
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De harde kern, Fawzia, Mounir, Nicolette, Rodney, Sonja, Sum en Wing: dank jullie wel voor 
alle gezelligheid. Nes: door onze drukte zien we elkaar maar een paar keer per jaar, maar als 
het dan zover is, is het altijd weer vanouds vertrouwd. Ik bewonder je hoe je met elke tegenslag 
omgaat en daardoor sterker wordt. 
Kokko, TK: ik weet dat ik altijd en voor alles bij jullie terecht kan en daar ben ik jullie erg 
dankbaar voor. Ting-ting en Jing-jing: jullie zijn mijn stralende zonnetjes.
Ma, pa: bedankt voor jullie onvoorwaardelijke steun, liefde en zorgen. Met het afronden 
van deze promotie is er in ieder geval één zorg minder, voor mij, maar ook voor jullie. Ik draag 
dit boekje dan ook graag aan jullie op. 
Robin: thank you for your care, your willingness to listen and great ability to put things into 
perspective. You always want to make me happy, and although you did not mind at all whether 
I would obtain my PhD title, I am sure you are happy for me now it is (almost) finished. 
Tenslotte, mijn liefste 立仁, Ip-In: dank je wel dat je me de energie en wilskracht hebt 
gegeven om mijn proefschrift af te maken. Mocht je ooit dit boekje doorlezen, dan wil ik je in 
ieder geval één wijsheid van 孔夫子 (Confucius) meegeven: “Our greatest glory is not in never 
falling, but in rising every time we fall.” 
Man-Chi
Addendum
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